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ABSTRACT 
 
Inhaled short acting β2–agonists are commonly used in the treatment of asthma, exercise 
induced bronchoconstriction (EIB) and airway hyperresponsiveness (AHR). The World Anti-
doping Agency (WADA) permits asthmatic athletes to use inhaled salbutamol with an 
accumulated dosage not exceeding 1600 µg over a 24-hour period. A key driver for the 
inclusion of β2-agonists on the WADA restricted list is associated with its potential impact on 
athletic performance according to previous research. However, the findings from previous 
studies are equivocal and focus almost exclusively on endurance performance. Furthermore, 
there are no available data examining the ergogenic effect of inhaling a single bolus of the 
upper daily limit of 1600 µg or the impact on urine concentration of the short-acting β2-
agonist and its relationship with the WADA code. Meanwhile, caffeine and theobromine 
have been regarded as bronchodilators and whilst the potential ergogenic effects of caffeine 
have led to its WADA monitored status no such information exists for theobromine. 
 
Study 1 investigated the ergogenic effect of 800 µg and 1600 µg of salbutamol in a 
randomised, single-blind and cross-over design on 5-km running time-trial performance in 
non-asthmatic endurance athletes (n = 7). The study revealed no significant improvement in 
performance after the inhalation of either doses of salbutamol (t = 1683.29 ± 179.74 sec for 
800 µg and t = 1683.57 ± 190.69 sec for 1600 µg) compared with placebo condition (t = 
1714.71 ± 186.22 sec).  Study 2 employed a simulated football protocol following the 
inhalation of 800 µg and 1600 µg of salbutamol in a randomised, single-blind placebo 
controlled trial in male (n = 7) and female (n = 6) football players. Results demonstrated 
there is an improvement of inhaled salbutamol on performance. Whilst the average urine 
salbutamol concentrations did not breach the WADA urinary threshold (1000 ng·mL-1), five 
individuals, two male and three female, recorded urine drug concentrations that exceeded the 
threshold. Study 3 examined the urine concentration of salbutamol following passive body 
mass loss of 2% or 5% following the inhalation of 800 µg and 1600 µg of salbutamol across 
ethnicity and gender (n = 32). The study demonstrated that following the inhalation of 
1600µg it is possible to present urine salbutamol concentrations above the current WADA 
upper limit that imposes a urinary drug threshold of 1000 ng·mL-1. Study 4 explored the 
ergogenic effect of caffeine and theobromine on non-asthmatic athletes during a 3-km time 
trial (n = 10). The findings suggest that both caffeine and theobromine resulted in an 
improved time-trial performance (t = 1168.7 ± 78.12 sec and t = 1176.5 ± 75.15 sec, 
respectively) compared with placebo condition (t = 1260.6 ± 110.65 sec), while caffeine 
resulted in a larger and more rapid enhancement compared to theobromine. Overall, 
salbutamol, the intake of which is restricted by WADA, did not have an ergogenic effect on 
athletes, while on the other hand, caffeine and theobromine, the usage of which are not 
controlled at all in sports competitions, had a performance enhancing effect on athletes, 
according to our results. Furthermore, although the inhalation of salbutamol did not improve 
the overall performance, athletes inhaling these substances might record urine concentration 
exceeding the WADA threshold, resulting in an adverse analytical finding (AAF).  
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CHAPTER I 
GENERAL INTRODUCTION  
 2 
1.1 Introduction 
 
Asthma is a chronic inflammatory disorder of the airways and is associated with bronchial 
(airway) hyperresponsiveness. According to World Health Organization (WHO) estimates, 
there are 235 million people suffering from asthma worldwide. Furthermore, asthma is the 
most common chronic disease among children (WHO, 2016). In the UK 5.4 million people 
(8.4% of UK population) are receiving treatment for asthma, including 1.1 million children 
(Asthma UK, 2015).  
 
Exercise induced bronchoconstriction (EIB), sometimes termed Exercise Induced Asthma 
(EIA), has been shown to develop during long duration exercise resulting in a reduction in 
endurance capacity leading to an impaired athletic performance and prolonged recovery time 
following exercise. Associated with different sport types, diagnostic methods used, and 
environments, reports on the prevalence of EIB in athlete populations have ranged from 9% 
to 55%. Many studies have shown that athletes who participate in summer sports have a 
lower incidence of EIB than those who participate in winter sports (Dickinson et al., 2005). 
The number of athletes using inhalers in Olympics Games has been increasing from 11% in 
1984 to 17% in 1998 in the US Olympic team alone (Dickinson et al., 2005). 
 
Exercise induced bronchoconstriction describes acute, transient airway narrowing that occurs 
during and most often after exercise. It can be objectively defined as a >10% decline in 
forced expiratory volume in 1 second (FEV1) after appropriate exercise provocation (Dheda 
et al., 2009). However, the decline in FEV1 is reversible either through inhalation of short 
 3 
acting β2-agonists which give immediate reversibility or natural recovery which can take up 
to four hours to reverse bronchoconstriction. Clinical symptoms of EIA include coughing, 
wheezing, shortness of breath, excessive mucus production, chest tightness, and chest pain 
(Donna et al., 2010). Exercise is the most common trigger of bronchospasm in those who are 
known to be asthmatic, and 50% to 90% of all individuals with asthma have airways that are 
hyperreactive to exercise (Rundell et al., 2002). However, EIB also occurs in up to 10% of 
subjects who are not known to be atopic or asthmatic (Dheda et al., 2009; Parsons et al., 
2014). 
 
Standard treatment for asthma and EIB includes short acting β2-agonists i.e. salbutamol, 
terbutaline, procaterol and fenoterol. In 2001, The International Olympic Committee - 
Medical Committee (IOC-MC) established the requirement for athletes using short acting β2-
agonists to present evidence of current asthma, EIB or airway hyperresponsiveness (AHR) 
through the therapeutic use exemptions (TUE) process. This regulation has recently been 
amended no longer requiring a full TUE, only confirmation of asthma and/or EIB from a 
certified medical professional.  
 
According to Lafontan (1988), the use of oral β2-agonists can increase muscle mass by 
stimulating protein anabolism as well as increasing the metabolism of lipids and 
carbohydrates. In addition, some studies from 1980s have reported effects of oral β2-agonists 
on the central nerve system consistent with antidepressant activity (Belmaker, 1982). A 
number of studies have reported remarkable changes in body composition following oral β2-
administration. Over comparatively short periods of time (between four and twelve weeks), 
specific β2-agonists (i.e. clenbuterol and salmeterol) have been shown to enhance skeletal 
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muscle size and strength in some animal species (Baker, 1983). Moreover, these treatments 
resulted in body fat loss irrespective of mode of administration (i.e. oral or implanted osmotic 
mini-pumps; Baker, 1983). These results may indicate the underlying reason why athletes 
searching for performance enhancement commonly use β2-agonists. However, in contrast to 
oral β2-agonists the ergogenic effect of inhaled (topical) β2-agonists is equivocal (Meeuwisse, 
1992; Freeman, 1989) indicating the need for further study. 
 
The IOC-MC investigated the use of inhaled β2-agonists at the 2000 Olympic Games and 
were concerned that some non-asthmatic athletes were using these medications 
inappropriately. Accordingly, the IOC-MC introduced its β2-agonists policy before the 2002 
Olympic Winter Games in Salt Lake City for health, not doping reasons. At that time a 
Therapeutic Use Exemption (TUE) certificate was required for the use of inhaled short acting 
β2-agonists. To carry out this policy, a medic was required to provide evidences through 
either a bronchodilator response or one of several Bronchial Provocation Tests (BPT) before 
an athlete was granted approval to use β2-agonists (Anderson et al., 2003). As a result, only 
445 athletes at the 2004 Summer Olympic Games in Athens provided evidence for the use of 
inhaled short acting β2-agonists, which was 162 athletes less than four years earlier in Sydney 
where TUE’s were not required (Anderson et al., 2006).  
 
In line with these findings, the International Olympic Committee (IOC) and World Anti-
Doping Agency (WADA) prohibited systemic use of β2-agonists, putting them on their 
doping lists from 2004 stating: “All β2-agonists (including both optical isomers where 
relevant) are prohibited except salbutamol (maximum 1600 micrograms over 24 hours) and 
salbutamol by inhalation which require a declaration of use in accordance with the 
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International Standard for TUE. The presence of salbutamol in urine in excess of use of the 
substance and will be considered as an adverse analytical finding (AAF) unless the athlete 
proves, through a controlled pharmacokinetic study, that the abnormal result was the 
consequence of the use of a therapeutic dose (maximum 1600 micrograms over 24 hours) of 
inhales salbutamol” (WADA, 2012).  
 
Recently WADA removed the requirement for TUE for inhaled short acting β2-agonists 
however, they remain on the WADA Monitoring Program. The World Anti-doping Agency 
(WADA) stipulates that athletes who declare the use of salbutamol in order to treat asthma 
and/or EIB should not exceed an accumulated dose of >1600 µg over a 24-hour period (~16 
inhalations of a standard salbutamol inhaler; WADA, 2013). This recommendation appears 
out with the scientific evidence where the majority of studies have only investigated doses of 
up to 800 µg of salbutamol. While the majority of these studies have demonstrated no 
ergogenic effect on performance there remains questions regarding the use of doses up to the 
recommended daily limit of 1600 µg. Furthermore, the majority of previous studies have 
focused on continuous, aerobic exercise challenges. To date, there is no available data for the 
impact of inhaled short acting β2-agonists on repeat sprint team sport performance, such as 
association football (soccer). 
 
Concern has been raised recently that the inhalation of 1600 µg in a single dose may result in 
urine concentrations close to the WADA upper limit of 1000 ng·mL-1 and, therefore, result in 
an adverse analytical finding (AAF). A small number of recent studies have examined the 
impact of inhaling the WADA daily upper limit on urine concentrations. These studies have 
focused on multiple dosing regimens such as 4 x 400 µg of salbutamol as opposed to a single 
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high dose (Elers et al., 2011). Whilst athletes are usually prescribed 200-400 µg of inhaled 
salbutamol they are often instructed to use their inhaler ‘pro re nata’ (i.e. on an as needed 
basis), that could be interpreted as a clearance to inhale unlimited amounts of salbutamol to 
combat respiratory symptoms. Individuals encouraged to administer salbutamol pro re nata 
may dose over and above the maximal recommended daily dose of 1600 µg either 
intentionally or inadvertently, however in both instances the individuals intent to dope for 
performance enhancement purposes may be nil. Such circumstances may lead to the current 
threshold being unintentionally breached and thus bring about an Antitussive and 
Antiashthmatic Film (AAF). A number of cases have been reported in the literature where 
athletes have tested positive following inhalation of high doses of short acting β2-agonists 
(Kindermann et al., 2006). Recently, a team sport athlete escaped a doping violation after he 
inhaled in excess of 1600 µg over the course of a match and then tested positive in the post-
match anti-doping test. The player’s defense was based on a prescribed ‘as needed basis’ with 
no guidance on an upper limit to its use (personal communication with UK Anti-Doing). 
Accordingly, in practice, 16 inhalations in a short period of time prior to competition may 
occur in poorly controlled, less well informed athletes, as well as potentially unscrupulous 
athletes, testing positive despite medicating within the recommended limit (WADA, 2013). 
 
In addition to the inhalation of high, single bolus doses of short acting β2-agonists the impact 
of dehydration through sweating associated with high intensity exercise in hot environments 
may have a profound effect on urine concentration. To date, little is known of the impact of 
dehydration on urine concentrations of short acting β2-agonists. In addition, WADA impose 
global regulations and as yet no data exists on the impact of ethnicity on the 
pharmacokinetics of inhaled short acting β2-agonist and their subsequent appearance in the 
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urine. To date, no studies have examined the impact of dehydration and ethnicity on the 
excretion of short acting β2-agonists.  
 
Caffeine (1,3,7-Trimethylpurine-2, 6-dione; C8H10N4O2) and theobromine (3,7-dimethyl-1,H-
purine-2, 6-dione; C7H8N4O2) are closely related alkaloids which can be found in a variety of 
food sources including: chocolate; tea leaves; cocoa; and kola nut (Wikipedia, 2016). 
Theobromine, caffeine and their related compounds are considered pharmacologically 
beneficial as they demonstrate significant positive effects.  
 
Caffeine, taken prior to exercise, has been shown to be an effective prophylaxis for EIB 
(Inman, 1996). Vanhaitsma (2010) comparative study on effects of Caffeine and β2-agonists 
for asthmatic athletes, showed that in athletes with asthma and EIB, moderate (6 mL/kg body 
mass) to high doses (9 mL/kg body mass) of caffeine provide a significant protective effect 
against EIB, and that a high dose of caffeine is equally as effective as salbutamol in 
attenuating the bronchoconstrictor response to exercise. Whilst the action of theobromine on 
the central nervous system (CNS) is generally considered weak or non-existent, a small 
number of studies have reported that theobromine primarily acts a diuretic and a bronchial 
smooth muscle relaxant. Theobromine is an active ingredient of bronchodilator drugs that are 
used in the treatment of acute and chronic asthma, and persistent cough (Irwin, 1997). The 
IOC does not consider theobromine an illicit substance in humans, though their 
administration to racing animals is prohibited. A large evidence base exists for the 
performance enhancing effects from caffeine. In contrast, little is known of the ergogenic 
effect of theobromine. 
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Accordingly, the global purpose of this thesis was to examine the impact of inhaling a short 
acting β2-agonist (salbutamol) at doses up to and including the maximum daily dose (1600 
µg) in a single bolus on endurance and team game performance. In addition, this thesis aims 
to contribute to the understanding of the impact of dehydration and ethnicity on the drug 
elimination in the urine following the inhalation of short acting β2-agonists at doses up to and 
including the maximal dose (1600 µg) as stipulated on the 2013 WADA Prohibited List. 
Finally, the impact of theobromine and caffeine, known bronchodilators, were assessed for 
their ergogenic impact on endurance performance. 
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2.1 Exercise Induced Asthma (EIA)  
Exercise-induced asthma (EIA), sometimes termed ‘Exercise Induced Bronchoconstriction 
(EIB)’, is a syndrome resulting in coughing or wheezing, and chest tightness or pain 
associated with continuous or strenuous exercise in individuals with and without known 
asthma (Randolph, 2007). EIA is presently defined as a transient narrowing of the airways 
following exercise and is present in approximately 80-90% of people with asthma (Anderson, 
1997). EIA is connected with airway inflammation leading to smooth muscle contraction and 
mucus production developing maximally about five to ten minutes following the cessation of 
exercise (Rundell et al., 2000).  
 
2.2 Prevalence of EIA 
The prevalence of EIA in athletes is higher than the 8% asthma prevalence in the general 
population of the UK (Asthma UK, 2001; Helenius et al., 1998; Wilber et al., 2000). The 
prevalence of EIA in athletic populations has progressively increased since data collection on 
the subject began in the early 1980’s. Data from the United States Olympic team reported an 
11% incidence in 1984 that grew to 14% in 1996 (Weiler et al., 1998). Athletes who compete 
in summer sports have a lower prevalence of EIA than those who compete in winter sports 
i.e. 17% of team U.S.A. athletes at the 1998 Winter Olympics were diagnosed with EIA 
(Weiler and Ryan, 2000; Rundell et al., 2000), which suggests the environment in which an 
individual trains and competes may be an important precursor in the development of EIA 
(Mannix et al., 1996). 
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2.3 Diagnosis of EIA 
The presence of EIA is difficult to diagnose through symptoms alone as clinical symptoms 
are often nonspecific (Jonathan, 2005). The main symptoms are cough, wheezing, tight chest 
and difficulties breathing; although other symptoms include a disparity between health and 
performance, and difficulties in sleeping (Storms, 1998).  
 
Methods for diagnosis of EIA that have been used include: questionnaire and symptom 
history; and exercise challenge, together with a range of indirect airway challenges including: 
eucapnic voluntary hyperpnoea (EVH); metacholine; saline; mannitol; and histamine 
(Anderson et al., 2001).  In athletes with normal findings on resting spirometry the Eucapnic 
Voluntary Hyperpnoea (EVH) Challenge is recommended as the ‘gold standard’ assessment 
of EIA (Anderson et al., 2001).  
 
Previous studies using FEV1 to identify EIA have suggested a magnitude of change ranging 
from a 7-20% fall in FEV1 (Anderson et al., 1971; Helenius et al., 1998). The International 
Olympic Committee - Medical Commission (IOC-MC) has ruled that an exercise or EVH 
challenge is positive for EIA when the FEV1 falls ≥10% from the baseline measurement. 
However, work carried out by Helenius et al. (1998) suggested that a fall of 10% in FEV1 
following an exercise test is not sensitive enough to diagnose EIA in elite athletes. Whilst 
lacking ecological validity, an EVH test conducted in the laboratory has a better level of 
standardisation and may be more perceptive than an exercise challenge in the diagnosis of 
EIA (Rundell et al., 2004).  
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2.4 Asthmatic Therapy  
There are pharmacologic and non-pharmacologic therapies available for asthmatics that 
decrease the severity of asthma and control its progression. In general, both pharmacologic 
and non-pharmacologic therapies are necessary to optimize the management of asthma and 
avoid adverse effects. These are presented in Table 1 and Table 2 (Randolph, 2009). 
 
Pharmacologic 
Inhaled short-
acting β2-agonists 
Short-acting β2-agonists relax smooth muscle, decrease vascular 
permeability, increase airflow, and moderately inhibit mediator 
release, but only last for 3 - 6 hours (Williams and Shapiro, 1995). 
Typical forms include salbutamol (albuterol) and terbutaline.  
Inhaled long-
acting β2-agonists 
Long-acting β2-agonists relax smooth muscle, decrease vascular 
permeability, increase airflow, and moderately inhibit mediator 
release and work up to 12 hours following inhalation (Williams 
and Shapiro, 1995). Typical forms include salmeterol and 
formoterol.  
Inhaled 
corticosteroids 
Inhaled corticosteroids reduce the number of airway inflammatory 
cells including: mast cells; eosinophils; and lymphocytes, and 
decreases the number of mononuclear cells, CD4+ type 2 T-helper 
cells, in order to improve airway epithelium (Ward et al., 2002; 
Bocchino et al., 1997). 
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Oral anti-
histamines 
Anti-histamines have been proved only in some circumstances to 
prevent inflammation of airways and thereby reducing responses 
to stimuli such as exercise and cold air, leading to a reduction in 
symptoms (Bianco, 1989)  
Oral anti-
leukotrienes 
Anti-leukotrienes are a form of anti-inflammatory drug, the use of 
which reduces bronchoconstriction and inflammation of the 
airways, thereby enhancing the control of asthma (Ducharme, 
2002).  
Inhaled cromolyn 
sodium 
Cromolyn sodium prevents the release of substances that cause 
inflammation or swelling of the airways. Therefore, it is used to 
prevent shortness of breath, wheezing, and troubled breathing 
induced by asthma. It is also used to prevent breathing difficulties 
during exercise (Medline Plus, 2014).  
Table  1. Pharmacologic interventions for the treatment of asthma 
 
Non-Pharmacologic 
Refractory period 
(Warm-up) 
A warm-up induces a refractory period, which limits the 
magnitude of EIA in subsequent vigorous exercise and therefore 
resulting in fewer symptoms, decreased medication use, and 
improved exercise performance (Stickland et al., 2012) 
Change training 
environment 
It has been well recognised that the role of environmental is a 
trigger of asthma. Changing training environment can decrease the 
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exposure to allergens, as a result reducing asthma-associated 
symptoms (NEEF, 2005).  
Breathing 
exercises 
Researchers found that the asthmatics breathe faster than non-
asthmatics, which exposes the lung to cooler and drier air and 
triggers asthma. Breathing exercises that encourage shallow 
breathing at a controlled rate have been proved to reduce asthma 
symptoms (Bottrell, 2011) 
Low salt diet Low sodium diet decreases the bronchoconstrictor response to 
exercise in asthmatics and improves lung function in adults with 
asthma (Mickleborough and Fogarty, 2006).  
Poly-unsaturated 
fatty acids 
Poly-unsaturated fatty acids reduce airway narrowing and as a 
result prevent asthmatic symptoms. A typical form is fish oil 
(Mickleborough and Rundell, 2005).  
Anti-oxidants 
(Vitamin C and E)  
An efficient endogenous antioxidant defence mechanism prevents 
excessive production of oxidants. An unbalanced exposure to 
oxidants and endogenous antioxidants will lead to oxidative stress 
which can trigger a number of diseases including lung pathologies 
such as asthma. Anti-oxidants can prevent asthma by maintaining 
the right balance (Van Toan and Hanh, 2013).  
Table  2. Non-pharmacologic interventions for the treatment of asthma 
 
2.4.1 Non-Pharmacological Treatment in Asthma 
There is increasing interest in breathing retraining techniques in asthma, particularly among 
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patients and the lay press. The Buteyko technique, for example, which uses hypoventilation 
in an attempt to raise the partial pressure of carbon dioxide in the blood, has been advocated 
as a method to allow reductions in, or even withdrawal of, asthma medication. Unfortunately 
rigorous trials of these methods have not yet been published and they should therefore be 
viewed with caution. It has recently been recognized, however, that many patients treated for 
asthma in primary care also have symptoms suggestive of dysfunctional breathing patterns 
(Thomas, 2001). Results of a physiotherapy based breathing retraining programme in such 
patients have reported significant improvements in health status in the short-term (Thomas, 
2003). It is likely that retraining techniques may improve symptoms and health status where 
there is dysfunctional breathing, either in the context of mild asthma or where asthma has 
been misdiagnosed. Physical training methods have been shown to improve cardiovascular 
fitness but not lung function in patients with asthma but effects on symptoms and quality of 
life have not been assessed (Ram, 2000). 
 
The exposure of patients with atopic asthma to the allergens that they are sensitized to has 
been shown to increase asthma symptoms and airway hyper-responsiveness leading to 
bronchoconstriction (Boulet, 1993). Changes of training environment is in order to control 
the exposure of house dust mite and pet allergens, however, have not conclusively been 
shown to improve asthma outcomes and larger trials have been advocated (Gotzsche, 2001). 
Studies of allergen control measures in infancy have shown reductions in respiratory 
symptoms (Custovic, 2001; Chan-Yeung, 2000), but it remains to be seen if such measures 
will prevent the development of atopy and asthma in later life. 
 
Allergen specific immunotherapy, or desensitization, involves the administration of specific 
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allergen extracts via subcutaneous injections of increasing concentration with the aim of 
inducing immunological tolerance. The process may work by generating interleukin-10 
producing regulatory T-cells. Immunotherapy appears to be particularly useful in allergic 
rhinitis but has also been shown to improve symptoms and airway responsiveness in patients 
with allergic asthma (Abramson, 2000). Overall the benefits appear to be modest, the 
technique is labour intensive, and major concerns about its safety remain since life 
threatening anaphylactic reactions can occur. Thus, while some patients may gain dramatic 
benefits immunotherapy for asthma is not recommended in the UK (Report of a BSACI 
working party, 1993).  
 
According to the information listed above, the non-pharmacological treatments for asthma or 
EIA might not be the ideal treatments for symptom relief or fundamentally therapy, therefore 
further studies are still needed to prove their efficacy and reliability. 
 
2.4.2 Pharmacological Treatment in Asthma 
There are a number of treatment methods that can treat asthma according to the severity (see 
Table 1). Mild intermittent asthma is normally treated with inhaled short acting β2-agonists, 
such as salbutamol and terbutaline, they are effective bronchodilators and should be 
prescribed to all patients with symptomatic asthma (British Thoracic Society, 2003; Global 
Initiative for Asthma, 1995). They are useful in preventing symptoms of exercise-induced 
asthma when given before the start of exercise (Anderson, 1976), and are important in the 
treatment of acute severe asthma. Their mechanism of action is thought to occur primarily by 
the relaxation of airway smooth muscle cells, but they also increase mucociliary clearance. 
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They do not have any effective anti-inflammatory activity. Although sympathomimetic 
agents, short acting β2-agonists have few side effects when inhaled, but tremor, palpitation, 
and tachycardia can occur with high doses. They should be used for symptom relief on an as 
required basis, since studies have shown that their regular use provides no additional benefit 
and may even be harmful (Dennis, 2000; Walters, 2000). Furthermore, individual patients’ 
requirement for short acting β2-agonists provides a useful guide to the need for a step-up in 
treatment; current guidelines suggest that if they are used on a daily basis for symptom 
control then regular anti-inflammatory agents are indicated (Global Initiative for Asthma, 
2003). The use of more than one canister of short acting β2-agonists per month has been 
particularly associated with poorly controlled disease and should therefore alert the prescriber 
to the need for increased regular anti-inflammatory treatment (Suissa, 1994). Tolerance to the 
effects of short acting β2-agonists can occur, particularly to the protection against 
bronchoconstriction induced during indirect challenges (O’Connor, 1992). 
 
Corticosteroids are currently the most effective anti-inflammatory agents for the treatment of 
asthma and inhaled corticosteroids are currently recommended for all patients with mild 
persistent asthma who require short acting β2-agonists more than once per day (British 
Thoracic Society, 2003) or those with intermittent asthma who experience severe 
deteriorations (Global Initiative for Asthma, 1995). They exert their anti-inflammatory 
effects through a diverse range of mechanisms including the activation of the glucocorticoid 
receptor leading to the regulation of transcription of target genes, and the direct inhibition of 
a range of inflammatory cells, particularly eosinophils. Studies have consistently shown that 
treatment with regular inhalations of corticosteroids results in significant improvements in 
airway inflammation in asthma, an effect demonstrated on bronchial biopsies (Djukanovic et 
al., 1992) and also on non-invasive markers of airway inflammation such as the differential 
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eosinophil count in induced sputum or nitric oxide concentrations in exhaled breath 
(Jatakanon et al., 1999).  Furthermore, there is evidence that corticosteroid treatment is not 
helpful in the absence of eosinophilic airway inflammation (Pavord et al., 1999). In 
conjunction with these improvements in airway inflammation, inhaled corticosteroids 
improve symptoms (Djukanovic et al., 1992), health status (Mahajan et al., 1997), airway 
hyper-responsiveness and lung function (Haahtela et al., 1991), and reduce asthma 
exacerbations (O’Byrne et al., 2001).  
 
The crommones sodium cromoglycate and nedocromil sodium, both given by inhalation, 
have also been used as controller therapies in mild persistent asthma (Blobal Initiative for 
Asthma, 1995). Their mechanism of action is not fully understood, although they are believed 
to suppress IgE-mediated inflammatory responses and may inhibit inflammatory cells (Diaz 
et al., 1984). Sodium cromoglycate has been shown to reduce symptoms and deterioration 
frequency (Edwards et al., 1994) and nedocromil sodium to improve symptoms, lung 
function, and airway responsiveness (Bel et al., 1990). Overall, however, they appear to be 
rather less effective than low dose inhaled corticosteroids (Szefler et al., 1998) and their 
long-term effects on airway inflammation are unknown. Therefore the use of these agents in 
adults has been aborted, instead is to use low dosed of inhaled steroids for most of mild 
persistent asthma patients. 
 
For moderate persistent asthma, there are a number of options that patients can use: 
i. Long acting β2-agonists (salmeterol and formoterol), they are currently generally 
recommended as the first choice for patients who have symptoms that persist despite 
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regular inhaled corticosteroids. Salmeterol is a partial agonist of the β2-receptor while 
formoterol is a full agonist. Both appear to have similar clinical effects, but formoterol 
has a more rapid onset of action (van Noord et al., 1996). Side effects of tachycardia, 
tremor, and muscle cramps are rarely a problem unless given in high doses. Tolerance to 
the effects of long acting β2-agonists with loss of bronchodilator activity after the 
subsequent administration of both short and long acting β2-agonists has been reported 
(Newnham et al., 1995; Grove et al., 1995). As with short acting β2-agonists, these 
agents work primarily via the relaxation of airway smooth muscle, with additional 
effects on mast cells and vascular permeability, but without significant anti-
inflammatory activity (Nelson et al., 1995). This lack of anti-inflammatory activity 
precludes their use as first line agents in asthma (Lazarus et al., 2001) and current 
guideline recommend that they are only prescribed alongside regular inhaled 
corticosteroids (British Thoracic Society, 2003; Global Initiative for Asthma, 1995). 
When uses in this way, long acting β2-agonists have been shown to improve daytime 
and night time symptoms and the need for reduce β2-agonists (Pearlman et al., 1992; 
Kesten et al., 1991). In a randomized controlled trial of 852 patients treated with low 
dose inhaled corticosteroids (the FACET study) the addition of formoterol to inhaled 
low or high dose budesonide improved symptoms and lung function. In addition, the 
number of both mild and severe asthma exacerbations was reduced, where mild 
deteriorations are defined as a fall in peak expiratory flow (PEF) of > 20% from baseline 
on two or more days, increase use of rescue short acting β2-agonists or nocturnal 
wakening and severe deteriorations defined as a fall in PEF of > 30% from baseline on 
two or more days or deterioration in symptoms requiring rescue oral corticosteroids 
(Pauwel et al., 1997).  
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ii. Increasing the dose of inhaled corticosteroids. The traditional approach to patients 
with persistent symptoms despite low doses of inhaled corticosteroids was to increase 
the corticosteroid dose, but the evidence for this is somewhat inconsistent. While some 
studies have demonstrated clear dose related improvements in symptoms and lung 
function (Pauwels et al., 1997; Nathan et al., 2000; Dahl et al., 1993), others have not 
demonstrated clinically important benefits with moderate or high doses (Adams et al., 
2000). Overall the beneficial effects of increasing the dose of inhaled corticosteroids 
appear to be modest and may be largely outweighed by the increased risk of side effects. 
Some studies have suggested that higher doses of inhaled steroids are less effective at 
controlling symptoms and peak flow variability compared with the addition of long 
acting β2-agonists (Pauwels et al., 1997; Greening et al., 1994). There is increasing 
evidence that asthma deteriorations are associated with eosinophilic airway 
inflammation (Pizzichini et al., 1999; Turner, 1998), and the benefits of the high doses 
of inhaled corticosteroids on deterioration frequency are therefore likely to reflect dose 
related anti-inflammatory effects. Turner and colleagues (1998) have shown that a 
doubling of the dose of beclomethasone in subjects with symptomatic asthma and a 
persistent sputum eosinophilia despite treatment with inhaled corticosteroids improved 
symptoms and significantly reduced the sputum eosinophil count, whereas the addition 
of salmeterol led to improvements in symptoms but no change in the sputum eosinophil 
count. Similarly, in a study of increasing doses of budesonide in patients with steroid 
naïve asthma, Jatakanon et al. (1999) demonstrated a dose dependent reduction in the 
percentage of eosinophils in induced sputum. While low doses of inhaled corticosteroids 
are therefore probably appropriate for the majority of patients, higher doses of these 
drugs may be indicated in some patients who experience frequent severe deteriorations 
of asthma or who have persistent airway inflammation. 
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iii. Leukotriene antagonists. Monteukast and zafirlukast are both effective cysteinyl 
leukotriene receptor antagonists capable of markedly inhibiting exercise-induced 
bronchoconstriction (Finnerty, 1992; Manning, 1990) and the early and late response to 
inhaled allergen (Taylor, 1991; Diamant, 1999). When added to as required β2-agonists, 
clinical trials have shown improvement in lung function (Spector, 1994; Reiss, 1997), 
reduction in the need for rescue bronchodilators (Spector, 1994; Leff, 1998), and some 
evidence of a reduction in eosinophilic airway inflammation (Pizzichini, 1999). In the 
UK, leukotriene antagonists are currently licensed for use in patients who remain 
symptomatic despite treatment with inhaled corticosteroids. Clinical trials have shown 
evidence of efficacy in patients taking high doses of inhaled steroids (Christian, 2000), 
and the introduction of montelukast has been shown to allow a reduction in the dose of 
inhaled corticosteroid without loss of asthma control (Lofdahl, 1999). Some studies have 
also shown that the addition of long acting β2-agonists results in greater improvements 
in asthma control than the addition of leukotriene antagonists (Nelson, 2000; Fish, 2001). 
iv. Theophylline. It has been used for many years in relatively high doses as a 
bronchodilator, but due to adverse effects it has often been reserved for use in patients 
with more severe asthama. Gastrointestinal upset is particularly common (Pollard et al., 
1997) but tachycardia and arrhythmia can also occur and measurements of serum 
concentrations are generally advised with high dose treatment (Blobal Initiative for 
Asthma, 1995). Recent interest has been in the use of theophylline at lower doses where 
the risk of side effects is minimized. The combination of low dose inhaled 
corticosteroids and theophylline has been shown to result in comparable asthma control 
as higher doses of inhaled corticosteroids and may provide slightly greater 
improvements in lung function (Evans et al., 1997; Ukena et al., 1997; Lim et al., 2000). 
A metanalysis has suggested that long acting β2-agonistsare more effective than 
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theophylline in patients taking low doses of inhaled corticosteroids and result in fewer 
side effects (Wilson, 2000). Unlike long acting β2-agonists, however, theophylline has 
been shown to have possible anti-inflammatory activity and may therefore have a role in 
some patients (Sullivan, 1994). 
 
2.5 β2-Adrenergic Receptor Agonists 
2.5.1 Development of β2-Adrenergic Receptor Agonists 
β2-agonists are the most common and effective therapy for the anticipation of symptoms of 
EIA in asthmatic patients (Dempsey, 1977). β2-agonists relax smooth muscle, decrease 
vascular permeability, increase airflow, and moderately inhibit mediator release (Williams 
and Shapiro, 1995). For most patients, inhaled β2-agonists are the first-line treatment of 
asthma and EIA (Collomp et al., 2010). An extracted alkaloid identified nowadays as 
ephedrine was found from ma huang (Ephedra equisetina), a traditional Chinese medicine, 
which was used for more than 2000 years for the short-term treatment of aspiratory 
symptoms. The nonselective α-Adrenergic Receptor agonist and β-Adrenergic Receptor 
agonist epinephrine was brought into clinical practice and conducted by the subcutaneous 
route for the treatment of acute asthma at the beginning of 20th century (Bullowa and Kaplan, 
1903). Epinephrine was far from the ideal drug even though it was a major advancement in 
medical field, the side effects caused hypertension and tachycardia due to its effect on α1- and 
β1-Adrenoreceptors in the cardiovascular system in bronchodilation use. In addition, it has a 
short duration of action and has to be administered parenterally due to its metabolic 
instability (Waldeck, 2002). The nonselective β-agonist became the standard-of-care 
bronchodilator, though the adverse effects were complicated (Waldeck, 2002), and caused 
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tachycardia and predisposes patients to cardiac dysrhythmias. Isoproterenol has another 
defect in its short duration of action due to its ready transportation into cells by the uptake 
process for catecholamines (Gryglewski and Vane, 1970), except in the gut, it is converted by 
catechol-O-methyltransferase (COMT) to 3-O-methylisporenaline (Blackwell et al., 1974). A 
noncatechol resorcinol derivative of isoproterenol named metaproterenol was subsequently 
developed in the early 1960s. Although it was an effective bronchodilator when inhaled, it 
still produced cardiac side effects because it did not distinguish between β1- and β2-
Adrenoreceptors. The modern era of selective β2-agonists started after the discover of 
salbutamol (albuterol in USA) by Sir David Jack and colleagues working at Allen and 
Hanburys in the UK (Jack, 1991). 
 
β2-agonists consist of a benzene ring with a chain of two carbon atoms and either an amine 
head group or a substituted amine head group, and the majority of the β2-agonists currently 
used in asthma are structurally related to adrenaline (Figure 1). If a hydroxyl (OH) group is 
present at positions 3 or 4 on the benzene ring, the structure is catechol nucleus and hence the 
agent is termed a catecholamine. If these OH groups are substituted or repositioned, the drug 
is generally less potent than the synthetic catecholamine isoproterenol, which has both strong 
β1-agonist and β2-agonist properties and is the more powerful bronchodilator (McFadden, 
1981).  
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Adrenaline (Epinephrine) 
 
 
 
Short-acting β2-agonisits 
Salbutamol 
 
Terbutaline 
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Long-acting β2-agonists 
Salmeterol 
 
Formoterol 
 
Figure 1. Chemical structure of adrenaline (epinephrine) and currently used short- and 
long-acting beta-2 agonists. 
 
The short duration of action (4 to 6 hours) of β2-agonists was the major limitation of its use 
between 1960s and 1970s, thus, the next step of β2-agonists was the development of the long-
acting drugs salmeterol and formoterol, the duration of action of which is about 12 hours, and 
it made their use for maintenance treatment (e.g., for reducing nighttime symptoms) more 
appealing (Lotvall, 2002). A pure R-isomer of salbutamol, levalbuterol (Berger, 2003), and 
the R,R-enantiomer of formoterol, arformoterol (Cazzola et al., 2010b), have been developed. 
It is claimed that they do not have the S-enantiomer and therefore safer, at least for (S)-
salbutamol, which is now known to have unwanted effects in the lung (Page and Morley, 
1999). At present, several once-a-day ultra-long-acting β2-agonists are in different stages of 
clinical development (Cazzola and Matera, 2009; Cazzola et al., 2011). 
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2.5.2 Short-Acting β2-Adrenergic Receptor Agonists 
Short-acting β2-agonists are mainly used to alleviate asthma symptoms rapidly and often in 
emergent situations. They can normally be divided into two broad groups according to 
duration of action after inhalation of conventional doses: (1) The catecholamines isoprenaline 
and rimiterol, which have a very short action of one to two hours; and (2) Those 
conventionally described as short-acting, such as fenoterol, salbutamol, and terbutaline, 
which are active for three to six hours, though the action of fenoterol may be slightly longer 
(Beardshaw et al., 1974). In general, higher dosage of any inhaled β2-agonist has a 
considerably longer action, for instance, 1600 µg salbutamol works longer than 200 µg 
salbutamol (Corris et al., 1983). It is not recommended to use short-acting β2-agonists as 
regular treatment for asthma as they are only reliever medication (Karjalainen, 2008) and 
might lead to increased asthma exacerbation (Sears et al., 1990) and worsen airway 
inflammation (Manolitsas et al., 1995).   
 
Salbutamol has negligible α-agonist activity at recommended clinical doses and demonstrates 
a substantial greater selectivity between β2- and β1-Adrenoreceptors than any other product 
previously available (Sears and Lotvall, 2005). In vitro tests that used guinea pig isolated 
atria for β1-Adrenoreceptors and tracheal preparations for β2-Adrenoreceptors, respectively, 
documented that isoproterenol has equal affinity for β2- and β1-Adrenoreceptors, 
orciprenaline is slightly more selective for β1-Adrenoreceptors, whereas salbutamol is more 
selective for β2-Adrenoreceptors (O’Donnell, 1972). Therefore salbutamol has approximately 
equivalent potency at relaxing human isolated bronchi in vitro and bronchodilator potency in 
subjects with asthma compared with epinephrine (Baldwin et al., 1994). However, the effects 
of salbutamol and epinephrine on histamine-induced contraction in vitro are significantly 
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different from their effects on histamine reactivity in vivo. Salbutamol has no effect on the 
maximal response to histamine, whereas epinephrine reduces it by 54% in vitro. In contrast, 
salbutamol is more potent in vivo (Baldwin et al., 1994). Other in vitro studies have also 
demonstrated that salbutamol acts as a partial agonist at β2-Adrenoreceptors compared with 
isoproterenol (O’Donnell and Wanstall, 1978). In human isolated bronchi, salbutamol is a 
partial relaxant of airway smooth muscle (ASM), whereas isoproterenol has greater efficacy 
(Goldie et al., 1986). Nonetheless, compared with isoproterenol, salbutamol is at least as 
potent a bronchodilator, has a much longer duration of action, and is much less likely to 
influence blood pressure or heart rate. Nevertheless, isoproterenol produces tachycardia that 
runs parallel to bronchodilation. In contrast, salbutamol causes the same maximum 
bronchodilation but with minimal cardiovascular responses. After inhalation of salbutamol, 
maximum brochodilation can be seen within 15 minutes of inhalation (Price and Clissold, 
1989). Salbutamol binds only weakly to the receptor and quickly diffuses back into the 
microcirculation accounting for its short duration of action (4-6 hours; Sears and Lotvall, 
2005). However, because of its rapid onset of action, which is a clear clinical advantage for 
the reversal of bronchoconstriction, salbutamol is usually considered the drug of choice as 
relief medication for symptoms of bronchospasm. This thesis will discuss the results of the 
experiments on non-asthmatic athlete especially taking salbutamol in later content. 
 
2.5.3 Long-Acting β2-Adrenergic Receptor Agonists 
Long-acting β2-agonists such as salmeterol and formoterol provide twelve-hour 
bronchodilation (Lotvall, 2002). It has been demonstrated that long-acting β2-agonists can be 
used for treatment of asthma as an add-on to inhaled corticosteroids, which have the effect of 
improving lung functions, relieving asthma symptoms and reducing asthma exacerbations 
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(Lemanske et al., 2001, cited in Karjalainen, 2008).  
 
The different chemical structures of formoterol and salmeterol grant remarkably different 
pharmacological characteristics, even though they are both potent and effective β2-
Adrenergic Receptor agonists. It has been suggested that salmeterol specifically binds to the 
β2-AR via the salbutamol “head group”, whereas a secondary exosite has been proposed in 
which the lipid tail binds to grant the long duration of action (Green et al., 1996). The exosite 
is an auxiliary binding site, a domain of highly hydrophobic amino acids within the fourth 
domain of the β2-AR (Johnson, 1998). When the lipid tail is in association with the exosite, 
the salmeterol is prevented from dissociating from the β2-AR, but the head can freely engage 
and disengage the active site by the Charniere (hinge) principle, the fulcrum being the oxygen 
stom in the side chain. The position of this oxygen atom is critical for the long duration of 
action (Johnson, 2001). The salmeterol molecule is >10,000 times more lipophilic than 
salbutamol. It partitions rapidly into the cell membrane and then diffuses laterally to 
approach the active site of the β2-AR through the membrane. The process is relatively slow 
(>30 minutes) and accounts for the slow onset of action of salmeterol compared with 
salbutamol (Johnson, 2001). 
 
By contrast, formoterol is not thought to be able to access the exosite and an alternative 
hypothesis for its long duration of action has been propsed whereby the lipophilic, basic 
nature of this drug allows formoterol to partition effectively into the lipid bilayers of ASM 
after inhalation. This partitioning then permits an effective concentration of agonist to be 
present over time in the form of a depot within the ASM, from where formaterol 
progressively leaches out to interact with the active site of the β2-AR, providing a prolonged 
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duration of action. This is known as the diffusion microkinetic theory (Anderson et al., 
1994). The size of the depot is determined by the concentration or dose of formoterol applied. 
In airway preparation, the onset of action of formoterol is somewhat delayed compared with 
salbutamol, and the duration of relaxant activity, although longer, is concentration-dependent 
(Johnson, 2001). In any case, formoterol is somewhat less lipophilic than salmeterol and is 
believed to diffuse more rapidly through the lung tissues, reaching the site of action faster 
than salmeterol (Anderson, 1993). 
 
2.6 Action of β2-adrenergic receptor agonists 
For more than four decades, β2-agonists have been used to relieve asthma symptoms. Potent 
bronchodilators exist in the lungs to provide rapid relief from bronchoconstriction for 
asthmatic athletes. Bronchodilators are known to relax smooth muscle of the airway, which 
will then increase airway calibre (Sporer, 2006). β2-agonists act through the β2-receptor 
which can be found in high concentrations in both the bronchial epithelium and bronchial 
smooth muscle (Lotvall, 2001). β2-receptors are a member of the seven transmembrane 
domains G protein-coupled family of receptors. β2-receptors in airway cells are stimulated by 
the sympathomimetic agents to generate a number of effects, including smooth muscle 
relaxation and bronchodilation mediated by the activation of adenyl cyclase, which will 
produce cyclic 3'5' adenosine monophosphate (cAMP). This leads to an inhibition of myosin-
actin biding in the bronchial smooth muscle (Sporer, 2006). The end result is smooth muscle 
relaxation, which has been shown in both asthmatics and non-asthmatics. 
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2.6.1 β2-Adrenergic Receptor Agonists on Non-asthmatic Athletes 
Oral β2-agonists are generally used for asthma patients’ brochodilating effect, it is also 
known that oral β2-agonists increase muscle mass as well, by stimulating protein anabolism 
and they also increase the metabolism of lipids and carbohydrates (Lafontan, 1988; Price, 
1989; Martineau, 1992). In addition, some early studies identified effects of oral β2-agonists 
on the central nervous system consistent with antidepressant activity (Belmaker, 1982). 
 
A number of studies have pointed out that a fall in arterial oxygen saturation may take place 
in highly trained athletes during high intensity exercise (Dempsey, 1999). There are many 
possible reasons which cause this exercise-induced arterial hypoxemia (EIAH), temperature- 
and acid-induced shifts in O2 dissociation at any given arterial PO2 contribute to EIAH, as do 
both an excessive alveolar-to-arterial PO2 difference and inadequate compensatory 
hyperventilation (Harms, 2000). However, the effect on performance level after a drop in 
arterial oxygen saturation is questioned (Koskolou, 1994). Notionally, the use of β2-agonists 
may result in an improvement in the oxygen transfer from the alveoli to the arterial blood in 
elite endurance athletes with extreme demands to the oxygen transport system, because it 
reduces the risk of pulmonary edema by up-regulating the sodium-driven clearance of 
alveolar fluid (Sartori, 2002). In contrast, Stewart et al. (2003) demonstrated no enhancement 
of arterial oxygen saturation during exercise when an acute, inhaled, therapeutic dose of 
salbutamol was administered to highly trained non-asthmatic athletes with EIAH. 
 
It is improbable that salbutamol and other β2-agonists bronchodilators are ergogenic, because 
in healthy, non-asthmatic subjects bronchoconstriction is not a performance-limiting factor. 
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Thus, β2-agonists would need to reach the systemic circulation in order to display its assumed 
ergogenic action. Comparing with orally administered therapeutic doses, clinically relevant 
doses in the form of aerosols result in much lower systemic plasma concentrations (Walker, 
1972).  The adaption of the human body to exercise is strongly associated with β2-agonists 
stimulation. Increased muscle contractility, transport capacity as well as increased availability 
of substrates for energy metabolism are all, more or less, mediated by stimulation of β-
adrenergic receptors. Some studies have demonstrated increased plasma lactate 
concentrations after systemic administration of β-adrenergic agonists during exercise, which 
together with changes in the respiratory exchange ratio (RER), could be seen as indirect 
measures of carbohydrate oxidation and glycolytic flux (Collomp, 2000; Van Baak, 2000; 
Hallen, 1996). 
 
2.7 Inhaled β2-agonists 
In the case of acute break through episodes of asthma, corticosteroids and other similar 
treatments are ineffective and bronchodilator therapy in the form of inhaled short-acting β2-
agonists is recommended (Rundell and Jenkinson, 2002). Inhaled short-acting β2-agonists 
relax smooth muscle, increase airflow, decrease vascular permeability and moderately inhibit 
mediator release (Williams and Shapiro, 1995). In addition to their use following an acute 
episode, it is recommended that the short acting β2-agonist should be inhaled 30 minutes 
before exercise. Treatment with two ‘puffs’  (200 µg; a standard dose ‘puff’ is 100 µg) of a 
short-acting β2-receptor agonists shortly prior to exercise will give peak bronchodilation in 15 
to 60 minutes and protection from EIA for at least 3 hours in most patients (Bierman, 1984). 
This type of treatment has been shown to improve pulmonary function in 90% of individuals 
with EIA (Anderson et al., 1979). The degree of attenuation to EIA observed following short-
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acting β2-agonist administration has ranged from 50-100% in clinical trials using both adults 
and children (Anderson et al., 1976; Boulet et al., 1989).  
 
Short acting β2-agonists are not recommended as the only source of treatment for EIA if they 
are inhaled more than three times a week (BTS, 2004). Furthermore, Anderson and Brannan 
(2004) suggest the following limitations in the use of β2-agonists: (1) daily use of inhaled β2-
agonists can result in the development of tolerance and reduction in the duration of their 
protective effect; (2) the severity of EIA may increase when exercise is performed between 8-
12 hours following the last inhaled dose and; (3) prolonged recovery of lung function after an 
asthma attack. These responses are believed to be due to desensitisation of the β2-receptors on 
mast cells leading to greater mediator release. Since inhaled β2-agonists are used by a large 
number of asthmatics in the UK, these findings may have implications for initial therapy 
given to individuals diagnosed with mild EIA (See Table 3). 
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Step Medication 
1.  Mild Intermittent Asthma Inhaled short-acting β2-agonists 
2. Introduction of regular preventer therapy  Corticosteroids 
3. Add on therapy 
 
  
Increase current medication, Inhaled long 
acting β2-agonists, theophylines, 
leukotrienes receptor antagonists, anti-
histamines 
4. Poor control on moderate dose of 
corticosteroid and add on therapy 
Add forth drug from list above 
5. Continuous or frequent use of oral 
corticosteroids 
Oral corticosteroids 
Table  3. The British Thoracic Society 5 Step asthma medication guidelines (British 
Thoracic Society. (2004). ‘British Guidelines on the Management of Asthma: A national 
clinical guideline’) 
	
2.8 Anti-Doping: The World Anti-Doping Authority (WADA) and the 
International Olympic Committee – Medical Commission (IOC-MC) 
The Prohibited List published by the World Anti-doping Authority (WADA, 2014) states that 
all β2-agonists, including all optical isomers (e.g. d- and l-) where relevant, are prohibited 
with the exception of three formats: inhaled salbutamol (maximum 1600 micrograms over 24 
hours); inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and 
salmeterol only when taken by inhalation in accordance with the manufacturers’ 
recommended therapeutic regimen.  
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Prior to the 2002 Salt Lake City Winter Olympic Games, short-acting β2-agonists were 
permitted for use by an asthmatic athlete with a letter of support from a medical officer to 
explain symptoms and diagnosis. For the 2002 Winter Olympics the IOC-MC mandated the 
requirement for a formal Therapeutic Use Exemption (TUE) for the use of inhaled 
salbutamol, formoterol, salmeterol and terbutaline for asthmatic athletes. This rule was 
changed again in 2010, where TUE is no longer required for salbutamol and salmeterol with 
formoterol and terbutaline remaining on the restricted list. Athletes who have asthma, EIA, 
EIB or AHR can use inhaled salbutamol and salmetorol as long as they declare they are using 
the drug therapeutically to treat their condition. The regulations for the use of salbutamol and 
salmeterol are relatively relaxed when compared with terbutaline and formotorol.  
 
2.9 Ergogenic (performance enhancing) Effects of Short Acting β2-agonists 
It has been suggested that oral salbutamol appears to have performance-enhancing effects 
mediated by its role in increasing strength (Martineau et al., 1992). Oral salbutamol is 
therefore not permitted to be used by athletes. Oral salbutamol, however, is distinguishable 
from the inhaled form and can be easily identified by anti-doping involving a urinary 
concentration upper threshold of 1000 ng/mL salbutamol (free plus gluconuride) and the ratio 
of the S1 and R-enantiomers (Fitch et al., 2008; Berges et al., 2000).  
 
In contrast, the majority of studies examining the efficacy of inhaled short acting β2-agonists 
have failed to observe an ergogenic effect (Wolfarth et al., 2010). The majority of previous 
studies has focused on endurance performance in Caucasian males and has reported no effect 
of inhaled short acting β2-agonist on performance (Larson et al., 2005). A very small number 
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of studies have examined the ergogenic effect of inhaled short acting β2-agonist outside of 
endurance performance. One study reported an increased peak power output in a 15s supra-
maximal cycling test (Signorile et al., 1992) however; others have failed to replicate this 
result (Sporer et al., 2008) following the administration of 200 µg, 400 µg and 800 µg of 
salbutamol. 
 
Kindermann and Meyer (2006) reviewed twenty previous studies that addressed the 
performance-enhancing effects of inhaled β2-agonist on non-asthmatic athletes, most of 
which have failed to show an improvement in athletes’ performance. Meeuwisse et al. 
(1992), Fleck et al. (1993), Lemmer et al. (1995) and Norris et al. (1996) conducted four 
separate and different endurance cycling studies on male athletes, with dosage of salbutamol 
ranging from 200 µg to 400 µg. All four studies reported no significant improvement in the 
athletes’ performance as well as no significant enhancement in VO2max. Similarly, McKenzie 
et al. (1983) and Morton et al. (1992) conducted studies of middle and long distance running 
with a dosage of 200 µg salbutamol and concluded no significant improvement compared 
with placebo condition. Of note, these two studies included female athletes as well as male 
athletes, therefore expanding the study results across gender. A small number of other studies 
in a similar field were conducted with cross-country skiers, triathletes, or a combination of 
these exercises (Goubault et al., 2001; Sandsund et al., 1998; Stewart et al., 2002) and similar 
conclusions were drawn showing no significant performance enhancing effects of inhaled 
salbutamol.  
 
A small number of studies have also demonstrated the ergogenic effects of inhaled β2-agonist 
on non-asthmatic athletes. Bedi et al. (1988) have performed a study on 14 male and one 
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female cyclist and triathletes with inhalation of 180 µg salbutamol and report a significant 
increase in ride time during a maximal effort workload to exhaustion following one-hour 
heavy continuous exercise. Van Baak et al. (2004) also conducted a placebo controlled study 
with 16 cyclists and triathletes, all male, and concluded a significant improvement in cycling 
time trial after the inhalation of 800 µg salbutamol. Signorile et al. (1992) conducted a study 
on recreational athletes reporting a significant increase in peak power during a 15-second 
Wingate test following inhalation of 180 µg salbutamol, they report.  
 
In contrast, a number of studies have revealed the opposite findings, where the performance 
after inhalation of β2-agonist was reduced compared with placebo conditions (Heir and 
Stemshaug, 1995; Carlsen et al., 1997). Carlsen et al. (1997) reported a significant decrease 
in running time to exhaustion after the administration of 800 µg of inhaled salbutamol. Heir 
and Stemshaug (1995) reported a similar conclusion and found a reduced endurance time at 
110% VO2max following the inhalation of 0.05 mg·kg-1 of salbutamol. In another study 
Carlsen et al. (1997) conducted the same test over the same participant, following the 
inhalation of 50 µg of salmeterol, demonstrating similar results compared with the use of 
salbutamol.  
 
A recent systematic review on previous studies of the effects of inhaled β2-agonist on 
physical performance was conducted by Pluim et al. (2011), which reviewed 26 placebo-
controlled studies involving 403 participants. The results revealed no significant 
enhancement on VO2max, peak power and exercise time to exhaustion. Another important 
finding was that the types of β2-agonist used, whether salbutamol, salmeterol, formoterol, or 
terbutaline, made no significant difference. However, care is warranted in the interpretation 
 37 
of this finding given the low and moderate doses of inhaled β2-agonists used in previous 
studies. Limited data exists examining the use of higher doses of salbutamol up to the 
WADA recommended daily upper limit of 1600 µg, particularly when inhaled in a single 
bolus. Furthermore, limited data exists examining the impact of inhaled short-acting β2-
agonists on team game performance. Given the popularity of team games such as association 
football, it is clear that research is required to investigate any potential ergogenic impact. 
 
2.10 Urinary concentration of inhaled salbutamol  
Sporer, Sheel and McKenzie (2008) undertook a time-trial performance with healthy non-
asthmatic athletes. The results from their study show the urine concentration of salbutamol 
increases as the dose of inhaled salbutamol increases, yet the highest urine concentration did 
not exceed the WADA daily upper limit of 800 µg even with the largest inhaled dose of 800 
µg. Pichon et al. (2006) examined urine concentration after inhalation of multiple small doses 
of salbutamol and reported the urine concentrations far below the WADA daily upper limit. 
Elers et al. (2010) studied athletes with doctor-diagnosed asthma and found peak urine 
concentration below the WADA upper threshold after inhalation of 800 µg of salbutamol. 
Elers et al. (2011) investigated the differences in urine concentrations between asthmatic and 
healthy subjects. No significant difference was found and urine concentrations for both 
groups did not exceed the WADA daily upper limit when corrected for the urine specific 
gravity. To date, a limited number of studies have examined the impact of inhaling the 
WADA recommended daily limit of 1600 µg in a single administration. Accordingly, it is not 
known what impact this dose of salbutamol would have on urine concentration. Dehydration 
in exercise can significantly reduce body mass, which might affect the urine concentration to 
exceed the WADA limit. However, little is known in this potential impact of dehydration and 
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we believe it is important to understand this relationship between dehydration and urine 
concentration.  
 
2.11 The pharmacological and ergogenic effect of Caffeine 
Caffeine (1,3,7-Trimethylpurine-2, 6-dione; C8H10N4O2) is a bitter, white crystalline purine, a 
methylxanthine alkaloid, and is closely related chemically to the adenine and guanine 
contained in deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Caffeine can be 
found in a variety of food sources including: coffee, tea, soft drinks, chocolate, and kola nuts. 
 
2.11.1 Caffeine Action 
An important mode of action for caffeine has been identified as the inhibition of adenosine 
receptors within the physiological concentration range of caffeine (normally less than 70 
µmol/L). Caffeine has a similar structure to adenosine and can bind to cell membrane 
receptors for adenosine, hence blocking their action. Adenosine receptors are found in the 
brain, heart, smooth muscle, adipocytes and skeletal muscle etc., most tissues. The ubiquitous 
nature and varied types of adenosine receptor facilitates caffeine simultaneously affecting a 
variety of tissues, resulting in a wide range of often interacting responses (Palmer et al., 
1995; Shryock et al., 1997; Ralevic et al., 1998; Fredholm, 1995). 
 
The mechanisms listed below may explain why caffeine could possibly enhance athletes’ 
performance during the competition: 
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1. Antagonism of adenosine (Holtzman et al., 1991): caffeine blocks adenosine receptors 
because of its close conformity to adenosine, thus emulously restraining its action (Rieiro 
et al., 2010). Caffeine can reduce cerebral blood flow (Cameron et al., 1990), and 
adenosine-mediated vasodilatation can be reduced by antagonize adenosine receptor in 
blood vessels and myocardial blood flow is reduced accordingly (Namdar et al., 2009).  
2. Increased fatty acid oxidation: enhancement of lipolysis results in sparring of glycogen 
(Spriet et al., 1992). Caffeine switches the substrate preference from glycogen to fat by 
increasing hormone sensitive lipase (HSL) activity and inhibition of glycogen 
phosphorylase activity (Rush et al., 2001). 
3. Caffeine acts as a nonselective competitive inhibitor of the phosphodiesterase enzymes 
(Umemura et al., 2006): Phosphodiesterases hydrolyze the phosphodiesterase bond in 
molecules such as cyclic adenosine monophosphate (cAMP), inhibiting the breakdown of 
cAMP. CAMP activates lipolysis by activating HSL and is an important molecule in the 
epinephrine cascade (Chesley et al., 1995). It further activates protein kinase A, which in 
turn can phosphorylate a number of enzymes involved in glucose and lipid metabolism 
(Graham, 2001). 
4. Increased post-exercise muscle glycogen accumulation: enhanced recovery by increased 
rate of glycogen resynthesis following exercise (Taylor et al. 2011). Battam et al. (2004) 
reported that caffeine ingestion has no effect on glycogen accumulation during recovery 
in recreationally active individuals. Pedersen et al. (2008) recently reported that caffeine 
(8 mg/kg body weight) co-ingested with carbohydrates (CHO) increases rates of post-
exercise muscle glycogen accumulation compared with consumption of CHO alone in 
well-trained athletes after exercise-induced glycogen depletion. Caffeine added to post-
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exercise CHO feeding seems to have the potential to improve glycogen resynthesis, 
although this issue needs further study. 
5. Mobilization of intracellular calcium: It has been shown that caffeine can enhance 
calcium release from the sarcoplasmic reticulum (Supinski et al., 1984) and can also 
inhibit its reuptake (Endo, 1977). Via this mechanism, caffeine can enhance contractile 
force during submaximal contractions in habitual and non-habitual caffeine consumers 
(Tarnopolsky et al., 2000). Intracellular calcium favors the activation of endothelial nitric 
oxide synthase, which increases nitric oxide (Echeverri et al., 2010). Some of the 
ergogenic effects of caffeine might therefore as well be mediated partly by affecting the 
neuromuscular system and increasing contractile force (Tarnopolsky, 2008). 
 
2.11.2 Caffeine and athletic performance 
The possible ergogenic effect of caffeine has been recognised by the researchers since the 
late 18th century (Jacobson and Kulling, 1989). Schirlitz (1930) (cited in Jacobson and 
Kulling, 1989) was the first to present laboratory evidence that the use of caffeine could 
increase work output. This finding was confirmed by Ivy et al. (1979) who reported that total 
work output was increased after the ingestion of 250 mg caffeine. Similarly, Costill et al. 
(1977) concluded that the cycling time to exhaustion at 80% VO2max was significantly 
increased after the administration of 330 mg caffeine. Given the potential for caffeine to act 
as powerful ergogenic aid a large number of studies over the last four decades have examined 
the role of caffeine in enhancing athletic performance across a range of sports.  
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Since these early findings about caffeine could be a powerful ergogenic aid, the research in 
this field has expanded rapidly. Researchers tested the ergogenic effect of caffeine on 
different types of sports, using different doses as well as controlling for other conditions. 
Jenkins et al. (2008) found that the cycling performance was significantly improved in 13 
cyclists following the administration of low doses of caffeine (2-3 mg/kg) compared with 
placebo conditions. A more recent study by Desbrow et al. (2012) investigated this effect by 
placing two different doses of caffeine, 3 mg/kg and 6 mg/kg, using a randomised, placebo 
controlled, double-blind design. The results demonstrated a significant improvement in 
cycling performance with dose of 3 mg/kg of caffeine, but no additional improvement was 
observed with of the higher caffeine intake (6 mg/kg).  
 
Caffeine with a concentration > 12 µg/mL in the urine was considered doping, and was on the 
WADA banned list from 1962 to 1972 and then 1984 till 2003 when it was placed on the 
monitored list in order to monitor the possible potential of misuse in sport. In opposition to 
this move by WADA, caffeine has been demonstrated to be ergogenic at doses lower than 
those that result in a urine concentration of 12 µg/mL, and higher doses appear to reveal no 
additional performance enhancing effect (Graham, 2011). A large number of athletes tested 
positive for caffeine during the second banned period. The sanctions ranged from warnings 
up to 2-year suspensions, although suspensions usually were only 2 to 6 months. According 
to WADA, one of the reasons caffeine was removed from the Prohibited List was that many 
experts believe it to be omnipresent in beverages and food and that having a threshold might 
lead to athletes being sanctioned for social or dietary consumption of caffeine (Prohibited list, 
2012). Furthermore, urinary caffeine concentrations can very considerably because it is 
metabolized at very different rate in individuals (Fenster et al., 1998), and does not always 
correlate to the dose ingested.  
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A number of studies have reported significantly improved cycling time-trial performance, 
which is most likely related to a greater reliance on fat metabolism (Mc Naughton, et al., 
2008); or improved maximal cycling power, which is related to decreased neuromuscular 
fatigue (Del Coso, et al., 2008). According to Greer et al. (2000), theophylline (a metabolite 
of caffeine) is more effective in doing so. However, the effect of caffeine on fat oxidation 
may only be significant during lower exercise intensities and may be blocked at higher 
intensities (Gonzalez, 2012). Spriet et al. (1992) discovered that ingestion of a high dose of 
caffeine before exercise reduced muscle glycogenolysis in the initial 15 minutes of exercise 
by increasing free fatty acid (FFA) levels, which inhibits glycolysis and spares glycogen for 
later use. Caffeine’s effect on the inhibition of glycogen phosphorylase has also been shown 
in vitro (Rush et al., 2001) as well as its effect on increasing HSL activity (Donsmark et al., 
2003). Following caffeine administration prior to and after the onset of cycling, Ivy et al. 
(1979) found that plasma free fatty acid levels were increased 30% compared to placebo. 
This action might be mediated by inhibition of the enzyme phosphodiesterase, thereby 
yielding higher levels of cAMP, which has been identified as an important molecule for 
glycogen metabolism and lipolysis (Nehlig & Debry, 1994). Pedersen et al. (2008) found 
higher rates of muscle glycogen accumulation after the co-ingestion of caffeine with CHO 
during recovery in highly trained subjects. This might be partly mediated by the activation of 
AMP-activated protein kinase (AMPK) (Egawa et al., 2009) as it is involved in the 
translocation of glucose transporter 4 (GLUT4) to the plasma membrane. This mechanism 
enables the cell to take up glucose from the plasma and store it as glycogen.  
 
While the ergogenic impact of caffeine in moderate-to-highly trained endurance athletes is 
quite clear and well documented, its effects on anaerobic, high-intensity tasks are less well 
investigated. Mora-Rodriguez et al. (2012) found that caffeine ingestion of 3 mg/kg could 
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counter reductions in maximum dynamic strength and muscle power output in the morning 
(2.5-7.0%) thereby increasing muscle performance to the levels found in the afternoon. 
Especially with regard to anaerobic performance caffeine’s adenosine receptor blocking 
effect in the CNS may be important (Daves & Green, 2009). Whilst caffeine seems to benefit 
trained athletes who show specific physiological adaptations whereas performance gains in 
untrained subjects might be lost or masked by a high variability in performance.  
 
Graham et al. (1998) have found out that coffee contains phenolic compounds such as 
chlorogenic acids, which elicits metabolic effects independent of caffeine. These compounds 
may counteract the physiological responses of caffeine. The issue therefore is whether 
absorbing the same amount of caffeine through a food source is as effective as absorbing 
isolated caffeine in the form of a tablet. As discussed above that the performance enhancing 
effect of caffeine is very clear. However, only a few studies have shown a positive effect of 
coffee on performance (McLellan & Bell, 2004; Wiles, et al., 1992; Hodgson, et al., 2013; 
Costill, et al., 1978), and others did not (Graham, et al., 1998; Butts, 1985; Lamina & Musa, 
2009). 
 
One of the earlier studies by Costill et al. (1978) found improvements in time-trail 
performance of cyclists only in the coffee trail group (330 mg caffeine an hour prior to 
exercise) but not in the decaffeinated coffee trail. Graham et al. (1998) studied exercise 
endurance in different groups of runners, to ingest caffeine (4.45 mg/kg body weight (BW)) 
or placebo capsule with water or either decaffeinated coffee, decaffeinated coffee with added 
caffeine or regular coffee. They found only caffeine significantly improved running time to 
exhaustion at 75% VO2max but neither did regular coffee nor decaffeinated coffee plus 
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caffeine. Based on these results, Graham et al. (1998) concluded that some elements in coffee 
possibly influence in the ergogenic response of caffeine alone. 
 
This is over against Hodgson et al. (2013) who studied at time trail performance in trained 
subjects after administration of caffeine (5 mg caffeine/kg BW), coffee (5 mg caffeine/kg 
BW), decaffeinated coffee and placebo an hour prior to exercise. They have reported similar 
significant improvement of ~5% in time trail performance in both the caffeine and the coffee 
supplemented group with no effects in the decaf or placebo group. The authors speculated 
that coffee consumed an hour prior to exercise, at a high caffeine dose improved performance 
to the same degree as caffeine. 
 
One of the reasons for the variance of the two studies mentioned above could be the different 
performance tests used. While Graham et al. (1998) used a time to exhaustion test which 
reportedly can exhibit a coefficient of variation as high as ~27% (Jeukendrup, 1996), 
Hodgson et al. (2013) used a time trail which have been shown to be more renewable, and 
they have concluded that due to lower statistical power, Graham et al. (1998) were not able to 
detect a difference between caffeine and coffee absorption on performance. In a word, both 
coffee and caffeine seem to exhibit a performance enhancing effect and further research will 
be needed to help us understand this issue. 
 
Not only does caffeine impact endurance, it has been reported to benefit cognitive function 
and fine motor skills (Foskett et al., 2009). Accordingly, caffeine is commonly used by 
athletes as an ergogenic aid due to its associated reduction in fatigue, and enhancement of 
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concentration and alertness (Paluska, 2003). Trained athletes benefit from a moderate dose of 
5 mg/kg (Woolf et al., 2008), although lower doses of caffeine (1.0-2.0 mg/kg) may improve 
performance (Cox et al., 2002). Another reason explains why caffeine is widely used in 
competitive activities might be its small but significant paregoric effect (Derry et al., 2012), 
possibly mediated by augmenting plasma endorphin concentrations (Grossman & Sutton, 
1985). It is also defined that caffeine reduces the rate of perceived exertion during exercise 
(Doherty & Smith, 2005), proposing that athletes are able to undertake higher intensities but 
do not perceive this effort to be different from placebo conditions. 
 
Of note, there are a small number of studies reporting no ergogenic effect on work 
performance when participants received a high dose of caffeine, including endurance 
(Cameron et al., 1990; Tarnopolsky, 2008; Davis & Green, 2009; Mora-Rodriguez et al., 
2012; Butts, 1985; Grossman & Sutton, 1985; Goniewicz et al., 2013; Ryder, 1994; 
Martinsen & Sundgot-Borgen, 2012). Perkins and Williams (1975) performed an exercise to 
exhaustion under four different conditions: placebo; caffeine doses in 4 mg/kg; 7 mg/kg; and 
10 mg/kg. The results demonstrated no significant difference in time to exhaustion between 
different doses compared with placebo. Butts and Crowell (1985) made a similar conclusion 
in time to exhaustion at 75% VO2max with a dosage of 300 mg caffeine.  
 
2.12 The pharmacological and ergogenic effect of theobromine 
Theobromine (3,7-dimethyl-1, H-purine-2, 6-dione; C7H8N4O2) is a closely alkaloid to 
caffeine (1,3,7-Trimethylpurine-2, 6-dione; C8H10N4O2), which can be found in a variety of 
food sources including: chocolate; cocoa; and kola nut. 
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2.12.1 Theobromine and athletic performance 
Due to its similarity with caffeine, theobromine may also provide performance enhancement 
as well as protection against bronchoconstriction, although the studies around this specific 
field are rare. Theobromine is widely consumed in the diet and is currently used in 
metabolism-enhancing sporting supplements for its stimulant effects (Pearce, et al., 2012). 
Furthermore, theobromine is not prohibited or restricted in any form by the WADA.  
 
Despite the absence of subjective or behavioral changes, Mumford et al. (1994) did note an 
increased: alertness; headache; and irritability in some individuals, suggesting the possibility 
of individual differences in sensitivity. Using a higher dose, Mitchell et al.  
(2011) found that 700 mg theobromine lowered blood pressure, decreased self-reported 
calmness and increased subjects’ ratings of how interesting they found performance of study 
tasks. Mattew et al. (2013) demonstrated that theobromine responses differed according to 
dose with limited subjective effects at 250 mg and negative mood effects at higher doses. 
They also observed a dose-dependent increased in heart rate. Therefore the study concluded 
that theobromine at normal intake ranges may contribute to the positive effects to exercise 
performance, but at higher intakes the performance effects become negative. 
 
2.12.2 Clinical Use of Theobromine 
Clinically, theobromine is used as a vasodilator, a diuretic, and cardiac contractile stimulant 
(William, 1943). Accordingly, theobromine has been used to treat high blood pressure 
(Theobromine Chemistry, 2015). A recent paper published suggested that the decrease in 
blood pressure might be associated with flavanols (Kelly, 2005). Importantly, previous 
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empirical research has claimed a potential bronchodilator effect of theobromine in vitro, 
although the effect is not as significant compared with caffeine (Simons, Becker and Simons, 
1985). Whilst theobromine may be used to control asthma the effects of theobromine on 
athletic performance are under-researched. Although there is no evidence that consumption 
of theobromine will increase athletic performance, Pearce et al. (2012) strongly advice the 
need for further research.  
 
Theobromine is useful in asthma and in other respiratory tract problems such as cough for 
which no definitive drug has been developed. Codeine is very effective but its metabolism to 
compounds acting on opioid receptors limits its use (Prieto-Lastra, et al., 2006). A safety and 
natural alternative could be theobromine since it is able to prevent cough provoked by citric 
acid in guinea-pigs and by capsaicin (an irritant component of chili peppers) in humans. A 
report from van Zyl, et al. (2008) showed that the diffusion of theobromine in lung 
substructures is higher than that of other drugs used in the therapy of respiratory diseases. 
The authors indicate that not only lipophilicity but also the position of alkyl groups in the 
purine ring affect the ability of caffeine and theobromine to cross biological membranes. The 
differential capability of tissue penetration and accumulation may explain why theobromine 
may achieve higher effects than caffeine. The efficacy of theobromine may become higher if 
it readily crosses membranes and reaches high interstitial concentrations even though 
theobromine may have less affinity for receptors than caffeine. 
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2.12.3 Caffeine vs. Theobromine 
According to Smit (2011), that theobromine appears to be toxic in some mammals, including 
pets. However, the action mechanisms of theobromine in humans may be different from those 
observed in other mammals with a number of clinical trials demonstrating that theobromine is 
not toxic for humans (Penleton et al., 2012, 2013; Baggott et al., 2013). 
 
An increasing amount of evidence in the last decade has showed that theobromine has 
psychoactive actions in humans that are qualitatively different from those of caffeine 
(Mitchell, et al., 2011; Baggott et al., 2013). The effect of theobromine on blood pressure 
(van den Bogaard, et al., 2010) is also qualitatively different than that of caffeine (Mitchell, 
et al., 2011) but the reasons for these differences are not established. One possible reason for 
the conflict in the effects of caffeine and theobromine could be their different half-life. The 
half-life of caffeine is the time required for the body to eliminate one-half of the caffeine. It 
varies widely among individuals according to factors such as pregnancy status, body weight, 
medication intake, and liver enzyme function level (needed for caffeine metabolism). In 
healthy adults, the half-life is approximately 3 to 7 hours (Ananya, 2014). Nicotine decreases 
the half-life by 30–50% (Fredholm et al., 1999). Additionally, it is known that oral 
contraceptive use can double caffeine half-life (Abernethy and Todd, 1985; Patwardhan et 
al., 1980), however, the effects of newer oral contraceptives on caffeine half-life have not 
been studied. Pregnancy can raise it to as much as 15 hours during the last trimester 
(Fredholm et al., 1999). In newborn babies the half-life can be 80 hours or more, dropping 
very rapidly with age, possibly to less than the adult value by age 6 months (Fredholm et al., 
1999). The antidepressant fluvoxamine (Luvox) reduces the clearance of caffeine by more 
than 90%, and increases its elimination half-life more than tenfold; from 4.9 hours to 
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56 hours (Drug Interaction: Caffeine Oral and Fluvoxamine Oral.). Caffeine can accumulate 
in individuals with severe liver disease, increasing its half-life (Verbeeck, 2008). A study 
conducted by Statland & Demas (1980) has showed that people with compromised liver 
function had a significantly longer half-life (a 49-year-old woman having alcoholic hepatic 
disease had a serum half-life of 168 hours).  
 
Half-life of theobromine is higher than caffeine even in rodents, which have a faster hepatic 
metabolism. Therefore, half of the theobromine administered to rats is excreted unchanged 
(Bonati et al., 1984). In humans, the mean half-life of theobromine in plasma from healthy 
volunteers is approximately 10 hours and the percentage of unmodified compound present in 
urine collected for 48 hours after a single dose of 10 mg/kg is relatively high (16-18% 
depending on the technique for isolation and quantitation) (Tarka et al., 1983). The 
importance of this fact is evidenced when methylxanthines are used as bronchodilators in the 
management of asthma patients in whose serum the half-life is also higher for theobromine 
than for caffeine (Becker et al., 1984). When one of the main xenobiotic metabolizing 
enzymes, cytochrome P450 1A2 (YP1A2), is expressed in heterologous cells the rate of 
transformation is much lower for theobromine (5%) than for caffeine (81%; Gu et al., 1992) 
therefore confirming that caffeine is more labile in terms of degradation than theobromine. 
 
In recent years, theobromine is starting to be widely studies to look for common and 
differential mechanisms with caffeine. The effect of theobromine in respiratory diseases is 
not due to inhibition of mediators of inflammation in asthma, histamine or slow reacting 
substance of anaphylaxis (Hillyard et al., 1984). A novel differential target of 
methylxanthines is poly(ADP-ribose)polymerase-1, a nuclear enzyme that is poorly inhibited 
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by caffeine but significantly inhibited by theobromine (Geraets et al., 2006). In this sense, 
Ahmad et al. (2015) have recently shown that inhibition of poly(ADP-ribose)polymerase-1 
significantly reduces inflammation of lungs caused by gamma-carrageenan. Recent evidence 
demonstrates neovascularization in an animal model of asthma (Wagner et al., 2015). 
Interestingly, theobromine may reduce neovascularization accompanying tumor growth and 
metastasis (Gil et al., 1993) and, therefore it may reduce both acute symptoms and 
angiogenesis in asthma. 
 
2.12.4 Theobromine and Performance 
In terms of the psychoactive effect of theobromine, early studies failed to observe mood 
effects following theobromine ingestion (Brunk et al., 1973; Dorfman & Jarvik, 1970) 
however, more recently Mumford et al. (1994) reported that 5 out of 7 subjects were able to 
recognize a high dose of theobromine (560 mg) from a placebo or caffeine dose. The 
combination of caffeine (19 mg) and theobromine (250 mg) in capsules increased the self-
reported mood construct “energetic arousal”, and improved epistemic function as measured 
with a simple reaction time test (Smit et al., 2004) compared to placebo capsules. 
 
Some animal studies have reported that theobromine has inappreciable effects on cerebral 
blood flow and glucose use (Brome & Stefanovich, 1986). Kuribara & Tadokoro (1992) have 
pointed out that animals do show increases in motor activity with high doses of theobromine. 
According to the report from Mumford et al. (1994), caffeine increased subjective alertness 
in subjects, whilst theobromine did not, and Mitchell et al. (2011) for the first time found that 
theobromine did not act as an incentive alone or combined with caffeine, however, it may 
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have a tension-raising effect. In conclusion, caffeine has strong alerting effects with 
inappreciable contribution from theobromine; caffeine produced ergogenic effects at early 
time points, while theobromine decreased calmness at a later time point; caffeine may have 
more CNS-mediated effects on alertness and theobromine may be acting mostly via 
peripheral physiology.  
 
The performance improvement contributions of theobromine are less clear and its 
psychoactive effects appear subtle compared to caffeine. Mumford (1994) postulated that 
theobromine is one tenth as potent as caffeine. Pharmacological assays also confirm that 
theobromine is less active than caffeine. Furthermore, individual variation in sensitivity to 
caffeine and theobromine is likely to play a role in the ergogenic efficacy of these 
compounds. Similar to caffeine, the ingestion of lower doses of theobromine may result in 
performance improvement, however at higher doses may causes a negative effect. 
 
2.13 Summary 
There are a large number of studies examining the ergogenic effect of inhaled short-acting β2-
agonists, however, their findings are contradictory. No strict comparison can be made 
between the studies because of different types of exercise, methods, and doses employed in 
each study. The vast majority of evidence suggests no ergogenic effect of inhaled salbutamol, 
however, a single high dose of up to the WADA recommended upper daily limit of 1600 µg 
has not been investigated. Furthermore, the majority of previous studies have examined 
endurance performance with no available data in team game performance. 
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Compared with the ergogenic effect of salbutamol, the urine concentration of salbutamol has 
received much less attention. Among the existing findings, the urine concentration of 
salbutamol did not exceed the WADA upper limit after the inhalation of salbutamol up to 800 
µg. To date, the impact of inhaling the WADA recommended daily upper limit of salbutamol 
in a single bolus on urine concentration remains unknown. Furthermore, dehydration has 
been previously implicated in positive anti-doping results despite the paucity of data 
examining the impact of body mass loss through dehydration on urine concentration of 
salbutamol.  
 
Caffeine and theobromine have been used in the control of asthma. The ergogenic effect of 
caffeine has again been examined by many previous studies despite a strong-link to enhanced 
performance, it is not banned and remains on the WADA monitored list. In contrast, little is 
known of the ergogenic impact of theobromine, although theobromine has been proved to be 
somewhat similar to caffeine in a number of aspects.   
 
Main Hypotheses 
1. Inhalation of 800 µg or 1600 µg of salbutamol will have no ergogenic effect on 5 km time 
trial performance. 
2. Inhalation of 800 µg or 1600 µg of salbutamol will have no effect on simulated association 
football (soccer) performance. 
3. Dehydration resulting in either a 2% or 5% reduction in body mass will not result in a 
positive doping violation following the inhalation of 800 µg or 1600 µg of salbutamol. 
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4. Caffeine and theobromine will have no effect on 3 km running performance in non-
asthmatic athletes. 
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EIB is closely related to asthma and is defined as a transient narrowing of the airways, 
limiting expiration that usually occurs during and most often after exercise, and is reversible 
spontaneously or through the inhalation of β2-agonists (Anderson, 1997). This thesis has 
previously reported the prevalence of EIB is 55% in athletes’ population, which is much 
higher than the prevalence of asthma in the general British population (8.4% in UK adults).  
Accordingly, the use of short-acting β2-agonists is prevalent during training and competition. 
This thesis sought to examine the ergogenic effects of short-acting β2-agonists in non-
asthmatic athletes to establish possible ergogenic effects. 
 
The eucapnic voluntary hyperpnoea (EVH) challenge is a surrogate for exercise (Anderson et 
al., 2001), and has been demonstrated to possess a high specificity and sensitivity in the 
diagnosis of EIB in elite athletes (Dickinson et al., 2006). Therefore, the IOC-MC 
recommends that athletes are tested for EIB using an EVH challenge in order to provide 
evidence of EIB and permit the use of inhaled short-acting β2-agonists during training and 
competing (International Olympic Committee- Medical Commision, 2010).  
 
This chapter describes general procedures and equipment that are common to more than one 
study in the thesis, and general information with regards to laboratory standards and 
equipment used. 
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3.1 Spirometry – Maximal Flow Volume Loop 
Spirometry is a medical test that measures the volume of air an individual inhales or exhales 
as a function of time. It is an effort dependent manoeuvre that requires co-operation, 
coordination and understanding by the subject. For these reasons the American Thoracic 
Society (ATS) and European Respiratory Society (ERS) have collaborated to publish 
spirometry guidelines (Miller et al., 2005), which were employed when spirometry 
measurements were performed in this thesis. The ATS/ERS guidelines ensure there is a 
global standard for the manoeuvre and the equipment used to test flow volume that is reliable 
and specific.  
 
Spirometer 
In the following collection of studies all maximal flow volume loops were collected using a 
MicroLab ML3500 Spirometer (Cardinal Health Ltd, UK), which met the ATS/ERS 
guidelines for diagnostic spirometers. The volume accuracy of the spirometer was checked 
using a three-liter syringe.  
 
Measurement of Maximal Flow Volume Loop 
The maximal flow volume manoeuvre (see Figure 2) was conducted as described in the 
following section. Following explanation of the test to the participant they were asked about 
recent illness, medication use, smoking and training they had completed in the 24 hours 
immediately prior to the test. The participant’s data was entered into the spirometer and a 
forced vital capacity manoeuvre was selected. Throughout the whole manoeuvre the 
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participant was asked to remain in a seated position. Verbal instruction (see Table 4) and a 
correct demonstration of the manoeuvre were given following ATS/ERS guidlines. The 
participant was asked to attach a nose clip and inhale maximally. They then placed the 
mouth-piece in their mouth and exhaled maximally until they felt they had reached residual 
volume. Once they had reached residual volume they were instructed to inspire maximally to 
total lung capacity. According to ATS/ERS recommendations (see Table 5), an adequate test 
requires a minimum of three acceptable forced vital capacity (FVC) manoeuvres. Acceptable 
repeatability is achieved when the difference between the largest and the next largest FVC is 
≤0.150 L and the difference between the largest and next largest FEV1 is ≤0.150 L 
(Hankinson & Bang, 1991). For those criteria are not met in three manoeuvres, additional 
trials should be attempted, up to, but usually no more than, eight manoeuvres, eight is 
generally a practical upper limit for most subjects (Ferris et al., 1978; Kanner et al., 1983). 
After several forced expiratory manoeuvres, fatigue can begin to take its toll on subjects and 
additional manoeuvres would be of little added value. Therefore, this manoeuvre was 
completed a minimum of 3 times and no more than 8 times. The maximal flow-volume loop 
with the best FEV1 was recorded as long as the second highest FEV1 was within 0.2 L. Each 
individual maximal flow volume loop effort was accepted if they met the criteria listed in 
Table 6. 
 58 
 
Figure 2. Spirometry Measurement 
 
1. Sit up straight and try to be relaxed 
2. Place nose clip on 
3. Hold the mouth piece to the side of you head 
4. Inhale until your lungs are full 
5. Place the mouth piece in your mouth and exhale as fast as possible 
6. Keep breathing out until you feel your lungs are empty 
7. Following complete exhalation keep the mouth piece in your mouth and inhale 
maximally until your lungs are completely full.  
Table  4. Verbal instruction given to participant 
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ATS/ERS recommendations are as follow: 
FVC minimum duration 6 s, (3 s for children) or plateau in the volume-time curve. 
Subject cannot or should not continue to exhale. 
FVC end of test criteria • subject cannot or should not continue further 
exhalation, or 
• the volume time curve shows an obvious plateau, or 
• the forced exhalation is of reasonable duration 
FVC maximum number of 
maneuvers 
8, both in adults and children 
FVC maneuver acceptability: 
none of the following applies 
• unsatisfactory start of expiration 
• back extrapolated volume >5% of FVC or 150 mL, 
whichever is greater 
• coughing that interferes with the measurement of 
FEV1 and/or FVC 
• early termination of expiration 
• Valsalva maneuver 
• A leak 
• An obstructed mouthpiece, no glottis closure 
• Effort that is not maximal throughout 
FVC and FEV1 repeatability the largest and second largest FVC and or FEV1 must not differ 
by more than 150 mL 
Table  5. ATS/ERS recommendations (Quanjer et al., 1993; American Thoracic Society, 
1994; Enright et al., 1991; Ferguson et al., 2000; Miller et al., 2005) 
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Within-manoeuvre criteria 
Individual maximal flow-volume loops were accepted if: 
Participant is free from 
Cough during the first second of exhalation 
Early termination or cut – off 
Effort that is not maximal throughout 
Leak 
Obstructed mouth piece 
Participant demonstrates satisfactory exhalation 
Duration of >6 seconds or a plateau in volume time curve 
Table  6. Criteria for acceptance of maximal flow-volume loops (Adpated from Miller et 
al. (2005). ‘Standardisation of Sprirometry’. European Respiratory Journal, vol. 26, pp. 
319-338) 
 
3.2 Bronchoprovocation Challenge 
Bronchoprovocation challenges are used to establish a diagnosis of Exercise Induced 
Bronchoconstriction (EIB). Bronchoprovocation challenges such as methacholine and 
histamine were not used to test for EIB in this thesis as they are not specific to EIB (Mahler, 
1993; Haby et al., 1995; Clough et al., 1991; Rundell et al., 2002; Holzer et al., 2002). Two 
challenges that are thought to be specific to diagnose EIA are: (1) exercise; and (2) eucapnic 
voluntary hyperpnoea (EVH). The poor reproducibility of exercise challenges has resulted in 
EVH becoming the ‘Gold Standard’ in the diagnosis of EIA (Pearsons et al, 2013). We have 
also considered the Mannitol challenge, which is an alternative choice for the EVH challenge. 
However, the Mannitol challenge is known to be more sensitive for detection of summer EIB 
athletes, while less sensitive in detection of winter EIB athletes (Sue-Chu et al., 2010).  
 
In preparation for all bronchoprovocation challenges participants were instructed to stop 
pulmonary medications (see Table 7). The participants were told not to exercise within 4 
hours of the challenge as this may exert a protective effect against EIA (Edmunds et al., 
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1978; Anderson, 1993). On the day of the test the participants completed a questionnaire 
stating any medication they were using and whether they were suffering from any illness or 
injury. If a participant was suffering from an illness or injury that may limit the results of the 
test, they were instructed to return when they were symptom free and fit to complete the test. 
The participants were also told not to drink coffee, tea, cola drinks or eat chocolate on the day 
of the test (Henderson et al., 1993). Following the bronchoprovocation challenge the 
participant was not allowed to leave until their FEV1 was within 10% of their baseline FEV1. 
If a participant had not returned to within 10% of FEV1 within 15 minutes after stopping the 
challenge, bronchodilator therapy was offered in the form of an inhaled short acting β2-
agonist (e.g. 200 mcg salbutamol). 
 
Medication Minimum time interval 
from last dose to challenge 
Reference 
Inhaled Short Acting 
β2-Agonist 
8 hours Ahrens et al., 1984; 
Greenspon et al., 1984 
Inhaled Long Acting β2-
Agonist  
48 hours Derom et al., 1992; 
Cockcroft and Swystun, 
1997 
Cromolyn Sodium 8 hours ATS 2000 
Leukotriene modifiers 24 hours ATS 2000 
Inhaled corticosteroids 24 hours Anderson et al., 2001 
Table  7. Time scales for stopping Pulmonary Medication (adapted from: American 
Thoracic Society. (2000) ‘Guidelines for Methacholine and Exercise Challenge Testing – 
1999’. American Journal of Respiratory Critical Care Medicine, vol. 161, pp. 309-329) 
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3.3 Eucapnic Voluntary Hyperpnoea (EVH) Challenges 
An EVH test is conducted in the laboratory (see Figure 3). It is a surrogate for exercise to 
identify EIB in athletes (Anderson et al., 2001). Before the athlete starts the EVH challenge 
they completed 3 maximal voluntary flow-volume loops with the best FEV1 being recorded 
as their baseline measurement. The athlete is then asked to ventilate at a target minute 
ventilation of 85% of their maximal voluntary ventilation rate (MVV). This was calculated 
by multiplying their baseline FEV1 by 30. The air which is inspired during the EVH 
challenge consists of 21% O2, 5% CO2 and 74% N2 and was delivered via a gas cylinder (see 
figure 3). There is a 5% CO2 concentration present to prevent syncope during the test. The 
hyperventilation lasts for 6 minutes during which verbal feedback and encouragement is 
given to the athlete. During the EVH challenge minute ventilation (VE) was monitored by 
calculating the volume of air passing through the dry gas meter every minute. This allowed 
the athlete to know whether to increase, maintain or decrease VE. After stopping the EVH 
challenge maximal voluntary flow-volume loops are taken at 3, 5, 7, 10 and 15 minutes. 
   
Figure 3. EVH Challenge 
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3.4 Urinalysis 
All urinalysis was performed at HFL Sport Science (Fordham, UK), the world’s largest 
independent provider of drug surveillance, doping control and research activities to human 
and equine sports; it is also a former part of the Quotient Bioresearch Group which has over 
40 years’ continuous experience in the science of sports doping control (equine, canine and 
human). This includes experience testing within the framework of the WADA. The HFL 
Laboratory in Fordham, UK, is one of the pioneering laboratories provide unrivalled and 
internationally trusted expertise in all aspects of doping control for sports; it has accreditation 
to ISO 17025, for laboratory testing and calibration services. HFL’s qualified team of 
scientists delivers both operational screening services and innovative research into prohibited 
substance detection and, over the past 40 years, has published more than 300 scientific 
papers, pioneering innovative bioanalytical techniques (About HFL Sport Science, 2015). 
This study’s aim was to examine urinary levels in line with WADA Anti-Doping rules, and it 
was important to use a lab that had experience in WADA procedures. HFL’s accreditations 
and rich experience in laboratory testing demonstrate that they are able to provide valid data 
and reliable results, we therefore had chosen HFL Sport Science to conduct all of the urine 
tests and analyses in this study. 
 
Sample preparation involved the addition of 200 mg of salbutamol-D3 (NMI) as an internal 
standard to 1 mL of urine. Following the addition of 2 mL of 0.1 M phosphate buffer pH 6.8 
and 100 µL of E. Coli enzyme (β-glucuronidase) solution the mixture was incubated 
overnight at 37ºC. Strata XC 60 mg solid phase extraction cartridges (Phenomenex, 
Macclesfield, UK) were conditioned with 3 mL of methanol followed by 3 mL of reagent 
grade water. Following centrifugation at 3500 rpm for 5 minutes the samples were applied to 
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the cartridges. The cartridges were then washed with 3 mL of 0.1 M acetate buffer pH 9.0 
followed by 3 mL of reagent grade water, 3 mL of 0.1 M HCl, 3 mL of methanol and 3 mL of 
diethyl ether. The cartridges were then dried for 5 minutes under vacuum and samples were 
eluted into glass vials with two, 1 mL of basic drug elution solvent (160 mL ethyl acetate, 34 
mL propan-2-ol and 6 mL 34% ammonia solution). Samples were then evaporated to dryness 
at ambient temperature using a centrifugal vacuum concentrator (Genevac Ltd, Ipswich, UK) 
and reconstituted in 10 µL of isopropanol followed by 200 µL of basic reconstitution solution 
(495 mL of 0.1 acetic acid mixed with 5 mL Benzyldimethylphenyl Ammonium). Samples 
were centrifuged at 3000 rpm for 10 minutes prior to LCMS submission. Samples were 
injected onto a Thermo Scientific Accela HPLC system coupled to a Thermo Scientific LTQ 
Orbitrap Discovery Mass Spectrometer (Thermo Fisher Scientific, Waltham, USA). 
Chromatographic separation was performed on a Waters Atlantis T3 column (2.1 x 100 mm, 
particle size 3 um; Waters Ltd, Elstree, UK) at 35ºC. The mobile phase was a gradient system 
of 0.1% acetic acid aqueous solution containing uracil (300 ng·mL-1) and 0.1% acetic acid in 
acetonitrile containing uracil (300 ng·mL-1) set at a flow rate of 0.4 mL·min-1.  
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3.5 Statistical Data Collection 
	
Figure 4. Statistical Data Collection 
 
VO2max was assessed using a graded, incremental treadmill (Woodway Ergo ELG 55 
treadmill; Woodway GmbH, Weil am Rhein, Germany) protocols designed to elicit VO2max 
in 8 to 12 minutes (See Figure 4). Expired ventilation (VE) and fractions of expired oxygen 
(FeO2) and expired carbon dioxide (FeCO2) were measured during the test with gas exchange 
and ventilatory variables being analysed breath-by-breath using a calibrated computer-based 
exercise system (Jaeger Oxycon Pro, Germany). The analysers were calibrated before each 
test using a two-point measure: a calibration gas (CO2 4%, O2 16%, N2 balance) and a 
reference gas room air after ATPS (ambient temperature and pressure, saturated) to STPD 
(standard temperature and pressure, dry). Heart rate (HR) and rating of perceived exertion 
(RPE) was continuously recorded (Polar; Lake Success, NY, USA).  
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Following the measurement of each subject’s stature (Holtain Stadiometer; Holtain Ltd., 
Crymych, Wales) and body mass (Seca 888 Class III floor scale; Seca, Birmingham, UK) 
subjects performed 5 minutes light running at a self-selected pace. The protocol for the 
exercise test was preinstalled to allow automatic and accurate increments in speed (km·h−1) 
and gradient (%). 
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CHAPTER IV 
STUDY 1 & STUDY 2 
THE ERGOGENIC AND 
PHARMACOKINETIC IMPACT OF SHORT 
ACTING β2-AGONISTS ON 5 KM TIME-
TRIAL RUNNING PERFORMANCE 
& ASSOCIATION FOOTBALL 
PERFORMANCE 
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4.1 Introduction 
Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of 
bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease which 
was first brought to market in 1968 (Fitch et al., 2008). β2-agonists are the most common and 
effective therapy for the anticipation of symptoms of exercise-induced bronchoconstriction 
(EIB) in asthmatic patients (Dempsey et al., 1977). β2-agonists relax smooth muscle, 
decrease vascular permeability, increase airflow, and moderately inhibit mediator release 
(Williams and Shapiro, 1995). For those affected by EIB, treatment with two ‘puffs’ (2 x 100 
µg) of a short-acting β2-receptor agonists shortly following exercise will give peak 
bronchodilation in 15 to 60 minutes and protection from EIB for at least 3 hours in most 
patients (Bierman et al., 1984).  
 
Due to fears of their potential ergogenic effect in non-asthmatic athletes, most forms of β2-
agonists are prohibited except salbutamol, salmeterol, formoterol and turbutaline by 
inhalation, which until recently required a declaration of use in accordance with the 
international standard for therapeutic use exemptions (TUE) (Dickinson et al., 2005). The 
World Anti-doping Agency (WADA) stipulates that athletes who declare the use of 
salbutamol in order to treat asthma or EIB should not exceed an accumulated dosage of 1600 
µg over a 24-hour period. Evaluation of the potential abuse of salbutamol is undertaken 
during routine anti-doping testing with a urine concentration of greater than 1000 ng·L-1 
considered a doping offence.  
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Oral salbutamol appears to have performance-enhancing effects mediated by its role in 
increasing strength (Martineau et al., 1992) and is therefore not permitted for use by athletes. 
Oral salbutamol however, is distinguishable from the inhaled, topical form and is currently 
identified by anti-doping authorities associated with a urinary concentration upper threshold 
of 1000 µg/mL salbutamol (free plus gluconuride) and the ratio of the S1 and R-enantiomers 
(Fitch et al., 2008; Berges et al., 2000). In contrast, the majority of studies examining the 
efficacy of inhaled short acting β2-agonists have failed to observe an ergogenic effect of acute 
inhalation of salbutamol in non-asthmatic individuals (Wolfarth et al., 2010). 
 
Oral β2-agonists are acknowledged to induce significant changes in body composition. 
Relatively short periods (4-12 weeks) of specific β2-agonists, especially clenbuterol and 
salmeterol, have been shown to increase skeletal muscle strength and size in several animal 
species. In addition, the administration of these β2-agonists orally or via implanted osmotic 
minipumps, has been associated with a decline in body fat (Sporer et al., 2008; Elers et al., 
2011; Anderson et al., 2001; Drust et al., 2000). Of note, this anabolic effect on skeletal 
muscle has, however, never been observed in either healthy animals or humans following the 
administration of oral salbutamol, possibly because of the short elimination half-life (Drust et 
al., 2007; Draper et al., 1997). In contrast, following an initial study from Martineau et al. 
(1993) reporting an improved endurance performance following the administration of oral 
salbutamol a number of further studies demonstrated improved endurance during intense 
submaximal exercise (Kindermann, 2007), increased strength following resistance exercise 
(Elers et al., 2012), and increased strength and endurance (Haverkamp et al., 2007) and 
power (Decorte et al., 2008), although side effects could be unpleasant (The World Anti-
Doping Agency 2010) including fine tremor, anxiety, headache, muscle cramps, dry mouth, 
and palpitation. 
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Previous studies have examined the effects of topical (inhaled) β2-agonists on performance 
after acute administration (Dickinson et al., 2006a; Dickinson et al., 2006b; Anderson et al., 
2003) and after short-term administration (Rundell et al., 2004; Parsons et al., 2007; Pluim et 
al., 2011; The World Anti-Doping Agency 2012; Elers et al., 2011; Anderson et al., 2011; 
Kindermann, 2007). Based on the results of these studies, the performance after acute 
therapeutic inhalation has no ergogenic impact. This has, in part, been explained by the lack 
of systemic bioavailability with such low-dose topical administration. There are, however, a 
number of limitations to these previous studies, for example, most studies investigating the 
effect of inhaled salbutamol on running performance have investigated doses of up to 800 µg 
while few higher dose trials including the permitted upper limit of 1600 µg are available in 
the literature. Furthermore, the majority of previous studies have focused on VO2max or 
running time to exhaustion rather than a more ecologically valid assessment i.e. sports 
specific time-trial.  
 
The World Anti-Doping Agency (WADA) stipulates that athletes who declare the use of 
salbutamol in order to treat asthma or exercise induced bronchoconstriction (EIB) should not 
exceed an accumulated dose of 1600 µg over a 24-hour period. To date, however, there are 
no available data examining the ergogenic effect of 1600 µg or the urine concentration of the 
short-acting β2-agonist following the administration of a single bolus of 1600 µg and its 
relationship with the WADA code. Most studies investigating the effect of inhaled 
salbutamol on maximal flow volume values, such as FEV1, have investigated doses of up to 
800 µg. Furthermore, previous studies have failed to control for the presence of exercise 
induced bronchoconstriction (EIB) in apparently healthy subjects during exercise 
performance studies (Elers et al., 2010).
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Whilst oral salbutamol appears to have an ergogenic effect, and despite its presence on the 
WADA restricted list, previous studies examining acute doses of inhaled salbutamol have 
failed to demonstrate an improved athletic performance (Dickinson et al., 2005; Dickinson et 
al., 2006b; Anderson et al., 2003; Rundell et al., 2004; Parsons et al., 2007; Pluim et al., 
2011; Signorile et al., 1992; Sporer et al., 2008; Elers et al., 2011; Anderson et al., 2001; 
Miller et al., 2005). In a recent meta-analysis (Pluim et al., 2011), reported no performance 
enhancement as a result of inhaled salbutamol administration. The majority of previous 
studies have focused on continuous, aerobic exercise challenges. There are a limited number 
of studies that have examined the impact of a hot environment on combined salbutamol 
administration (up to 1600 µg) and endurance running performance, or on the resultant 
salbutamol elimination in urine; there is no available data for the impact of inhaled short 
acting β2- agonists on association football (soccer) performance. In addition to the inhalation 
of high, single bolus doses of salbutamol, the impact of dehydration through sweating 
associated with high intensity exercise in hot environments may have a profound effect on 
urine concentration that will affect urinalysis.  
 
Exercise affects the pharmacokinetics of inhaled drugs in several ways. Pulmonary 
absorption is higher during exercise through exercise-induced increases in pulmonary blood 
flow and alveolar permeability (Schmekel et al., 1992). Exercise may also compromise blood 
flow to the splanchnic region and reduce gastro-intestinal uptake of the part of the drug that is 
swallowed during inhalation (up to 80% for inhaled salbutamol; Khazaeinia et al., 2000; 
Lipworth, 1996). Furthermore, exercise-induced sweat loss concentrates the urine, thus 
leading to a higher urine concentration of β2-agonists (Lipworth, 1996; Dickinson et al., 
2014; Hostrup et al., 2014). Sporer et al. (2008) observed that the urine concentrations of 
salbutamol were close to exceeding the urinary threshold in exercising subjects after 
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inhalation of 800 µg. It is likely that the urinary threshold and decision limit for salbutamol 
would have been exceeded in that study, if subjects had inhaled the maximal allowed dose of 
1600 µg salbutamol. Real-life doping control is mostly conducted immediately after a 
competitive event or a training session. Athletes using β2-agonists, usually inhale them a 
prophylaxis prior to competition or training (McKenzie & Fitch, 2011; Price et al., 2014). 
While athletes typically inhale repetitive doses of salbutamol below the current therapeutic 
threshold of 1600 µg, the 2015 WADA anti-doping regulations for salbutamol allow 
inhalation of 1600 µg as a single dose. Therefore, pharmacokinetic data of the maximal 
allowed dose of 1600 µg salbutamol conducted during exercise in hydrated and dehydrated 
state in controlled settings are important to evaluate the WADA urinary threshold and 
decision limit for salbutamol on the list of prohibited substances. 
  
Accordingly, the aim of this study was to investigate the effect of inhaling 800 µg and 1600 
µg of salbutamol prior to a 5 km time-trial in temperate and hot environmental conditions in 
non-asthmatic subjects. Furthermore, the pharmacokinetics of 800 µg and 1600 µg of inhaled 
salbutamol was examined. It was hypothesised that the inhalation of 800 µg and 1600 µg of 
salbutamol will not improve 5 km running time-trial performance in non-asthmatic subjects 
in either temperate or hot environment. Also in order to investigate the impact of inhaling 
short acting β2-agonists (salbutamol) up to the WADA upper limit of 1600 µg, on simulated 
football (soccer) performance, it was hypothesized that inhaling up to 1600 µg salbutamol 
would have no ergogenic effect on simulated association football (soccer) and repeated sprint 
performance. 
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4.2 Methodology 
4.2.1 Participants 
Prior to the commencing the study ethical approval was obtained from Liverpool John 
Moores University Local Ethics Committee (ethics No: 09E18GW). 
 
Study 1 
Ten male non-asthmatic runners (mean ± SD; age 22.4 ± 4.3 years; stature 179.7 ± 7.0 cm; 
body mass: 76.6 ± 8.6 kg) were recruited for the study. Prior to testing all participants 
undertook an EVH test to exclude asthma or EIB. Prior to arrival at the laboratory 
participants were asked to monitor hydration status with a urine colour chart for 24 hours 
prior to testing. Participants completed a 5km time-trial in a temperate environment (18ºC, 
40% Relative Humidity (RH)) and hot environment (30ºC, 40% RH) 3 times respectively, 
following the administration of an inhaled placebo, inhaled 800 µg salbutamol, and inhaled 
1600 µg salbutamol in a randomised, cross-over, single-blind fashion:
 
Figure 5. Schematic of participant protocol on day of each 5 km time-trial 
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Treatment 2: 8 inhalations of 100 µg salbutamol, 8 inhalation of placebo (SAL800) 
Treatment 3: 16 inhalations of 100 µg salbutamol (SAL1600) 
Hot (30ºC, 40% RH) environment: 
Treatment 4: 16 inhalations of placebo (PLA) 
Treatment 5: 8 inhalations of 100 µg salbutamol, 8 inhalation of placebo (SAL800) 
Treatment 6: 16 inhalations of 100 µg salbutamol (SAL1600) 
 
Study 2 
Seven non-asthmatic male (mean ± SD, age 23 ± 4 years, stature 177.0 ± 4.7 cm, body mass 
73.0 ± 4.3 kg) and 6 non-asthmatic female (mean ± SD age 21 ± 1 years, stature 162.3 ± 7.0 
cm, body mass 64.0 ± 5.8kg) football players volunteered and provided written informed 
consent.   
 
The participants visited the laboratory on three separate occasions. Each visit was separated 
by approximately 6 days. Each visit entailed the assessment of the individual’s maximal 
oxygen consumption (VO2max) using a graded exercise test to volitional exhaustion (Thoden, 
1990). The criteria of the British Association of Sport and Exercise Sciences (BASES) were 
used to ensure that VO2max had been reached (Bird and Davison, 1997). Players were required 
to complete a 52-minute football specific running protocol (laboratory temperature and 
relative humidity were 18ºC and 40%, relatively). The football-specific intermittent protocol 
devised for the study was performed on a motorized treadmill (Woodway Ergo ELG 55 
treadmill; Woodway GmbH, Weil am Rhein, Germany) and consisted of the different 
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exercise intensities that are observed during football match-play (e.g. walking, jogging, 
cruising, sprinting). Each participant undertook two familiarisation sessions before the trials. 
During the familiarisation sessions, participants were educated with necessary guidance and 
trained to use relevant equipment. Fifteen minutes prior the initiation of each football specific 
run, players inhaled one of the following treatments, via a pocket chamber, in a randomised 
single blind design:  
 
Treatment 1: 16 inhalations of placebo (PLA) 
Treatment 2: 8 inhalations of 100 µg salbutamol, 8 inhalation of placebo (SAL800) 
Treatment 3: 16 inhalations of 100 µg salbutamol (SAL1600) 
 
Maximal flow volume loops were recorded at baseline, 10 minutes post-treatment inhalation 
and 5 minutes post-simulated football match. A urine sample was obtained between 30 and 
180 minutes following the Maximal Flow Volume Loops. 
 
Figure 6. Schematic of football trial  
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4.2.2 Eucapnic Voluntary Hyperpnea (EVH) Test 
Participants undertook an EVH test prior to the start of testing to exclude asthma or Exercise 
Induced Bronchoconstriction (EIB). Three baseline maximal flow-volume loops were 
measured using a commercially available spirometer (ML3500, Cardinal Health, 
Basingstoke, UK). Flow-volume values were taken from the flow-volume loop with the best 
combined Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC). 
Each participant then completed an EVH challenge test (Anderson et al. 2001) involving 6 
minutes hyperventilation at approximately 85% of maximal voluntary ventilation (30 x 
baselines FEV1) pre-determined from a maximal flow volume loop.  Maximal flow volume 
loops were measured at baseline and at 3, 5, 7, 10 and 15min following completion of the 
challenge. A fall of ≥10% in FEV1 from baseline was deemed positive.  
 
4.2.3 Baseline Measurement 
In order to exclude the possible performance improvement effect from caffeine due to 
caffeine’s half-life as this study discussed earlier, all of the participants were requested to 
refrain from caffeine consumption before the tests and eat within 2 hours prior to each trial. 
Considering the time range of caffeine’s half-life for healthy adults, we informed the 
participants not to take any caffeine within 24 hours prior to the tests. After arriving at the 
laboratory, all of the participants were required to complete a pre-trial questionnaire before 
the measurement of body mass (kg) and stature (cm), as well as blood sample taken by finger 
prick, which including the checklist if they had consume any caffeine within 24 hours, only 
participants who had not taken any caffeine could proceed to the experiments.   
 
 77 
Baseline spirometry was measured three times to record maximal lung function. Following 
the completion of baseline measurements, inhalation of placebo or salbutamol (800 µg or 
1600 µg) was administered in a randomised, cross-over and single-blind fashion. Following a 
10-minute post-inhalation period, post inhaler spirometry was then measured, again for three 
times to record the maximal lung function.  
 
4.2.4 Performance 
Study 1: 5 km Time-Trial Performance 
On the test day, participants were asked to refrain from caffeine consumption for 24 hours 
and to refrain from eating within 2 hours of the 5 km time-trial. After arriving at the 
laboratory participants completed a pre-trial questionnaire and provided written informed 
consent prior to the measurement of body mass (kg) and stature (cm). Each participant was 
familiarized to running on a non-motrorised treadmill (Woodway Curve, Woodway, USA) 
prior to initiating the 5 km time-trial. Then under controlled laboratory conditions, 
participants took 3 trials in temperate conditions (18ºC, 40% RH) and 3 trials in hot 
environment (30ºC, 40% RH). Prior to starting the time-trial participants were fitted with a 
heart rate monitor (Polar RS400; Polar Electro Oy, Kempele, Finland) and connected to a 
breath-by-breath gas analyser via a facemask (Oxycon Pro, Jager, Wuerzberg, Germany). 
Over the course of the 5 km time-trial the following were measured: time, average heart rate 
(HR), oxygen consumption (VO2), carbon dioxide production (VCO2), minute ventilation 
(VE), respiratory exchange ratio (RER) and rating of perceived exertion (RPE). Two minutes 
following the completion of the 5 km time-trial capillary blood lactate was measured (Lactate 
Pro, Arkray KDK, Japan).  
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Following the completion of baseline measures inhalation of salbutamol (800 µg or 1600 µg) 
or placebo was administered in a randomised, crossover, single-blind fashion. Following a 
20-minute rest period post-inhalation spirometry was obtained. The participants mounted the 
treadmill and following a 10-minute free warm-up were asked to begin the 5 km time-trial. 
During the time-trial RPE, HR, and 500 m split time was measured. During the time-trial the 
participants were able to observe the distance they had covered, however, no feedback related 
to the time, speed, or HR was provided. During the time-trial participants were not allowed to 
drink however, on completion they were allowed to drink water ad libitum to provide urine 
samples within 3 hours of completion, in line with WADA guidelines. Post 5 km time-trial 
spirometry was measured. Each participant was asked to repeat the trial three times in a 
single-blind, randomised design separated by a minimum of 3 days to allow for sufficient 
recovery. 
 
Study 2: Simulated Football Trial 
The participants were then asked to start a 52-minute (45-minute of a half football match-
play, plus seven 1-minute stationary rest period to measure HR, RPE, VO2, RER and the 
collection of blood sample by finger prick) intermittent football specific trial, which included 
five low intensity sets (walk and jog; Figure 7) and two high intensity sets (cruise and sprint; 
Figure 8), in the order of low-low-high-low-low-high-low. High intensity exercise bouts were 
separated by low intensity recovery. The order of these bouts was devised to replicate the 
non-cyclical nature of the exercise pattern observed in football. The low set is 6”25 minutes, 
the highest speed of low intensity phase is 15 km/h; and the high set is 7 minutes, with the 
highest speed of 23 km/h. The duration of each bout was determined by matching the percent 
total time for each separate activity pattern during the protocol (after the deduction of the 
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total time for the treadmill speed changes) to that observed during match-play, base upon the 
data of Reilly and Thomas (1976). The participants were reminded every time before the 
speed going to change. The treadmill speeds for each activity in the protocol were based upon 
the speeds observed for each specific movement category during soccer match-play (Van 
Gool et al., 1988). The speeds chosen for each activity pattern were as follows: walking 6 
km·h-1; jogging 12 km·h-1; cruising 15 km·h-1; and sprinting 21 km·h-1. The speeds for 
female footballers were 10% slower than male protocol.  
 
During each of the seven 1-minute stationary rest periods, each participant’s heart rate was 
monitored by a pre-fitted heart rate monitor (Polar RS400; Polar Electro Oy, Kempele, 
Finland) and connected to a breath-by-breath gas analyser via a facemask (Oxycon Pro; 
Jagear, Wuerzberg, Germany). Over the course of the football match-play the following were 
measured: average heart rate (HR), oxygen consumption (VO2), respiratory exchange ratio 
(RER) and rating of perceived exertion (RPE). HemoCue Hb 201+Hemoglobin Analyser and 
Haemoglobin Hematocrit Centrifuge were used to analyse the blood sample collected by 
finger prick. A total of seven sets of HR, RPE, VO2, RER and blood lactate were obtained. 
Body mass and post football run spirometry were then measured at the end of the simulated 
football trial.  
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Figure 7. Low intensity exercise block 
 
 
 
Figure 8. High intensity exercise block 
 
Following the completion of the trial, participants were able to drink water ad libitum 
according to WADA guidelines.  
Time	
KM/H	
Time	
KM/H	
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4.2.5 Urine Collection 
Prior to the commencement of each trial in these two studies, subjects were asked to provide 
a urine sample in order to void themselves of urine, after which placebo or salbutamol was 
administered as described above. Subjects were instructed to collect the first sample of urine 
passed following completion of the laboratory-based tests in line with in-competition anti-
doping procedures as outlined in the World Anti-Doping Code International Standard for 
Testing 2012. Urine samples were provided by participants between 30 and 180 minutes 
following the completion of the trails. Consumption of water during this period was 
encouraged ad libitum to ensure diuresis. From the sample provided by each subject a 20 mL 
aliquot of urine was stored at -80ºC until analysis. Urinalysis to quantify salbutamol 
enantiomers was performed using the analytical method outlined by Berges et al. (1999) 
which involves a solid-phase clean-up procedure followed by a chiral HPLC separation and 
fluorescence detection (see General Methods). 
 
4.2.6 Urinalysis 
All urinalysis was performed at HFL Sport Science (Fordham, UK), an independent drug 
surveillance laboratory and former WADA-accredited laboratory. Sample preparation 
involved the addition of 200 ng of salbutamol-D3 (NMI) as an internal standard to 1 mL of 
urine. Following the addition of 2 mL of 0.1 M phosphate buffer pH 6.8 and 100 µL of E. 
Coli enzyme (β-glucuronidase) solution the mixture was incubated overnight at 37ºC. Strata 
XC 60 mg solid phase extraction cartridges (Phenomenex, Macclesfield, UK) were 
conditioned with 3 mL of methanol followed by 3 mL of reagent grade water. Following 
centrifugation at 3500 rpm for 5 minutes the samples were applied to the cartridges. The 
cartridges were then washed with 3 mL of 0.1 M acetate buffer pH 9.0 followed by 3 mL of 
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reagent grade water, 3 mL of 0.1 M HCl, 3 mL of methanol and 3 mL of diethyl ether. The 
cartridges were then dried for 5 minutes under vacuum and samples were eluted into glass 
vials with two, 1 mL of basic drug elution solvent (160 mL ethyl acetate, 34 mL propan-2-ol 
and 6 mL 34% ammonia solution). Samples were then evaporated to dryness at ambient 
temperature using a centrifugal vacuum concentrator (Genevac Ltd, Ipswich, UK) and 
reconstituted in 10 µL of isopropanol followed by 200 µL of basic reconstitution solution 
(495 mL of 0.1 acetic acid mixed with 5 mL Benzyldimethylphenyl Ammonium). Samples 
were centrifuged at 3000 rpm for 10 minutes prior to LCMS submission. Samples were 
injected onto a Thermo Scientific Accela HPLC system coupled to a Thermo Scientific LTQ 
Orbitrap Discovery Mass Spectrometer (Thermo Fisher Scientific, Waltham, USA). 
Chromatographic separation was performed on a Waters Atlantis T3 column (2.1 x 100 mm, 
particle size 3 um; Waters Ltd, Elstree, UK) at 35ºC. The mobile phase was a gradient system 
of 0.1% acetic acid aqueous solution containing uracil (300 ng·mL-1) and 0.1% acetic acid in 
acetonitrile containing uracil (300 ng·mL-1) set at a flow rate of 0.4 mL·min-1.  
 
The urine salbutamol concentrations reported correspond to the sum of the free and 
glucuronide conjugates. The samples were analysed over the calibration range of 10 to 2000 
ng·mL-1. Samples with salbutamol concentrations greater than the upper limit of 
quantification were diluted with blank human urine prior to analysis. The lower limit of 
quantification was accepted as the lowest standard on the calibration curve (10 ng·mL-1) 
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4.2.7 Statistical analysis 
Following the completion of 5 km time-trial and associated football performance under each 
condition, statistical analyses were done using the statistical software program SPSS (SPSS, 
Inc., Chicago, IL), and a two-way analysis of variance (ANOVA) was performed to compare 
differences in heart rate, oxygen consumption, minute ventilation, respiratory exchange ratio, 
rating of perceived exertion, blood lactate, forced expiratory volume in one second, forced 
vital capacity, peak expiratory flow rate and forced expiratory flow between 25 and 75% of 
forced vital capacity (study 1); differences in sprint time, peak power, peak velocity, heart 
rate, blood lactate, oxygen consumption, minute ventilation, respiratory exchange ratio, rating 
of perceived exertion (study 2). Normally distributed continuous variables are expressed as 
mean (SD). Statistical significance for this test was set at a p-value of ≤0.05. An effect size 
was also calculated to estimate the magnitude of the difference between groups. This 
provides a way to describe the meaningfulness of the differences, especially when the sample 
size is small. The size of the effect was classified according to the system proposed by Cohen 
(1988), where an effect size of 0.3 represents a small effect, one of 0.5 represents a moderate 
effect and one of 0.8 or above represents a large effect. All data was tested with Mauchly’s 
test of sphericity. The primary variable is the amount of salbutamol inhaled, being nil, 800 µg 
or 1600 µg. A total number of ten non-asthmatic males and thirteen non-asthmatic males and 
females completed all trials in Study 1 and Study 2 respectively. 
 
4.3 Results 
Study 1: 5 km Time-Trial Performance 
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Throughout all trials participants reported no side effects from inhalation of up to 1600 µg 
inhaled salbutamol. Due to a number of measurements errors associated with three 
participants which excluding them from analysis. Accordingly, the data from 7 participants 
were analysed. All participants were free from chest infection for at least 4 weeks prior to 
assessment; they were not taking any medication and there were no other health or medical 
contradictions to them taking part in the study as confirm by information provided on a 
physical activity readiness questionnaire. All participants were actively engaged in endurance 
running training (>45 minutes continuous running) at least 3 times per week and were 
members of a competitive team. All participants were free from asthma and bronchial 
hyperresponsiveness confirmed by the presentation of a negative Eucapnic Voluntary 
Hyperpnoea (EVH) challenge (Anderson et al., 2001). 
 
Performance trial in moderate environment (18ºC, 40% RH) 
All seven participants completed all three 5 km time-trial. No significant difference was 
noted for overall completion time between trials (see Figure 9). No significant difference was 
observed over each 1 km split between conditions (see Figure 10). Furthermore, over each 1 
km split no significant difference between conditions for mean: HR; VO2; VCO2; VE; and 
RER were observed (see Figure 11). There was no significant difference between conditions 
in the post 5 km time-trial blood lactate values (see Figure 11). At 2, 3 and 4 km RPE was 
significantly increased under the SAL800 and SAL1600 when compared to PLA (Figure 11d) 
(See Appendix 1 for results of 1-5 km time-trial).  
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Figure 9. Individual and mean ± SD 5 km time-trial performance in a moderate 
environment (18ºC, 40% RH) following the inhalation of placebo (PLA), 800 µg of 
salbutamol (SAL800) and 1600 µg of salbutamol (SAL1600). 
 
 
Figure 10. Average time in seconds in a moderate environment (18ºC, 40% RH) 
following the inhalation of placebo (PLA), 800 µg of salbutamol (SAL800) and 1600 µg 
of salbutamol (SAL1600). 
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a)   
b)  
c)   
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d)  
e)    
f)  
Figure 11. Mean ± SD for HR, VO2, VCO2, VE, RPE and Blood Lactate at each 1 km 
split of the 5 km time-trial (a-e) and post-5 km time-trial blood lactate (f) in a moderate 
environment (18ºC, 40% RH). * = SAL800 and SAL1600 significantly different from 
PLA. 
* 
* 
* 
* 
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Performance trial in hot environment (30ºC, 40% RH) 
All seven participants completed all three 5 km time-trial. No significant difference was 
noted for overall completion time between trials (see Figure 12). Furthermore, over each 1 
km split no significant time difference between conditions was observed (see Figure 13). 
Average VO2 during the 1st km was significantly greater (p=0.046) during PLA (3.941± 
0.490 L·min-1) when compare with SAL800 (3.591 ± 0.544 L·min-1) and SAL1600 (3.516 ± 
0.416 L·min-1) trials, however overall mean: HR; VO2; VCO2; and RPE during the 5 km 
time-trial were not significantly different between trials (see Figure 14). There was no 
significant difference between conditions in the post 5 km time-trial blood lactate values (see 
Figure 14; see Appendix 1 for results of 1-5 km time-trial). 
 
  
Figure 12. Individual and mean ± SD 5 km time-trial performance in a hot environment 
(30ºC, 40% RH) following the inhalation of placebo (PLA), 800 µg of salbutamol 
(SAL800) and 1600 µg of salbutamol (SAL1600). 
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Figure 13. Average time in seconds in a hot environment (30ºC, 40% RH) following the 
inhalation of placebo (PLA), 800 µg of salbutamol (SAL800) and 1600 µg of salbutamol 
(SAL1600).  
 
a)   
b)   
 90 
c)     
d)   
e)   
Figure 14. Mean ± SD for HR, VO2, VCO2, and RPE at each 1 km split of the 5 km 
time-trial (a-d) and post-5 km time-trial blood lactate (e) during 5 km time-trial in a hot 
environment (30ºC, 40% RH). 
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Lung Function Data: 
A significant difference in FEV1/FVC at baseline was observed following inhalation of 800 
µg, and 1600 µg of salbutamol (p<0.05). 
 
FEV1  FVC FEV1/FVC 
PLA SAL800 SAL1600 PLA SAL800 SAL1600 PLA SAL800 SAL1600 
Baseline 4.57 ± 0.86 4.61 ± 0.82 4.6 ± 0.91 5.37 ± 0.91 5.28 ± 1.01 5.24 ± 0.98 86.42 ± 3.4 
87.42 ± 
4.57 
87.57 ± 3.4 
Post-SAL 4.62 ± 0.85 4.68 ± 0.87 4.69 ± 0.94 5.30 ± 0.94 5.25 ± 0.94 5.24 ± 0.95 
87.14 ± 
3.43 
89.14 
±3.97 
89.42 ± 
4.11 
Post-run  4.60 ± 0.92 4.65 ± 0.96 4.67 ± 0.94 5.13 ± 0.99 5.13 ± 1.02 5.09 ± 1.01 
89.85 ± 
5.39 
91 ± 3.82 92 ± 4.65 
Table  8. Lung Function Data in moderate temperature (18ºC, 40% RH) and 3 
conditions. 
 
 
FEV1  FVC FEV1/FVC 
PLA SAL800 SAL1600 PLA SAL800 SAL1600 PLA SAL800 SAL1600 
Baseline 4.57 ± 0.88 4.58 ± 0.92 4.63 ± 0.90 5.27 ± 0.98 5.29 ± 0.97 5.30 ± 1.04 
87.57 ± 
4.39 
86.43 ± 
4.35 
87.29 ± 
3.90 
Post-SAL 4.58 ± 0.79 4.72 ± 0.90 4.71 ± 0.95 5.32 ± 0.93 5.28 ± 0.99 5.25 ± 1.05 
86.43 ± 
2.94 
89.14 ± 
3.53 
89.86 ± 
3.72 
Post-run  4.65 ± 0.94 4.73 ± 0.91 4.69 ± 0.91 5.12 ± 0.95 5.13 ± 0.99 5.17 ± 1.00 
90.43 ± 
4.61 
92.43 ± 
4.28 
90.86 ± 
3.93 
Table  9. Lung Function Data in hot condition (30ºC, 40% RH) and 3 conditions. 
 
Study 2: Football Specific Match-play 
All seven males and six females completed the 52 minutes football specific match-play. 
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Male results 
Under each of the three treatments no significant difference was observed in average sprint 
time, peak power, peak velocity, peak HR or peak lactate in the male players (Figure 14). 
During the football specific treadmill run male players demonstrated a significantly greater 
average VO2 during stage 1 in SAL1600 (1.906 ± 0.174 L·min-1) when compared with PLA 
(1.630 ± 0.119 L·min-1; p=0.01) and SAL800 (1.726 ± 0.267 L·min-1; p=0.04). HR was 
significantly greater in SAL1600 when compared to PLA and SAL800 during stages 1 to 5, 
and 7. VE was significantly greater in SAL1600 when compared to PLA in all seven stages. 
Blood lactate values were significantly greater in SAL1600 than PLA during stages 1, 4 and 
5. There was no significant difference during any of the stages in VCO2 or RPE (Figure 15). 
 
There was no significant difference in maximal lung function during the baseline 
measurements between treatments. At 10 minutes post-inhalation of SAL800 and SAL1600 
FEV1 was significantly greater than PLA (p=0.03). 5 minutes following the football specific 
run FEV1 was significantly greater in SAL1600 (p=0.05) and SAL800 (p=0.03) when 
compared to PLA. FEV1% was significantly greater (p=0.03) 5 minutes post-trial in SAL800 
when compared with PLA (see Table 10).  
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*=SAL1600 and SAL800 significantly greater than PLA 
*=SAL1600 significantly greater than SAL800 and PLA        
*= SAL1600 significantly greater than PLA 
+=SAL1600 significantly greater than PLA             
^=SAL1600 significantly greater than PLA and SAL800； 
*=SAL 800 significantly greater than PLA 
^=SAL1600 and SAL800 significantly greater than PLA           
+=SAL1600 significantly great than PLA and SAL800  
*= SAL1600 significantly greater than PLA 
^ = SAL1600 and SAL800 significantly greater the PLA 
Figure 15.  VO2, VCO2, HR, VE, blood lactate and RPE over the seven stages of the 
football specific match-play test following inhalation of Placebo (PLA), 800 µg of 
salbutamol (SAL800), or 1600 µg of salbutamol (SAL1600) in male players (mean ± SD) 
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 PLA SAL800 SAL1600 
Baseline 
FEV1 (l) 4.2 ± 0.5 4.3 ± 0.5 4.3 ± 0.5 
FEV1 predicted  102.4 ± 11.7 105.2 ± 12.7 105.1 ± 11.5 
FVC (l) 4.9 ± 0.59 5.0 ± 0.61 5.0 ± 0.66 
FVC predicted 102.1 ± 17.9 106.7 ± 22.9 101.6 ± 19.4 
EV1 % 85.6 ± 9.1 84.7 ± 10.3 85.1 ± 7.9 
10 minutes post-inhalation 
FEV1 (l) 4.2 ± 0.6 4.4 ± 0.4* 4.4 ± 0.5* 
FVC (l) 4.9 ± 0.6 5.0 ± 0.6 5.0 ± 0.6 
FEV1 % 84.7 ± 8.8 87.7 ± 6.8 88.3 ± 7.9 
5 minutes post-football specific run test 
FEV1 (l) 4.2 ± 0.5 4.4 ± 0.4* 4.4 ± 4.3* 
FVC (l) 4.8 ± 0.57 4.8 ± 0.5 5.0 ± 0.6 
FEV1 % 87.0 ± 9.8 92.7 ± 8.3* 89.4 ± 8.3 
*=significantly (p<0.05) greater than placebo (PLA)  
Table  10. Maximal Lung Function in Male Football Players following inhalation of 
Placebo (PLA), 800 µg of salbutamol (SAL800), or 1600 µg of salbutamol (SAL1600) 
(mean ± SD) 
Predicted values from European Coal and Steel Community (Quanjer et al., 1997). 
 
 97 
Female results 
Under each of the three treatments the female players demonstrated no significant difference 
in average sprint time, peak power, peak velocity, peak HR or peak lactate (Figure 17). 
During the football specific treadmill run VO2, VCO2, HR and RPE were not significant 
during any stage of the protocol between treatments. VE was significantly greater SAL1600 
(p=0.02) and SAL800 (p=0.03) when compare to PLA during stage one. During stages 5, 6 
and 7, VE was significantly greater in SAL1600 when compared to PLA (Figure 16).  
 
Maximal lung function did not differ between treatments at baseline, 10 minutes after 
inhalation of treatment or 5 minutes after the completion of the football specific run (see 
Table 11). 
 
 
 
 
 
a)  
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b)  
c)   
d)  
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e)  
f)   
*= SAL1600 significantly greater than placebo and SAL800  
^= SAL1600 sig greater than PLA  
Figure 16.  VO2, VCO2, HR, VE, blood lactate and RPE (a-f) over the seven stages of the 
football specific match-play (mean ± SD) following inhalation of Placebo (PLA), 800 µg 
of salbutamol (SAL800), or 1600 µg of salbutamol (SAL1600) in female players. 
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 PLA SAL800 SAL1600 
Baseline 
FEV1 3.4 ± 0.2 3.4 ± 0.3 3.4 ± 0.3 
FEV1 predicted  103.5 ± 5.5 102.7 ± 9.0 102.0 ± 9.1 
FVC 3.8 ± 0.3 3.8 ± 0.4 3.8 ± 0.3 
FVC predicted 101.3 ± 5.9 100.0 ± 7.8 98.8 ± 7.9 
FEV1 % 89.3 ± 1.4 89.5 ± 2.1 90 ± 1.9 
10 minutes post-inhalation  
FEV1 3.5 ± 0.3 3.5 ± 0.2 3.5 ± 0.3 
FVC 3.9 ± 0.4 3.8 ± 0.3 3.8 ± 0.3 
FEV1 % 89.7 ± 2.3 92.2 ± 2.2 92.3 ± 2.1 
5 minutes post-football specific run test 
FEV1 3.4 ± 0.3 3.5 ± 0.2 3.5 ± 0.3 
FVC 3.7 ± 0.4 3.8 ± 0.3 3.8 ± 0.4 
FEV1 % 92.7 ± 3.6 93.3 ± 3.3 93.3 ± 3.3 
Table  11. Female maximal lung function following inhalation of Placebo (PLA), 800 µg 
of salbutamol (SAL800), or 1600 µg of salbutamol (SAL1600) (mean ± SD) 
Predicted values from European Coal and Steel Community (Quanjer et al., 1997). 
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Urine Analysis 
Study 1 
Following inhalation of 800 µg of Salbutamol and a 5 km time-trial under temperate (18ºC; 
40% RH) and hot (30ºC; 40% RH) ambient conditions mean ± SD urine concentrations were 
122.96 ± 69.22 ng·mL-1 and 138.83 ± 98.11 ng·mL-1, respectively (see Figure 17). Following 
inhalation of 1600 µg of salbutamol and a 5 km time-trial, mean ± SD urine concentrations 
were 574.06 ± 448.17 ng·mL-1 and 270.32 ± 183.90 ng·mL-1 under temperate and hot 
ambient conditions, respectively (Figure 17). Whilst there were no significant differences 
between drug urine concentrations under either condition there was a high degree of inter-
individual variation following the inhalation of 1600 µg of salbutamol (Figure 18). Only one 
sample reached the WADA upper limit of 1000 ng·mL-1 (1190 ng·mL-1 (in the temperate 
environment) however; the sample failed to reach the decision limit of 1200 ng·mL-1. 
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Figure 17. Mean (± SD) urine SAL concentration (µg·mL-1) post 5 km time-trial under 
temperate (18ºC; 40% RH) and hot (30ºC; 40% RH) conditions following inhalation of 
800 µg (SAL800) or 1600 µg of salbutamol (SAL1600). 
 
 
Figure 18. Urine SAL concentration (ng·mL-1) post 5 km time trial under temperate 
(18ºC; 40% RH) and hot (30ºC; 40% RH) conditions following inhalation of 800 µg 
(SAL800) or 1600 µg of salbutamol (SAL1600). 
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Study 2 
Following inhalation of 800 µg and 1600 µg of salbutamol and completion of a football-
specific running protocol under temperate (20ºC, 40% RH) ambient conditions the cohort 
reported mean (± SD) urine drug concentrations of 250.91 ± 234.51 ng·mL-1 and 804.02 ± 
568.46 ng·mL-1, respectively. Whilst mean (± SD) urine drug concentrations following 
inhalation of 800 µg of salbutamol was 301.47 ± 294.47 ng·mL-1 in males compared to 
180.12 ± 102.15 ng·mL-1 in females there was no significant difference according to gender 
(see Figure 19). Likewise there were no significant sex differences in urine drug 
concentrations following inhalation of 1600 µg of salbutamol in male 739.24 ± 549.21 
ng·mL-1 and female 879.58 ± 633.14 ng·mL-1 participants (see Figure 19). Nevertheless there 
was a high degree of inter-individual differences in urine drug concentrations amongst male 
and female participants (see Figure 20). Whilst mean urine drug concentrations did not 
breach the WADA urinary threshold for salbutamol, two male and two female subjects 
recorded urine drug concentrations that exceeded the threshold (1000 ng·mL-1), of which, 
two cases were above the WADA decision limit set at 1200 ng·mL-1.   
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Figure 19. Mean (± SD) urine SAL concentration (ng·mL-1) post football-specific 
running protocol in temperate (20ºC, 40% RH) environment following inhalation of 800 
µg or 1600 µg SAL in male and female players. 
	
 
Figure 20. Individual urine SAL concentration (ng·mL-1) post football-specific running 
protocol in temperate (20ºC, 40% RH) environment following inhalation of 800 µg or 
1600 SAL in male and female players. 
 
Decision Limit	
Threshold	
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4.4 Discussion 
This is one of the first studies to examine the impact of inhaled salbutamol at a dose of 1600 
µg versus 800 µg and placebo on time-trial endurance running performance, as well as on 
simulated association football performance in male and female players. The results from the 
current study suggest that inhaling up to 1600 µg of salbutamol 15 minutes prior to a 5 km 
time-trial does not result in any performance improvement or change in physiological 
function; inhaling up to 1600 µg of salbutamol 15 minutes prior to a football specific 
treadmill performance test does not result in any sprint performance improvement in either 
male or female players. 
 
Furthermore, this study is also one of the first studies to examine the salbutamol elimination 
in urine following inhalation of salbutamol at a doses of 1600 µg and 800 µg and competitive 
endurance performance in moderate environment (18ºC; 40% RH) and hot environment 
(30ºC; 40% RH); the pharmacokinetics of inhaled salbutamol at a dose 1600 µg and 800 µg 
following a simulated association football performance in male and female players. 
 
The current urinary threshold imposed by WADA is intended to enable differentiation 
between the use of oral and inhaled salbutamol and also approved therapeutic use and misuse. 
Oral use is associated with performance enhancement since it typically represents doses in 
the region of 10 times that of inhaled use. Nevertheless there has been limited research to 
examine this association. From an endurance exercise perspective only (Collomp et al., 2000) 
has demonstrated enhanced performance whereby short-term oral administration of 
salbutamol (12 mg/day for 3 weeks) improved time to exhaustion during sub-maximal 
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cycling exercise. Caruso et al. (1995) and Martineau et al. (1992) have demonstrated an 
increase in muscle strength following prolonged oral administration of salbutamol. Indeed 
protein synthesis and muscle hypertrophy have been shown to be an effect of β2-agonist use 
in animal models, particularly long acting β2-agonists such as Clenbuterol. However, research 
is clearly required to examine further the claim that oral administration has a positive impact 
on sports performance.    
 
There exists some ambiguity in terms of the therapeutic use of inhaled salbutamol. Whilst the 
recommended salbutamol maximal dosing regimen is 100 µg to 400 µg up to four times 
daily, it is typically prescribed pro re nata (PRN; when required) which may add to the 
confusion. Individuals encouraged administering salbutamol PRN may dose over and above 
the maximal recommended daily dose of 1600 µg either intentionally or inadvertently, 
however in both instances individuals intent to dope for performance enhancement purposes 
may be nil. Such circumstances may lead to the current threshold being unintentionally 
breached and thus bring about an adverse analytical finding (AAF). Clearly individuals 
administering inhaled salbutamol up to, and above the 1600 µg dose indicates uncontrolled 
asthma. Desensitisation or tolerance is experienced by those regularly administering inhaled 
salbutamol, and it not only increases the risk of unsuccessful treatment in an emergency but 
also increases the likelihood of further overdosing in an attempt to control EIB.  
 
The current study demonstrates that the possibility of a urinary salbutamol concentration 
above the current threshold following therapeutic use is possible. However, whilst the 
threshold as stated by the Prohibited List is 1000 ng·mL-1 (WADA, 2013), according to the 
International Standards for Laboratories Technical Document (WADA, 2010) salbutamol 
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should only be reported as an AAF when detected at a concentration greater than 1200 
ng·mL-1, a level referred to as the ‘Decision Limit’. On this basis the urinalysis of the current 
study would not warrant any sample to be reported as an AAF. This finding was true for a hot 
(30ºC, 40% RH) as well as a temperate environment (18ºC, 40% RH). The range of 
salbutamol concentrations in this study are similar to Sporer et al. (2008) who reported urine 
concentrations of salbutamol up to 800 ng·mL-1 60 minutes post time trial following 
inhalation of 800 µg salbutamol. Elers et al. (2012) reported urine salbutamol concentrations 
peaked between 0-4 hours. They reported peak salbutamol concentration was 1057 ng·mL-1 
following 800 µg inhaled salbutamol. Nevertheless, in this study the inter-individual variation 
was high in both temperate and hot environments and combined with the low subject 
numbers caution is advised and future studies should aim to examine the impact of high dose 
salbutamol (1600 µg) administration on urine concentration following endurance 
performance to establish the likelihood of the Decision Limit being breached. In line with 
current anti-doping practice the current study did not normalize drug concentrations for urine 
specific gravity. Elers et al. (2012) demonstrated that when urine samples are corrected for 
specific gravity no urine samples following inhalation of 800 µg salbutamol breached the 
WADA Prohibited List threshold of 1000 ng·mL-1. Normalising urine samples for specific 
gravity may be considered by WADA consider in the future. 
 
Previous studies that have focused on inhaled salbutamol have generally focused on non-
specific performance trials such as exercise time to exhaustion or physiological markers of 
performance (Decorte et al., 2008; Sporer et al., 2008). Some previous studies have 
demonstrated no improvement following acute inhalation of up to 800 µg of salbutamol on 
running time to exhaustion, VO2max, peak power, 20 km cycling time-trial and total work 
during a 30 s Wingate test (Pluim et al., 2011). A study conducted by Koch et al. (2013) 
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demonstrated no performance enhancement in 10 km cycling time trial performance 
following 400 µg inhaled salbutamol in athletes with and without a positive EVH challenge. 
The data in this study complements previous research by focusing on running time-trial 
performance, football performance in male and female players and adds to the current body 
of knowledge by reporting on the current upper WADA limit of 1600 µg per day of inhaled 
salbutamol. Further to our data, a recent study by (Elers et al., 2011) suggested that inhaling 
an acute dose of up to 400 µg of salbutamol resulted in no improvement in cycling time to 
exhaustion or oxygen uptake kinetics. Accordingly, from a performance perspective the 
current WADA upper limit of 1600 µg per day appears appropriate for endurance events 
given the absence of improvement in performance in non-asthmatic athletes. 
 
The main action of inhaled salbutamol is to act as a bronchodilator to reverse the 
bronchoconstriction of airway smooth muscle. This results in the asthmatic airway becoming 
dilated leading to reduced airway resistance, leading to improvements in VE and exercise 
performance (Haverkamp et al., 2007). It has been suggested that inhaled salbutamol may 
result in a performance improvement by causing a significant bronchodilation in the airways 
of non-asthmatics leading to an improved VE and increased oxygen uptake during exercise. In 
this study we observed a non-significant 0.1 Litre improvement in FEV1 10 minutes post-
salbutamol inhalation, which did not result in an improvement in VE during the 5 km time-
trial following inhalation of 800 µg or 1600 µg of salbutamol when compared to placebo. 
Previous studies have demonstrated non-significant improvements in FEV1 of 0.2 Litre 
following inhalation of 800 µg, which also did not result in in greater VE or improved 
endurance performance (Decorte et al., 2008). Therefore there is no evidence available that 
up to 1600 µg of inhaled salbutamol results in significant bronchodilation, improved VE or 
improved endurance performance. 
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The aim of the present study was to devise a laboratory-based exercise protocol 
representative of football match-play work rates, to find out whether inhaled salbutamol has 
any improvement effects on football match performance on both males and females, and if 
the upper limit dosage according to WADA regulations is reasonable. Few studies have 
directly assessed oxygen consumption during games, as the collecting procedures interfere 
with normal play. A more usual approach when determining the aerobic contribution to 
energy expenditure during match-play is to monitor heart rate and subsequently estimate 
energy expenditure from the individual hear rate-VO2 relationship. Mean values of 70-75% 
VO2max have been attributed to football using such procedures (Reilly, 1990).  
 
It is well documented that inhaled salbutamol, despite the dosage or the medication involved, 
do not have any performance enhancing effects in healthy subjects (Carlesen et al., 1997; 
Fleck et al., 1993; Freeman et al., 1989; Heir et al., 1995; Larsson et al., 1997; McKenie et 
al., 1983; Meeuwisse et al., 1992; Morton et al., 1996; Sandsund et al., 1998; Sporer et al., 
2008; Stewart et al., 2002). Thus, only two studies have demonstrated a statistically 
significant effect of a single inhaled therapeutic dose of salbutamol (Bedi et al., 1988; 
Signorile et al., 1992). By our knowledge, this is one of the first studies to report the acute 
effects on performance in male non-athletes without asthma after a single, inhalant 
administered therapeutic dose of salbutamol. Both Collomp et al. (2005) and Van Baak et al. 
(2000) have previously shown an improvement both in time to exhaustion and 
(supra)maximal workload in healthy male athletes after orally administered salbutamol, but 
the subjects were not highly endurance trained.  
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One potential mechanism for salbutamol to have ergogenic properties may be related to its 
ability to act as a potent bronchodilator. Even in non-asthmatic individual, salbutamol has the 
ability to increase airway caliber, resulting in a measurable increase in airway function 
(Carlsen et al., 1997; Goubault et al., 2001; Heir % Stemshaug, 1995; Meeuwisse et al., 
1992; van Baak, et al., 2004). Theoretically, this may lead to enhanced alveolar ventilation 
and/or a reduced work of breathing, thereby increasing available oxygen for working 
muscles. However, previous reports have shown that during physical activity, salbutamol 
does not have an accumulative effect on the normal bronchodilatory response to exercise 
(Carlsen et al., 1997; Goubault et al., 2001; Heir % Stemshaug, 1995; Meeuwisse et al., 
1992; van Baak et al., 2004), nor does it reduce respiratory resistance (Pichon et al., 2005). 
Theoretically, it is unlikely that the bronchodilatory action of salbutamol and other β2-
agonists has an ergogenic effect in healthy non-athletes, because bronchoconstriction is not a 
performance-limiting factor. What should be remembered, though, is that several studies 
have demonstrated that elite endurance athletes have a huge demand to the pulmonary 
diffusing capacity, as the pulmoneus transit time is reduced to 1/3 second or less (Dempsey & 
Wagner, 1999; Harms et al., 2000; Miyachi & Tabata, 1992). Additionally, through up-
regulation of the sodium-up-regulation of the sodium-driven clearance of alveolar fluid, and 
consequently a reduced risk of pulmonary oedema, the use of β2-agonists may result in an 
improvement in the oxygen transfer from the alveoli to the arterial blood in elite endurance 
athletes with extreme demands to the oxygen transport system. 
 
Our current findings, the applicability of football-specific test results to sport performance 
enhancement is questionable. The validity of a test to be representative of performance is an 
important factor when evaluating the ergogenic effects of a treatment (Hopkins, 1999). There 
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were no significant changes in terms of VO2max under the three experimental conditions in 
male players; however, it does show a significant VO2max difference during stage 1 between 
SAL1600 and PLA. The result indicates that inhaled salbutamol at 1600 µg dosage may 
improve vital capacity, thus, the amount of inhaled salbutamol may enhance athletes’ oxygen 
uptake during football match at the very beginning, with an immediate short-period effect 
that may improve player’s performance, when the match starts during the low intensity 
exercise stage. Further more, when focusing on heart rate, we observed significantly greater 
result in 1600 µg salbutamol than 800 µg and placebo during stage 1 to 5, and 7; VE with 
1600 µg salbutamol intake is also significantly greater than Placebo in all stages; 1600 µg 
inhaled salbutamol has much greater effect on blood lactate values compare to Placebo in 
stage 1, 4 and 5; the results have indicated that 1600 µg inhaled salbutamol can possibly 
improve non-asthmatic male football players’ endurance performance during the match, 
which is differ from the previous studies, therefore, further investigate with bigger amount of 
male participants would be needed to prove the reliability of this result.  
 
In female players’ experimental group, this study did not find any statistically significant 
changes in VO2, VCO2, HR, RPE and blood lactate values between treatments. However, 
during stage 1, VE with both 1600 µg and 800 µg inhaled salbutamol have significant 
difference compare to Placebo; and in stage 5, 6, and 7, 1600 µg inhaled salbutamol has 
significant difference compare to Placebo. These results indicate that for female, no matter 
how much salbutamol they took, it may always has positive effect on player’s vital capacity, 
therefore improvement on performance endurance is possible at the beginning of the match 
when the exercise is in low intensity; deeper insight, 1600 µg inhaled salbutamol could 
improve the female players’ performance towards to a later stage and last for a while till the 
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end of the test. Therefore, the present study cannot support the suggestion of no effect on 
simulated association football (soccer) performance for both male and female players.  
 
One of the proposed ergogenic mechanisms for inhaled salbutamol is a significant 
bronchodilation in non-asthmatic athletes resulting in an improved VE during exercise and 
increase in oxygen uptake. In the present study an improvement in FEV1 10 minutes post-
salbutamol inhalation was observed in male players (0.1 Litre) but no improvement in female 
players. The improvement in FEV1 in male players of 0.1 Litre following inhalation of 
SAL800 and SAL1600 was significantly (p=0.03) greater than PLA. Regardless of FEV1 
improvements following salbutamol inhalation we observed increases in VE for a given work 
load during the stages of the football specific treadmill run test in both male and female 
players. Previous studies have demonstrated non-significant improvements in FEV1 of 0.2 
Litre following inhalation of 800 µg, which did not result in greater VE or improved 
endurance performance (Decorte et al., 2008). The low participant number could explain our 
observed significant increase in VE as one participant may significantly impact on the group 
mean. It remains clear that the changes did not impact on player sprint performance however; 
the differential FEV1 response between genders is unclear and requires further investigation. 
 
Previous research has attempted to examine the excretion of salbutamol administered by 
different routes including oral and inhalation (Pichon et al., 2006; Elers et al., 2012) and 
across a range of acute doses from 200 µg and 800 µg (Sporer et al., 2008) and repeated 
doses over several hours (Elers et al., 2011). The current research is the first to examine the 
urinary excretion of an acute, high dose in comparison with an intermediate dose amongst 
male and female association football (soccer) players. Whilst the findings did not suggest any 
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significant differences according to sex there was a large variation between individuals at the 
various doses. This large inter-subject variation confirmed the likelihood that individuals 
inhaling acute, high doses of salbutamol may exceed the current WADA urinary threshold of 
1000 ng·mL-1. Indeed the current research also shows that following such a dosing regimen 
may also result in urine salbutamol levels in excess of 1200 ng·mL-1. This concentration is 
significant since it represents a level referred to by WADA as the ‘Decision Limit’ above 
which a sample would be classified as an adverse analytical finding (WADA, 2010) and 
warrant further investigation.      
 
The maximal recommended dosing regimen for salbutamol clearly acts as an upper limit for 
those requiring immediate relief of asthma symptoms.  Individuals who regularly use high 
doses of salbutamol or exceed these recommendations clearly demonstrate poor management 
of their condition. There lies the problem from an anti-doping regulatory perspective when 
the evidence to support any ergogenic properties is not present and the likelihood of poor 
control of asthma and EIB are high. From a sports medicine perspective improved care may 
constitute better diagnosis, management and education amongst athletes. 
 
4.5 Conclusion 
Study 1 
This study demonstrated no improvement in 5 km running time-trial performance following 
the inhalation of up to 1600 µg of salbutamol in non-asthmatic athletes in moderate or hot 
environments. This would suggest that the current WADA guidelines, which allows athletes 
to inhale up to 1600 µg is sufficient to avoid pharmaceutical induced performance 
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enhancement. However, such high doses not only suggest poor management of asthma but 
also mean that an athlete may be at risk of contravening the current urinary threshold. 
 
Applicability for doping control and advantages over existing methods: 
• There is no improvement in performance following the inhalation of up to 1600 µg of 
salbutamol in non-asthmatic athletes in temperate or hot environments.  
o The current WADA guidelines, which allows athletes to inhale up to 1600 µg 
is sufficient to avoid pharmaceutical induced performance enhancement. 
• Inhalation of 1600 µg may result in a urine concentration above the current WADA 
limit and decision limit. 
o Further, larger studies are required to corroborate these findings. 
 
Study 2 
There is an improvement in performance following the inhalation of up to 1600 µg of 
salbutamol in non-asthmatic female association football (soccer) players. Furthermore, 
inhalation of 1600 µg may result in a urine concentration above the current WADA upper 
limit and decision limit leading to a positive test finding. Data from this study will assist 
WADA in the implementation of regulations on the use of inhaled short acting β2-agonist and 
assist in the resolution of contested doping violations. 
 
Applicability for doping control and advantages over existing methods. 
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• There is a possible improvement in performance following the inhalation of up to 
1600 µg of salbutamol in non-asthmatic male and female association football (soccer) 
players.  
o The current WADA guidelines, which allows athletes to inhale up to 1600 µg 
whether is sufficient to avoid pharmaceutical induced performance 
enhancement is still questionable according to the result from this study. 
• Inhalation of 1600 µg may result in a urine concentration above the current WADA 
limit and decision limit. 
o Further, larger studies are required to corroborate these findings. 
 
4.6 Limitations 
One of the limitations to these two studies is the variability in actual dose inhaled. Whilst the 
use of a chamber aimed to reduce this limitation it remains possible that some participants 
with low urine concentration inhaled lower doses of salbutamol. In addition future work 
should investigate whether there is a relationship between body weight and the urinary 
concentration of salbutamol. A lighter athlete may be at a greater risk of breaching the 
threshold when administering high doses compared to a heavier athlete. Such findings would 
have implications to the care athletes receive in the future. 
 
Because of the time, location, region and funding issues, not many participants’ data were 
valid for these studies and the total number of the samples was very limited. An increase in 
the number of participants may provide more robust findings. Further study is required in a 
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larger number of participants including a range of gender and ethnicity to ensure an 
avoidance of Type II error. A power calculation would suggest that to detect a change in 1% 
in sprint performance a sample size of 48 participants would be required. Study 1 only 
focused on the male participants. Since male and female may respond differently to the 
higher doses of salbutamol inhalation, future studies should examine on female athletes. 
However, certain improvement has been made to study 2, by introducing female participants 
in the football trial, even though the results hasn't shown any significant difference, yet the 
range of people have been enlarged. The same situation is related to the issue of ethnicity for 
both studies, which may also have an impact on the findings. Furthermore, the participants 
were not elite endurance athletes. Elite athletes could not be included in this study as they 
would have been at risk of a doping violation. Therefore we cannot claim our results directly 
represent the effects of inhaled salbutamol in elite endurance athletes. 
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CHAPTER V 
STUDY 3 
THE IMPACT OF ETHNICITY, GENDER 
AND DEHYDRATION STATUS ON THE 
PHARMACOKINETICS OF SHORT ACTING 
Β2-AGONISTS  
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5.1 Introduction 
Inhaled short acting β2-agonists are commonly used in the treatment of asthma, exercise 
induced bronchoconstriction (EIB) and airway hyperresponsiveness (AHR). The principle 
role of inhaled short acting β2-agonists is to act as a bronchodilator to reverse the 
bronchoconstriction of airway smooth muscle. This results in the asthmatic airway becoming 
dilated leading to reduced airway resistance and improvements in minute ventilation (VE). It 
has been suggested that inhaled salbutamol may result in a performance improvement by 
causing a significant bronchodilation in the airways of non-asthmatic individuals leading to 
an improved VE, increased oxygen uptake and exercise performance (Haverkamp et al. 
2007), however, there is limited evidence to suggest that inhaled doses of β2-agonist (200 to 
800 µg) have a significant ergogenic effect. The small numbers of studies that do exist have 
focussed on endurance performance and have reported no performance effect of up to 800 µg 
of inhaled short acting β2-agonist (Pluim et al., 2011).  
 
Whilst there appears to be no ergogenic effect from inhaled salbutamol at low doses (200 to 
800 µg), the World Anti-Doping Agency (WADA) recommends a daily upper limit is 1600 
µg (~16 inhalations of a standard salbutamol inhaler; WADA, 2012). A small number of 
studies have reported an absence of an ergogenic effect of high dose inhaled short acting β2-
agonist (up to 4000 µg; Elers et al., 2012) however; concern has been raised that inhalation of 
1600 µg in a single episode may result in urine concentrations close to the WADA upper 
limit of 1000 ng·mL-1 and, therefore, result in an adverse analytical finding (AAF).  
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A small number of recent studies have examined the impact of inhaling the WADA daily 
upper limit on urine concentrations. These studies have focussed on multiple dosing regimens 
such as 4 x 400 µg of salbutamol as opposed to a single high dose (Elers et al., 2011). Whilst 
athletes are usually prescribed 200-400 µg of inhaled salbutamol they are often instructed to 
use their inhaler pro re nata (i.e. on an as needed basis) that could be interpreted as a 
clearance to inhale unlimited amounts of salbutamol to combat respiratory symptoms. 
Individuals encouraged to administer salbutamol pro re nata may dose over and above the 
maximal recommended daily dose of 1600 µg either intentionally or inadvertently, however 
in both instances an individual intent to dope for performance enhancement purposes may be 
nil. Such circumstances may lead to the current threshold being unintentionally breached and 
thus bring about an AAF.  
 
A number of cases have been reported in the literature where athletes have tested positive 
following inhalation of high doses of short acting β2-agonists. Recently, a Rugby League 
player escaped a doping violation after he inhaled in excess of 1600 µg over the course of a 
match and then tested positive in the post-match anti-doping test. The player’s defense was 
based on the prescription on an‘as needed basis’ with no guidance on an upper limit to its 
use. Accordingly, in practice 16 inhalations in a short period of time prior to competition may 
occur in poorly controlled, less informed, as well as potentially unscrupulous athletes and yet 
still working within the recommended limit stated on the WADA 2012 Prohibited List. 
Because of the potential ergogenic effects of β2-agonists, particularly with oral doses, 
unauthorized use of salbutamol is closely monitored through doping control. Even for 
athletes possessing a TUE, a urine concentration of nonsulphated salbutamol (cSAL) greater 
than 1000 ng·mL-1 is considered an adverse analytical finding, which can result in 
suspension. This cutoff point has been questioned of late, with recent reports of positive test 
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results using inhaled therapeutic doses, all with urine concentrations well over 1000 ng·mL-1 
after exercise (McKenzie, 2004; Schweizer et al., 2004). Although the majority of urine 
samples reported in the literature rarely exceed 500 ng·mL-1 (Pichon et al., 2006; Ventura et 
al., 2000), it has been suggested that with individual variations in dose, changes in hydration 
status after competition, and the ability to absorb, metabolize, and excrete salbutamol, the 
possibility for elevated concentrations exists (McKenzie, 2004). The percentage of 
salbutamol exist in urine is due to the absorption ability of the subjects, therefore in this 
study, the participants were not restricted from intake any fluid before the test and the first 
sample of urine, but they are not allowed to drink any more fluid during the test until the last 
sample has been collected. In addition to the inhalation of high, single bolus doses of short 
acting β2-agonists the impact of dehydration through sweating associated with high intensity 
exercise in hot environments may have a profound effect on urine concentration however, 
limited data exists to support this hypotheis. 
 
WADA impose global regulations and as yet little is known of the impact of ethnicity on the 
pharmacokinetics of inhaled short acting β2-agonist and their subsequent appearance in the 
urine. To date, no studies have examined the impact of dehydration and ethnicity on the 
pharmacokinetics of short acting β2-agonists. Accordingly, the global purpose of this study 
was to contribute to the understanding of the impact of dehydration and ethnicity following 
the inhalation of short acting β2-agonists at doses up to and including the maximal dose (1600 
µg) as stipulated on the 2012 WADA Prohibited List.  
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5.2 Methods 
Prior to the commencing the study ethical approval was obtained from Liverpool John 
Moores University Local Ethics Committee (ethics no: 09E18GW). Eighteen male and 14 
female athletes (9 Caucasian males, 9 Caucasian Females, 2 Afro-Caribbean males, 2 Afro-
Caribbean females, 6 Asian males and 4 Asian females) were recruited for the study. All 
participants were free from asthma, EIB and AHR confirmed by no previous history of 
disease and presenting with a negative Eucapnic Voluntary Hyperpnoea (EVH) challenge 
(Anderson et al., 2001).  Participants were allowed to drink water ad libetum prior and post to 
testing, but not during the test. The presence of salbutamol in urine is associated with the 
absorption rate of the individual subjects, therefore in this study, the participants were not 
restricted from consuming fluid before the test and providing the first sample of urine, but 
they are not allowed to drink any more fluid during the test until the last sample had been 
collected. Body weight is measured after their intake of water, but prior to the start of the 
trials. All participants were free from chest infection for at least 4 weeks prior to assessment; 
they were not taking any medication and there were no other health or medical contradictions 
to them taking part in the study as confirm by information provided on a physical activity 
readiness questionnaire. All participants were physically active (30 minutes of organised 
exercise at least 3 times per week).  
 
Naked body mass (BM) was measured at baseline following an initial urine sample and 
inhalation of low (800 µg) or high (1600 µg) dose salbutamol. Body mass was then measured 
after every 20 minutes of self-selected exercise in a hot, controlled environment (35ºC, 40% 
relative humidity) until the target weight loss (2% or 5%) was achieved. Pre- and post-
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dehydration haematocrit and haemoglobin were measured for the derivation of blood volume. 
Participants were required to complete 4 trials as follows: 
• 2% reduction in body mass (BM), low dose (800 µg) inhaled short acting β2-agonist 
(2% BM 800 SAL) 
• 2% reduction in BM, high dose (1600 µg) inhaled short acting β2-agonist (2% BM 
1600 SAL) 
• 5% reduction in BM, low dose (800 µg) inhaled short acting β2-agonist (5% BM 800 
SAL) 
• 5% reduction in BM, high dose (1600 µg) inhaled short acting β2-agonist (5% BM 
1600 SAL) 
 
 
Figure 21. Time-line schematic of dehydration trial. 
 
 123 
Exercise in the Heat Chamber 
The heat chamber (T.I.SS Environmental Extremes; Peak Performance Chamber; Hampshire, 
UK) was set at a constant 35ºC and 40% relative humidity. Participants were asked to 
exercise in heat chamber at a self-selected pace for 20 minutes using a motorised treadmill 
(Woodway Ergo ELG 55 treadmill; Woodway GmbH, Weil am Rhein, Germany), cycling 
ergometer (Corival; Lode Holding Company B.V. Medical Technology, Groningen, the 
Netherlands) or rowing ergometer (Concept 2 Rowing; Model D, USA). Participants could 
change mode of exercise during this 20 minutes if they desired. Following 20 minutes 
athletes exited the environmental chamber to measure BM. If BM had not reached the target 
(2% or 5%) participants re-entered the heat chamber and completed another 20 minutes bout 
of self-paced exercise. Participants repeated this process until they reached their target BM. 
Participants were instructed to stop 2% BM trial after 2 hours of exercise if they had not 
achieved target BM. Participants were instructed to stop 5% BM trial after 4 hours of 
exercise if they had not achieved target BM. Water consumption during the trials was kept to 
an absolute minimum. Once participants had reached the target weight they were able to 
drink fluid ad libitum. 
 
Urine collection 
Prior to the commencement of each trial subjects were asked to provide a urine sample in 
order to void themselves of urine, after which salbutamol was administered as described 
above. Subjects were provided with water after the test, in order to be ensure urination within 
three hours after dehydrated, and they were instructed to collect the first sample of urine 
passed following completion of the laboratory-based tests in line with in-competition anti-
doping procedures as outlined in the World Anti-Doping Code International Standard for 
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Testing 2012 (the sample could be collected at home and handed in the next day as long as it 
was within 3 hours post-test, the subjects did not need to stay in the laboratory until they had 
urinated). Consumption of water during this period was encouraged ad libitum to ensure 
diuresis. From the sample provided by each subject a 20 mL aliquot of urine was stored at -
80ºC until analysis. 
 
Urinalysis 
All urinalysis was performed at HFL Sport Science (Fordham, UK) an independent drug 
surveillance laboratory and former WADA-accredited laboratory.  
 
Sample preparation involved the addition of 200 ng of salbutamol-D3 (NMI) as an internal 
standard to 1 mL of urine. Following the addition of 2 mL of 0.1 M phosphate buffer pH 6.8 
and 100 µL of E. Coli enzyme (β-glucuronidase) solution the mixture was incubated 
overnight at 37ºC. Strata XC 60 mg solid phase extraction cartridges (Phenomenex, 
Macclesfield, UK) were conditioned with 3 mL of methanol followed by 3 mL of reagent 
grade water. Following centrifugation at 3500 rpm for 5 minutes the samples were applied to 
the cartridges. The cartridges were then washed with 3 mL of 0.1 M acetate buffer pH 9.0 
followed by 3 mL of reagent grade water, 3 mL of 0.1 M HCl, 3 mL of methanol and 3 mL of 
diethyl ether. The cartridges were then dried for 5 minutes under vacuum and samples were 
eluted into glass vials with two, 1 mL of basic drug elution solvent (160 mL ethyl acetate, 34 
mL propan-2-ol and 6 mL 34% ammonia solution). Samples were then evaporated to dryness 
at ambient temperature using a centrifugal vacuum concentrator (Genevac Ltd, Ipswich, UK) 
and reconstituted in 10 µL of isopropanol followed by 200 µL of basic reconstitution solution 
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(495 mL of 0.1 acetic acid mixed with 5 mL Benzyldimethylphenyl Ammonium). Samples 
were centrifuged at 3000 rpm for 10 minutes prior to LCMS submission. Samples were 
injected onto a Thermo Scientific Accela HPLC system coupled to a Thermo Scientific LTQ 
Orbitrap Discovery Mass Spectrometer (Thermo Fisher Scientific, Waltham, USA). 
Chromatographic separation was performed on a Waters Atlantis T3 column (2.1 x 100 mm, 
particle size 3 um; Waters Ltd, Elstree, UK) at 35ºC. The mobile phase was a gradient system 
of 0.1% acetic acid aqueous solution containing uracil (300 ng·mL-1) and 0.1% acetic acid in 
acetonitrile containing uracil (300 ng·mL-1) set at a flow rate of 0.4 mL·min-1.  
 
The urine salbutamol concentrations reported correspond to the sum of the free and 
glucuronide conjugates. The samples were analysed over the calibration range of 10 to 2000 
ng·mL-1. Samples with salbutamol concentrations greater than the upper limit of 
quantification were diluted with blank human urine prior to analysis. The lower limit of 
quantification was accepted as the lowest standard on the calibration curve (10 ng·mL-1). 
 
Statistical Analysis 
That data was considered as a case series. A case series is a type of research study that tracks 
subjects with a known exposure, such as patients who have received a similar examination. 
Therefore, the results are compared in between different cases but according to the same 
individual. Accordingly, data are presented as individual raw data. Sample size was 
determined for the primary response variable (urine concentrations of salbutamol) in a 
repeated measures analysis of variance (ANOVA) design. The effect size and standard 
deviation were chosen based on previous literature investigating urine concentrations of 
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inhaled salbutamol at rest and after exercise (Elers et al., 2012; Sporer et al., 2008). To detect 
differences in the urine concentrations of salbutamol between the two conditions across three 
different ethic groups, at least 13 subjects should complete the study. With the risk of having 
drop-outs, there were 18 male and 14 female subjects in this study. 
 
Statistical analyses were done using the statistical software program SPSS (SPSS, Inc, 
Chicago, Illinois). Normally distributed continuous variables were expressed as mean (SD). 
Skewed data were presented as median (range). Paired data were compared by Wilcoxon 
signed rank test. Comparisons of 3 independent groups were done using the Mann-Whitney 
test. Urinary concentrations were corrected for urine specific gravity before analyses. Where 
appropriate descriptive statistics (Mean ± SD) for urine salbutamol concentrations were 
presented and differences according to sex and ethnicity were assessed using independent t-
tests and hydration status assessed using the paired t-test. A p-value of <0.05 was accepted as 
significant.  
 
5.3 Results 
All participants were able to achieve a 2% BM loss, however, a number of participants had 
difficulty in attaining a 5% BM loss during the trials. The range in exercise time to achieve a 
2% BM loss was 76.0 ± 28.8 minutes (range 50 – 80 minutes) in Caucasian Males to 102.5 ± 
15.0 minutes (80 - 110 minutes) in Afro-Caribbean Males (Table 12). The range in exercise 
time to achieve a 5% BM loss was 213.8 ± 39.6 minutes (range 140 - 240 minutes) in 
Caucasian Males to 240.0 ± 0.0 minutes in all other ethnic and gender categories (See Table 
12). 
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 Caucasian Female Caucasian Male Asian Female Asian Male Afro-Caribbean 
Female 
Afro-Caribbean 
Male 
 Mean Range Mean Range Mean Range Mean Range Mean Range Mean  Range 
2% 
BM 
800 
SAL 
105.7 ± 
32.07 
50 – 
140 
92.0 ± 
37.9 
50 – 
170 
83.8 ± 
10.6 
50 – 
110 
80.0 ± 
22.7 
50 – 
110 
85.0 ± 
7.1 
80 – 90 102.5 ± 
15.0 
80-110 
2% 
BM 
SAL 
96.7 ± 
20.7 
80 – 
130 
76.0 ± 
28.8 
50 – 
110 
84.3 ± 
20.7 
50 – 
110 
76.25 ± 
19.2 
50 – 
110 
99.0 ± 
26.9 
80 – 
120 
87.5 ± 
28.7 
50 – 
110 
5% 
BM 
800 
SAL 
240.0 ± 
0.0 
240 – 
240 
213.75 
± 39.6 
140 – 
240 
240.0 ± 
0.0 
210 – 
240 
235.7 ± 
11.3 
210 – 
240 
240.0 ± 
0.0 
240 – 
240 
230 ± 
20.0 
200 – 
240 
5% 
BM 
1600 
SAL 
233.3 ± 
16.3 
240 - 
240 
226.3 ± 
26.7 
170 - 
240 
240.0 ± 
0.0 
240 - 
240 
240.0 ± 
0.0 
240 - 
240 
240.0 ± 
0.0 
240 - 
240 
240 ± 
0.0 
240 - 
240 
Table  12. Mean (± SD) and range of exercise time (minutes) to achieve target body 
mass (BM) percentage loss in each trial. 
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a)     
b)    
c)     
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d)    
e)     
f)    
Figure 22. Mean (± SD) %BM loss during each trial for male and female Caucasian, 
Asian and Afro-Caribbean participants. 
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Following inhalation of 800 µg of salbutamol and exercise in a heat chamber (35ºC and 40% 
relative humidity) the total cohort reported mean (± SD) urine drug concentrations of 188.35 
± 146.62 ng·mL-1 and 363.92 ± 284.84 ng·mL-1 under conditions of two and five percent 
dehydration, respectively. Following inhalation of 1600 µg of salbutamol and exercise under 
similar conditions the cohort reported mean (± SD) urine drug concentrations of 1055.37 ± 
981.03 ng·mL-1 and 1059.81 ± 709.33 ng·mL-1 under conditions of two and five percent 
dehydration, respectively. Relative dehydration was shown to have significant difference on 
the urine drug concentration following inhalation of 800 µg of salbutamol (t20 = -2.897, P = 
0.009) whereas no significant difference was found according to hydration status following 
inhalation of 1600 µg of salbutamol. Nevertheless, there was a high degree of inter-individual 
variation throughout the cohort following administration of 800 µg and 1600 µg salbutamol 
under both conditions (Figure 23). 
 
 
Figure 23. Urine drug concentration in all participants following inhalation of 800 µg or 
1600 µg salbutamol under dehydration of 2% and 5% of body mass. 
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This inter-individual variation was explored further in terms of ethnicity (see Figure 24). 
Following inhalation of 800 µg of salbutamol and exercise in a heat chamber (35ºC and 40% 
relative humidity) the mean (± SD) urine drug concentrations of 160.24 ± 99.78 ng·mL-1, 
263.38 ± 255.54 ng·mL-1 and 260.35 ± 185.13 ng·mL-1 under conditions of two percent 
dehydration were reported for Caucasian, Asian and Afro-Caribbean groups, respectively. 
Following inhalation of 800 µg of salbutamol and under conditions of five percent 
dehydration mean (± SD) urine drug concentrations of 323.36 ± 234.87 ng·mL-1, 209.05 ± 
108.41 ng·mL-1 and 612.25 ± 388.70 ng·mL-1 were reported for Caucasian, Asian and Afro-
Caribbean groups, respectively. Following inhalation of 1600 µg of salbutamol and under 
conditions of two percent dehydration mean (± SD) urine drug concentrations of 841.86 ± 
960.92 ng·mL-1, 937.46 ± 494.67 ng·mL-1 and 2757 ± 1068.29 ng·mL-1 were reported for 
Caucasian, Asian and Afro-Caribbean groups, respectively. Following inhalation of 1600 µg 
of salbutamol and under conditions of five percent dehydration mean (± SD) urine drug 
concentrations of 930.29 ± 532.55 ng·mL-1 and 1149.20 ± 884.50 ng·mL-1 were reported for 
Caucasian and Asian groups, respectively. Whilst subject number was particularly low in the 
Afro-Caribbean cohort, differences in urine drug concentrations were assessed following 
administration of either 800 or 1600 µg of salbutamol between Caucasian and Asian subjects 
under conditions of two and five percent dehydration. With 95% confidence, no significant 
statistical differences were found between ethnic groups (Caucasian and Asian subjects; p 
value under each condition is between 0.147 and 0.910).  
 
 
 
 
 132 
A
 
 
B  
Figure 24. Urine drug concentration following inhalation of 800 µg or 1600 µg 
salbutamol under dehydration of 2% (A) and 5% (B) body mass in different ethnic 
groups (Asian; Caucasian; Afro-Caribbean) 
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The elimination of varying doses of inhaled salbutamol under conditions of both two and five 
percent dehydration was also examined according to sex (see Figure 25). Whilst mean (± SD) 
urine drug concentrations following inhalation of 800 µg of salbutamol under conditions of 
two percent dehydration was 196.84 ± 162.93 ng·mL-1 in males compared to 177.03 ± 127.75 
ng·mL-1 in females there was no significant difference according to sex. Likewise there were 
no significant sex differences in urine drug concentrations following inhalation of 800 µg of 
salbutamol under conditions of five percent dehydration in male (Mean = 473.87 ± 340.85 
ng·mL-1) and female (Mean = 242.97 ± 142.04 ng·mL-1) participants. Mean (± SD) urine 
drug concentrations under conditions of two percent dehydration following inhalation of 
1600 µg of salbutamol were 1197.58 ± 1156.35 ng·mL-1 and 872.52 ± 694.57 ng·mL-1 for 
male and female participants respectively. Under conditions of five percent dehydration urine 
salbutamol levels following a dose of 1600 were 1027.81 ± 684.98 ng·mL-1 and 1088.24 ± 
770.60 ng·mL-1 for male and females respectively. Urine drug concentrations under both 
conditions of hydration status (2% and 5%) were not statistically significant according to sex.   
A   
 134 
B    
Figure 25. Urine drug concentration following inhalation of 800 µg or 1600 µg 
salbutamol under dehydration of 2% (A) and 5% (B) body mass amongst male and 
female subjects 
 
Further differentiation of the data set is illustrated in Figure 26 whereby male and female 
urine drug concentrations are categorised according to ethnic group. Whilst the data set 
attributed to Afro-Caribbean is particularly small, where possible descriptive statistics for 
Caucasian and Asian subjects are presented in Table 13. Therefore, the only significant 
difference found in these data was the urine concentration under each condition following 
inhalation of 800 µg of salbutamol, despite gender or ethnicity; whereas no significant 
difference when observed following inhalation of 1600 µg of salbutamol. As for inter-
individual, no significant differences were found between genders or ethnicities.  
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B   
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C   
Figure 26. Urine drug concentration following inhalation of 800 µg or 1600 µg 
salbutamol under dehydration of 2% and 5 % body mass amongst male and female 
Caucasian (A), Asian (B) and afro-Caribbean (C) subjects. 
	
 Caucasian Female Caucasian Male Asian Female Asian Male 
 Mean ± SD Mean ± SD Mean ± SD Mean ± SD  
2% BM 800 
SAL 
142.2 ± 78.34 178.29 ± 119.53 - - 246.60 ± 291.88 
2% BM 1600 
SAL 
586.52 ± 700.63 1097.20 ± 1150.89 1343.93 ± 286.06 666.48 ± 413.60 
5% BM 800 
SAL 
238.76 ± 149.48 436.17 ± 292.27 - - - - 
5% BM 1600 
SAL 
919.53 ± 592.20 946.43 ± 515.51 - - 667.97 ± 221.23 
Table  13. Mean and ± SD urine drug concentrations (ng·mL-1) following inhalation of 
800 µg or 1600 µg salbutamol under dehydration of 2% and 5 % body mass amongst 
male and female Caucasian and Asian subjects. 
 137 
5.4 Discussion 
This is the one of the first studies to investigate the impact of inhalation of up to 1600 µg of 
Salbutamol concomitant to a 5% BM loss through dehydration on urine salbutamol 
concentration. Our study demonstrates that following the inhalation of 1600 µg as a single 
dose resulted in several AAFs, hence exceeding the decision limit of the current WADA 
regulations that impose a urinary drug threshold of 1200 ng·mL-1 for salbutamol (WADA, 
2015). This concentration is significant since it represents a level referred to by WADA as 
the ‘Decision Limit’ above which a sample would be classified as an adverse analytical 
finding (AAF; WADA, 2015) and warrant further investigation. Whilst our findings do not 
suggest significant differences according to sex or ethnic origin there is a large variation 
between individuals at the various salbutamol doses and %BM loss. This large inter-subject 
variation confirms the likelihood that individuals inhaling acute, high doses of salbutamol 
and exercising in conditions that may results in BM loss, may present with an AAF.  
 
The current WADA urinary threshold (1000 ng·mL-1) and decision limit (1200 ng·mL-1) are 
based upon research that was able to provide a distinction between 1600 µg inhaled 
salbutamol (8 x 200 µg doses over a 24 hour period) and 20 mg oral salbutamol (Ventura et 
al., 2000). This research demonstrated that inhaled cumulative doses up to 1600 µg of 
salbutamol were unlikely to result in a urine concentration above 500 ng·mL-1, whereas 20 
mg oral salbutamol would result in a urine salbutamol concentration above 1400 ng·mL-1 
(Ventura et al., 2000). Others have added to this research by attempting to examine the 
excretion of salbutamol administered by different routes including oral and inhaled (Pichon et 
al., 2006; Elers et al., 2012) and across a range of acute doses from 200 µg and 800 µg 
(Sporer et al., 2008) and repeated doses over several hours (Elers et al., 2011). None of this 
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previous research investigating inhaled salbutamol doses within the WADA limit of 1600 µg 
over a 24 hour period has demonstrated it is possible to exceed 1000 ng·mL-1. However, the 
previous research has not examined acute doses up to 1600 µg. A recent case report 
suggested a urine salbutamol concentration in excess of 1000 ng·mL-1 may be possible with 
acute, high dose administration of inhaled salbutamol within the recommended daily dose 
(1600 µg; Schweiser et al., 2004).  
 
The purpose of the current WADA regulations that impose a urinary drug threshold of 1000 
ng·mL-1 for salbutamol (WADA, 2012) is to distinguish legitimate therapeutic use from 
misuse. Supporting such a threshold are maximal dosing recommendations of 1600 µg per 
day (WADA, 2012), with recommended dosing regimens between 100 and 400 µg up to four 
times daily. Our study adds to the previous existing data by asking participants to inhale the 
entire WADA 24 hour limit of 1600 µg inhaled salbutamol in a single dose. The rationale 
behind this is that athletes are regularly prescribed salbutamol pro re nata (when required). 
Individuals encouraged to administer salbutamol pro re nata may dose over and above such 
recommendations, for therapeutic purposes, either intentionally or inadvertently. In such 
cases athletes are at risk of exceeding the WADA threshold and in doing so, facing possible 
anti-doping sanctions. Given the results of this study it may be appropriate to educate athletes 
and support staff around the use of salbutamol and provide guidelines on the misuse (inhaled 
doses >800 µg) of salbutamol that may result in salbutamol levels exceeding the 1000 ng/mL 
threshold value. 
 
Similar to previous studies (Elers et al., 2011; Elers et al., 2012; Sporer et al., 2008; Pinchon 
et al., 2006; Ventura et al., 2000) we observed a high variability between individuals across 
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gender and ethnicity. Individual inhalation techniques and different deposition of the drug 
and thereby bioavailability might explain some of the variation between subjects. We did try 
to reduce this by requiring participants to inhale salbutamol via a pocket chamber to increase 
the dose of salbutamol that was inhaled into the lower airways.  
 
Other than under the 800 µg drug condition there was no significant difference in urine drug 
concentrations according to individuals’ hydration status equivalent to either 2% or 5% loss 
in body mass. Nevertheless it is clear from the current work that hydration status per se is a 
critical factor in relation to doping control and the likelihood of approaching or indeed 
breaching the current urinary threshold for salbutamol. In line with current anti-doping 
practice the current study did not normalised drug concentrations for urine specific gravity. 
The results would however suggest that WADA consider introducing such analysis in an 
attempt to negate the impact on hydration status on doping control tests.          
 
While the administered dose of 1600 µg salbutamol as a single inhaled dose used in the 
present study exceeds that considered as normal therapeutic treatment, athletes are often 
medically advised to inhale the amount that is needed to relieve asthma symptoms pro re 
nata (McKenzie & Fitch, 2011; Price et al., 2014). Atheles using salbutamol may inhale 
repetitive doses prior to a warm-up and again before and after competition (Price et al., 2014; 
Elers et al., 2011). Indeed, doping case reports have shown that athletes inhale salbutamol 
repetitively during competition (Elers et al., 2011; Schweizer et al., 2004). Athletes should as 
such be aware that supratherapeutic inhalation of the maximal allowed for salbutamol may 
increase the risk of presenting with a urine sample that exceeds the decision limit for 
salbutamol in doping control. Although doping cased of salbutamol were only reported 11 
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times in 2013 (World Anti-Doping Agency, 2015), it is important that athletes are not at risk 
of a false positive doping control test after inhalation within the current anti-doping 
regulations. As shown in Figure 25 of this study, large inter-individual differences exist in the 
urine excretion of salbutamol, while some individuals may exceed the decision limit for 
salbutamol when 1600 µg is inhaled as a single dose. Timing of urine sampling also has an 
impact on the concentration of salbutamol, with most of the AAFs observed within the first 4 
hours of sampling (Figure 25). Importantly, athletes that present an AAF of salbutamol in 
doping control are given the opportunity to prove that the AAF was due to therapeutic use 
through a pharmacokinetic study. Lung function is another factor may affect the absorption 
of salbutamol (Schmekel, et al., 1992; Khazaeinia, et al., 2000; Lipworth, 1996). Exercise 
also affects blood distribution (Khazaeinia et al., 2000; Kamimori et al., 1990), as cardiac 
output is re-directed to exercising muscles, and secondly that water will be driven from 
plasma to the muscles and the interstitial space surrounding the muscles (Costill & Fink, 
1974; Harrison et al., 1975). Nevertheless, given the large inter-individual difference in the 
urine salbutamol concentration observed in the present and previous studies after oral and 
inhaled administration (Eler et al., 2010; Hostrup et al., 2014; Elers et al., 2012; Elers et al., 
2011), it does not appear that blood samples are suitable for doping control purposes in the 
case of salbutamol.  
 
In conclusion 2% BM loss and greater concomitant with acute inhalation of 1600 µg of 
salbutamol may result in a urine concentration above the current WADA upper limit and 
decision limit leading to a false positive test finding. Although 1600 µg of inhaled salbutamol 
as a single dose exceeds that considered as normal therapeutic treatment, athletes using 
salbutamol should be made aware of this risk. This finding is independent of gender or ethnic 
origin. Data from this study will assist WADA in the implementation of regulations on the 
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use of inhaled short acting β2-agonist and assist in the resolution of contested doping 
violations. 
 
Applicability for doping control and advantages over existing methods. 
 
• A fluid loss of 2% body mass or greater concomitant with acute inhalation of 1600 µg 
of Salbutamol may result in a urine concentration above the current WADA upper 
limit and decision limit leading to a positive test finding, irrespective of gender or 
ethnic origin. 
o The current WADA guidelines, which allows athletes to inhale up to 1600 µg 
daily may result in a positive test when fluid loss of 2% body mass or greater . 
The current WADA upper limit and decision limit should be re-assessed in 
light of these findings 
 
5.5 Limitations 
A limitation to our study is the variability in actual dose inhaled. Whilst the use of a chamber 
aimed to reduce this limitation it remains possible that some participants with low urine 
concentration inhaled lower doses of salbutamol. In addition future work should investigate 
whether there is a relationship between body weight and the urinary concentration of 
salbutamol. A lighter athlete may be at a greater risk of breaching the threshold when 
administering high doses compared to a heavier athlete. Such findings would have 
implications to the care athletes receive in the future. Another limitation is with a relatively 
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wide group of ethic individuals, the number of participants within Afro-Caribbean and Asian 
groups were very small; this is due to the difficulties of recruitment. Small number of data in 
each group may affect the generality of the results. Furthermore, it may affect the comparison 
results across different groups. Future studies should look to recruit a larger number of 
subjects across ethic groups in order to improve the reliability of the data. The subjects were 
not elite athletes also limited the result of the present study. Nonetheless, previous 
pharmacokinetic studies found no difference in the urine concentrations of salbutamol 
between athletic and non-athletic subjects or between asthmatics and non-asthmatics after 
oral and inhaled administration (Elers et al., 2011; Elers et al., 2012). Therefore, the present 
findings may be applicable for WADA. 
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CHAPTER VI 
STUDY 4 
THE ERGOGENIC EFFECT OF CAFFEINE 
& THEOBROMINE ON 3 KM RUNNING 
PERFORMANCE  
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6.1 Introduction 
A number of nutritional products have been used in the treatment of asthma. Of note, caffeine 
and theobromine are commonly employed in asthma treatment associated with their influence 
on respiratory smooth muscle leading to bronchiodilation. In addition to their use as 
nutraceuticals caffeine and theobromine have been examined for their performance 
enhancing potential, caffeine to a far greater extent compared with theobromine. 
 
Caffeine, a non-specific adenosine receptor antagonist, is a bitter, white crystalline purine, a 
methylxanthine alkaloid, and is closely related chemically to the adenine and guanine 
contained in deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). It peaks in the blood 
30-40 minutes after ingestion of a 72 mg dose (Mumford et al., 1996). Caffeine can be found 
in a variety of food sources including: coffee, tea, soft drinks, chocolate, and kola nuts. 
 
Schirlitz first evidenced the possible ergogenic effect of caffeine in laboratory in 1930 (cited 
in Jacobson and Kulling, 1989), and some early findings (Ive et al., 1979; Costill et al., 1977) 
have examined the role of caffeine in enhancing athletic performance across a range of 
sports, using different doses as well as controlling for other conditions. Since these early 
findings research in this field has expanded rapidly leading to a large body of evidence 
supporting caffeine as a powerful ergogenic aid (Jenkens et al., 2008; Mc Naughton et al., 
2008; Desbrow et al., 2012; Gonzalez, 2012).  
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Caffeine was on the WADA banned list from 1962 to 1972 and then 1984 till 2003 when it 
was placed on the monitored list in order to monitor the possible potential of misuse in sport. 
It was then removed from the Prohibited List because many experts believe it to be 
omnipresent in beverages and food and that having a threshold might lead to athletes being 
sanctioned for social or dietary consumption of caffeine (Prohibite List, 2012). Furthermore, 
caffeine has only been demonstrated to be ergogenic at doses lower than those that result in a 
urine concentration of 12 µg/mL (Graham, 2011). In addition, urinary caffeine concentrations 
can very considerably because it is metabolized at very different rate in individuals (Fenster 
et al., 1998), and does not always correlate to the dose ingested. 
 
Theobromine is a caffeine derivative and metabolite found primarily in chocolate. It is highly 
fat soluble; peaking in the plasma 1-2 hours after ingestion (Mumford et al., 1996). An 
adenosine receptor antagonist, theobromine appears to have equal affinity for A1 compared to 
A2A receptors, while caffeine shows a slightly lower affinity for A1 receptors (Macht & 
Dettmer, 2006). Theobromine has one-tenth the stimulant effect of caffeine, but with a longer 
half-life in the body (Mumford, 1994). Theobromine is widely consumed in the diet and is 
currently used in metabolism-enhancing sporting supplements for its stimulant effects 
(Pearce et al., 2012). Furthermore, theobromine is not prohibited or restricted in any form by 
the WADA. 
 
Very few studies have investigated the behavioral effects of theobromine, and thus no clear 
conclusions can yet be made about its psychoactive profile. Although two early reports found 
null mood effects from theobromine (Brunk et al., 1973; Dorfman & Jarvik, 1970), a more 
recent study by Mumford et al. (1994) showed that 5 out of 7 subjects were able to 
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discriminate a high dose of theobromine (560 mg) from a placebo or caffeine dose. The 
combination of caffeine (19 mg) and theobromine (250 mg) in capsules increased the self-
reported mood construct “energetic arousal”, and improved cognitive function as measured 
with a simple reaction time test (Smit, 2004) compared to placebo capsules.  
 
An increasing amount of evidence in the last decade has showed that theobromine has 
psychoactive actions in humans and effect on blood pressure that are qualitatively different 
from those of caffeine (Mitchell et al., 2011; Baggott et al., 2013, Mitchell et al., 2011). One 
possible reason for the conflict in the effects of caffeine and theobromine could be their 
different half-life. In recent years, theobromine is starting to be widely studied to examine 
common and differential mechanisms with caffeine.  
 
This study examined the impact of caffeine and theobromine compared with placebo on 
endurance exercise in a group of non-asthmatic recreational athletes. It was hypothesized that 
caffeine and theobromine would have no improvement effect on 3 km running performance 
in non-asthmatic athletes. 
 
6.2 Methods 
Subjects  
Prior to the commencing the study, ethical approval was obtained from Liverpool John 
Moores University Local Ethics Committee (ethics approval code: 12/SPS/042). Ten male 
athletes (mean ± SD; age 22.4 ± 4.3 years; height 175.9 ± 3.9 cm; body mass 74.5 ± 9.9 kg) 
 147 
were recruited for the study. All participants were free from asthma and EIB and AHR 
confirmed with no previous history of disease and presenting with a negative Eucapnic 
Voluntary Hyperpnea (EVH) challenge (Anderson et al., 2001). All participants were free 
from chest infection for at least 4 weeks prior to assessment; they were not taking any 
medication and there were no other health or medical contradictions to them taking part in the 
study as confirm by information provided on a physical activity readiness questionnaire. All 
participants were actively engaged in endurance running training (>45 minutes continuous 
running) at least 3 times per week. Participants were asked to refrain from ingesting 
foodstuffs containing methylxanthines, such as caffeine (coffee) and theobromine (chocolate) 
for 24 hours prior to testing due to the half-life of caffeine and theobromine. 
 
Each of the participants was required to complete three, 3 km time-trial. Trials were 
conducted in the same laboratory, on the same treadmill (Woodway Curve, Woodway, USA) 
and under similar temperature and humidity environment (18ºC; 40% RH). During their first 
visit, participants completed a pre-trial questionnaire and provide written informed consent 
prior to the measurement of body mass (kg) and stature (cm). Fifteen minutes prior the 
initiation of each 3 km time-trial participants consumed one of the following in a randomized, 
single-blind fashion: placebo (sugar pill); caffeine (6 mg/kg body mass); or theobromine (6 
mg/kg body mass).  
 
3 km Running Time-Trial 
Participants were familiarized to running on a non-motorised treadmill (Woodway Curve, 
Woodway, USA) prior to initiating the 3 km time-trial. Familiarisation runs took place over a 
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distance of 3 km on at least two occasions. Paticipants progressed to the recorded 3 km time-
trial once they felt comfortable pacing themselves on the non-mortorised treadmill over the 3 
km distance. 
 
Each time-trial was conducted under controlled laboratory conditions in temperate of 18ºC, 
humidity of 40% RH environment. Participants completed three 3-km running time-trial 
following the administration of a placebo, caffeine (6 mg/kg BM) or theobromine (6 mg/kg 
BM) in a randomized, cross-over, single-blind fashion. The caffeine, theobromine and 
placebo were adminstered 30 minutes prior to the start of the time trial. Prior to starting the 
time-trial participants were fitted with a heart rate monitor (Polar RS400; Polar Electro Oy, 
Kempele, Finland) and connected to a breath-by-breach gas analyser via a facemask (Oxycon 
Pro, Jagear, Wuerzberg, Germany). Over the course of the 3 km time-trial the following were 
measured every 500 meters during each trial: average heart rate (HR), oxygen uptake (VO2), 
carbon dioxide production (VCO2), minute ventilation (VE), respiratory exchange ratio 
(RER), and rating of perceived exertion (RPE). Two minutes following the completion of the 
3 km time-trial capillary blood lactate was measured (Lactate Pro, Arkray KDK, Japan). 
Spirometry was used to measure lung function pre- and 20 minutes post-administration of 
placebo, caffeine or theobromine. Following a 10 minutes free warm-up, participants were 
asked to begin the 3 km time-trial. During the time-trial all participants were able to observe 
the distance covered, however, no feedback related to time, speed, or heart rate (HR) was 
provided. In addition to completion time, Spirometry was obtained immediately after each 
time-trial.  Participants were encouraged to complete the time-trial as fast as possible with 
prizes offered to the five fastest times. During the time-trial consistent positive 
encouragement was given to each participant. 
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Figure 27. Schematic of participant protocol on day of each 3 km time-trial 
 
Eucapnic Voluntary Hyperpnea (EVH) Test 
In-line with the previous studies in this thesis and to maintain consistency across studies, 
participants were free from asthma evidenced by an EVH test prior to the start of testing to 
exclude asthma or Exercise Induced Bronchoconstriction (EIB). Three baseline maximal 
flow-volume loops were measured using a commercially available spirometer (ML3500, 
Cardinal Health, Basingtoke, UK), 10 minutes after inhalation of placebo, caffeine and 
theobromine and then 10 minutes post 3 km time-trial. On each occasion maximal flow 
volumes were measured according to the European Respiratory Society criteria (Miller et al., 
2005). Flow-volume values were taken from the flow-volume loop with the best combined 
Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC) calculated. 
Each participant then completed an EVH challenge test (Anderson et al., 2001) involving 6 
minutes hyperventilation at approximately 85% of maximal voluntary ventilation (30 x 
baselines FEV1) pre-determined from their maximal flow volume loop. Maximal flow 
volume loops were measured at baseline and at 3, 5, 7, 10 and 15min following completion of 
the challenge. A fall of >10% in FEV1 from baseline was considered positive.  
 
Statistical analysis 
Maximal Flow 
Volume Loops 
Inhalation of 
PLACEBO, 
CAFFEINE OR 
THEOBROMINE 
Maximal Flow 
Volume Loops 3 km Time Trial 
Maximal Flow 
Volume Loops 
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Statistical analyses were performed using the statistical software program SPSS (SPSS, Inc., 
Chicago, IL), and a one-way analysis of variance (ANOVA) was performed to compare 
differences in time, heart rate, oxygen consumption, minute ventilation, respiratory exchange 
ratio, rating of perceived exertion. A paired t-test was performed to compare differences in 
blood lactate. Normally distributed continuous variables are expressed as mean (± SD). 
Statistical significance for this test was set at a p-value of <0.05. An effect size was also 
calculated to estimate the magnitude of the difference between groups. This provides a way 
to describe the meaningfulness of the differences, especially as the sample size is small. The 
size of the effect was classified according to the system proposed by Cohen (1988), where an 
effect size one of 0.2 represents a small effect, one of 0.5 represents a moderate effect and 
one of 0.8 or above represents a large effect. All data was tested with Mauchly’s test of 
sphericity. The primary variable is the active ingredient consumed, being nil, 6 mg/kg BW 
caffeine or 6 mg/kg BW theobromine.  
 
6.3 Results 
 
All ten participants successfully completed all three 3 km time-trial. The mean (± SD) body 
mass and stature of the athletes were 74.5 (± 9.9) kg and 175.9 (± 3.9) cm, respectively. All 
participants were free from chest infection for at least 4 weeks prior to assessment; they were 
not taking any medication and there were no other health or medical contradictions to them 
taking part in the study as confirm by information provided on a physical activity readiness 
questionnaire. All participants were free from asthma and bronchial hyperresponsiveness 
evidenced by a negative Eucapnic Voluntary Hyperpnea (EVH) test. All participants were 
actively engaged in endurance running training (>45 minutes continuous running) at least 3 
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times per week. Throughout all trials participants reported no side effects from consumption 
of caffeine or theobromine. 
 
3km Time-Trial Performance 
No significant difference was noted for overall completion time between trials (p = 0.844; see 
Figure 28). In addition to completion time, heart rate (HR), oxygen uptake (VO2), Rating of 
Perceived Exertion (RPE), minute ventilation (VE), were assessed every 500 meters during 
each trial following intake of placebo, caffeine or theobromine; blood lactate was assessed 
pre- and post-test (Figure 29). Overall mean: time (p = 0.133); HR (p = 0.676); VO2 (p = 
0.492); VE (p = 0.344); and RPE (p = 0.774) during the 3 km time-trial were not significantly 
different between trials (see Figure 29a-e). There was no significant difference between 
treatments in the post 3 km time-trial blood lactate values (p = 0.897; see Figure 29f). 
 
Of note, performance following the administration of caffeine (6 mg/kg) showed significant 
time improvement from the 2 km recording point of the time-trial (p<0.05), which was 
further increased throughout the time-trial (see Figure 29a). Theobromine showed a relatively 
slower enhancement of performance time, however towards to the end of the test, 
theobromine showed a bigger difference compare to caffeine (see Figure 29a). Furthermore, 
over each 500 metres split of the time-trial: from 1 km to the end, HR was significantly 
increased under theobromine (p<0.05), but no difference was found under caffeine for each 
recording point (see Figure 29b); VO2 was significantly increased under caffeine from 1 km to 
the end, the increase occurred under theobromine was at 1.5 km (see Figure 29c). 
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0.5km 1km 1.5km 2km 2.5km 3km 
PLA 199.0 ± 21.6* 395.8 ± 36.7 610.7 ± 51.7* 833.7 ± 71.6 1057.6 ± 95.2*^ 
1260.6 ± 
110.7*^ 
CAF 
181.5 ± 
17.76* 375.8 ± 29.6 579.1 ± 44.2* 798.0 ± 82.0 986.5 ±78.7* 1168.7 ± 78.1* 
THE
O 185.9 ± 16.3 383.8± 29.3 587.2 ± 43.7 798.5 ± 51.4 990.4 ± 61.4^ 1176.5 ± 75.2^ 
Table  14. Time (s) per 500 meters following the Administration of Placebo, Caffeine 
and Theobromine. * = Caffeine vs. Placebo (p<0.05), ^ = Theobromine vs. Placebo 
(p<0.05), ϕ = Caffeine vs. Theobromine (p<0.05). 
	
 
Figure 28. Individual and mean ± SD 3 km time-trial performance under each 
treatment. 
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a)   
b)                 
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    c)      
 
  d)    
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  e)     
 
  f)    
Figure 29. Mean ± SD for time, HR, VO2, VE, RPE and blood lactate at each 500 m 
point during the 3 km time-trial following the administration of placebo, caffeine or 
theobromine. 
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Lung Function 
There was no significant difference in FEV1 (p=0.060) between placebo, caffeine and 
theobromine at any time point. A significant difference was observed when comparing post-
run FVC (Litres) following the administration of placebo and theobromine (p=0.015). A 
significant difference was also observed between pre- and 20 minutes post-administration of 
theobromine (p=0.025). This, in turn, showed a significant difference in comparing post-run 
FEV1/FVC (%) following the administration of placebo and theobromine (p < 0.05) and a 
significant different between pre- and 20 minutes post-administration of theobromine (p < 
0.05).  
 
 
Figure 30. FEV1 at Baseline, Post Administration and Post Run. 
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Figure 31. FVC at Baseline, Post Administration and Post Run. 
	
 
Figure 32. FEV1/FVC at Baseline, Post Administration and Post Run. 
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6.4 Discussion 
The purpose of this study was to explore the effects of caffeine or theobromine consumption 
on 3 km time-trial running performance in non-asthmatic recreational athletes compared with 
placebo. The findings of this study suggest that both caffeine and theobromine have no 
significant effect on 3km time-trial performance at a dose of 6 mg/kg BM. However, a small 
improvement was observed with both caffeine and theobromine towards to the end of each 
trial, with caffeine’s impacting performance earlier than theobromine. 
 
Caffeine with a concentration > 12 µg/mL in the urine was considered doping, and was on the 
WADA banned list from 1962 to 1972 and then 1984 untill 2003 when it was placed on the 
monitored list in order to monitor the possible potential for misuse in sport. In opposition to 
this move by WADA, caffeine has been demonstrated to be ergogenic at doses lower than 
those that result in a urine concentration of 12 µg/mL, and higher doses appear to reveal no 
additional performance enhancing effect (Graham, 2011). A large number of athletes tested 
positive for caffeine during the second banned period. The sanctions ranged from warnings 
up to 2-year suspensions, although suspensions usually were only 2 to 6 months. According 
to WADA, one of the reasons caffeine was removed from the Prohibited List was that many 
experts believe it to be omnipresent in beverages and food and that having a threshold might 
lead to athletes being sanctioned for social or dietary consumption of caffeine (Prohibited list, 
2012). Furthermore, urinary caffeine concentrations can very considerably because it is 
metabolized at very different rate in individuals (Fenster et al., 1998), and does not always 
correlate to the dose ingested. 
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Ivy et al. confirmed the ergogenic effect of caffeine on athlete’s performance as early as 
1979, reporting that total work output was increased after the ingestion of 250 mg caffeine. 
Since some early findings about caffeine could be a powerful ergogenic aid, the research in 
this field has expanded rapidly. Researchers tested the ergogenic effect of caffeine on 
different types of sports, using different doses as well as controlling for other conditions. 
Jenkins et al. (2008) found that the cycling performance was significantly improved in 13 
cyclists following the administration of low doses of caffeine (2-3 mg/kg) compared with 
placebo conditions. A more recent study by Desbrow et al. (2012) investigated this effect 
following the ingestion of two different doses of caffeine, 3 mg/kg and 6 mg/kg, using a 
randomised, placebo controlled, double-blind design. The results demonstrated a significant 
improvement in cycling performance with a dose of 3 mg/kg of caffeine, but no additional 
improvement was observed with of the higher caffeine intake (6 mg/kg).  
 
Of note, the present study investigated the ingestion of 6 mg/kg of caffeine, and found no 
significant difference in overall time-trial performance compared to placebo. However, there 
was a significant difference towards to the end of the time-trial recording point till the end of 
the test (the final 1 km), suggesting that the comsumption of 6 mg/kg caffeine may have a 
positive impact on endurance exercise, but only at the end of the exercise, for a relatively 
short period. One possible explanation why the improvement appeared at such late stage was 
because the timing of caffeine ingestion was too close to the beginning of the test (30 
minutes), most previous studies administered it at least one hour prior of the test (Costill et 
al., 1978; Graham et al., 1998).  
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Of note, similar to the results in the present study, there are a small number of studies 
reporting no ergogenic effect on work performance when participants received a high dose of 
caffeine, including endurance performance (Cameron et al., 1990; Tarnopolsky, 2008; Davis 
& Green, 2009; Mora-Rodriguez et al., 2012; Butts, 1985; Grossman & Sutton, 1985; 
Goniewicz et al., 2013; Ryder, 1994; Martinsen & Sundgot-Borgen, 2012). Perkins and 
Williams (1975) performed an exercise to exhaustion under four different conditions: 
placebo; caffeine doses in 4 mg/kg; 7 mg/kg; and 10 mg/kg. The results demonstrated no 
significant difference in time to exhaustion between different doses compared with placebo. 
Butts and Crowell (1985) made a similar conclusion in time to exhaustion at 75% VO2max 
with a dosage of 300 mg caffeine. 
 
Not only does caffeine impact endurance, it has been reported to benefit cognitive function 
and fine motor skills (Foskett et al., 2009). Accordingly, caffeine is commonly used by 
athletes as an ergogenic aid due to its associated reduction in fatigue, and enhancement of 
concentration and alertness (Paluska, 2003). Trained athletes benefit from a moderate dose of 
5 mg/kg (Woolf et al., 2008), although lower doses of caffeine (1.0-2.0 mg/kg) may improve 
performance (Cox et al., 2002). Another reason explains why caffeine is widely used in 
competitive activities might be its small but significant paregoric effect (Derry et al., 2012), 
possibly mediated by augmenting plasma endorphin concentrations (Grossman & Sutton, 
1985). It is also defined that caffeine reduces the rate of perceived exertion during exercise 
(Doherty & Smith, 2005), proposing that athletes are able to undertake higher intensities but 
do not perceive this effort to be different from placebo conditions. 
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Mattew et al. (2013) demonstrated that theobromine responses differed according to dose 
with limited subjective effects at 250 mg and negative mood effects at higher doses. They 
also observed a dose-dependent increased in heart rate. Accordingly, their study concluded 
that theobromine at normal intake ranges may contribute to the positive effects on exercise 
performance, but at higher intakes the performance effects become negative. In the present 
study, theobromine showed a significant increase in heart rate at 1 km of time-trial whereas 
no heart rate increase under caffeine; and an improvement on performance from 2 km in 
time-trails, which is later than that observed with caffeine (from 1.5 km). The results of the 
present study suggest that the ingestion of caffeine results in a greater rapid enhancement on 
running performance than theobromine. The slower action of theobromine compared with 
caffeine may be associated with theobromine acting as a weaker analogue of caffeine (Becker 
& Simons, 1985). This suggested that caffeine is more efficient in performance enhancement 
than theobromine should be viewed with caution given the limited scope of this study. 
Longer distances, higher doses and variable times of ingestion prior to exercise are required 
to further explore this hypothesis. 
 
According to the report from Mumford et al. (1994), caffeine increased subjective alertness 
in subjects, whilst theobromine did not, and Mitchell et al. (2011) for the first time found that 
theobromine did not act as an incentive alone or combined with caffeine, however, it may 
have a tension-raising effect. In conclusion, caffeine has strong alerting effects with 
inappreciable contribution from theobromine; caffeine produced ergogenic effects at early 
time points, while theobromine decreased calmness at a later time point; caffeine may have 
more CNS-mediated effects on alertness and theobromine may be acting mostly via 
peripheral physiology. Further investigations examining the combination of caffeine and 
theobromine are indicated. 
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The performance improvement contributions of theobromine are less clear and its 
psychoactive effects appear subtle compared to caffeine. Mumford (1994) postulated that 
theobromine is one tenth as potent as caffeine. Pharmacological assays also confirm that 
theobromine is less active than caffeine. Furthermore, individual variation in sensitivity to 
caffeine and theobromine is likely to play a role in the ergogenic efficacy of these 
compounds. Similar to caffeine, the ingestion of lower doses of theobromine may result in 
performance improvement, however at higher doses may causes a negative effect. 
 
6.5 Conclusion 
The results of the present study suggested that the consumption of caffeine and theobromine 
at a high dose of 6 mg/kg BM have no improvement on 3 km time-trial running performance 
in non-asthmatic athletes. However, theobromine appeared to enhance performance during 
the later stages of the time-trial to a similar magnitude as caffeine (6 mg/kg BM), with the 
ingestion of caffeine resulting in a more rapid enhancement of running performance than 
theobromine. The present study suggests theobromine abuse may provide an ergogenic effect, 
which propses a field of future research to examine whether an upper limit of use for 
theobromine should be proposed on WADA list.  
 
6.6 Limitation 
One of the limitations to this study was the small sample size. An increase in the number of 
participants may provide more robust findings. Furthermore, the present study focused on 
male participants. Since male and female may respond differently to the caffeine or 
theobromine inhalation, future studies should examine on female athletes. The issue of 
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ethnicity is exists in this study, which may have an impact on the findings. Of note, the 
participants were not elite endurance athletes. Therefore, the results of the present study may 
not directly represent the effects of caffeine or theobromine in elite endurance athletes. There 
is no test for combining consumption of caffeine and theobromine together for the athletes 
while doing the 3 km time-trial, therefore this study failed to find out the inter-relationship 
between caffeine and theobromine, only the differences. For future study, should examine the 
combination of caffeine and theobromine to examine possible interactions on performance. 
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CHAPTER VII 
GENERAL DISCUSSION 
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7.1 Implications 
Exercise-induced bronchoconstriction (EIB) is a pulmonary disorder that result in a 
narrowing of the airways and a measurable reduction in lung function. This limitation may 
have a negative effect on exercise performance for athletes in comparison with their 
unaffected competitors (Kindermann et al., 2007). Short-acting β2-agonists are the most 
commonly prescribed medication for the acute control of EIB. In 2002, The International 
Olympic Committee (IOC) established the requirement for athletes to present evidence of 
current asthma, EIA, EIB or AHR through the therapeutic use exemption (TUE) process. 
These regulations, guided by the IOC Medical Commission, were based on health not doping 
(performance enhancing) concerns for athletes in light of a marked increase in the 
notification by athletes for the use of inhaled short acting β2-agonist from 3.7% in Atlanta, 
1996, to 5.7% in Sydney, 2000 (Fitch et al., 2008). A study conducted by Dickinson et al. 
(2005) provided support for the health justification of adding inhaled short acting β2-agonist 
to the prohibited substances list in the Sydney, 2000 and Athens, 2004 Great Britain Olympic 
Team. Their data demonstrated that the establishment of a TUE for inhaled short acting β2-
agonist had no impact on the proportion of Team GB presenting with asthma, EIA, EIB or 
AHR (c. 21% at both Olympic Games) however; it identified a number of athletes with false 
positive diagnoses and athletes who had not been previously identified. Accordingly, it was 
concluded that the requirement of demonstrable evidence through the TUE process improved 
the quality of care for athletes. Furthermore, data from others (Dickinson et al., 2006a; 
Dickinson et al., 2006b; Anderson et al., 2003; Rundell et al., 2004; Parsons et al., 2007) has 
demonstrated the improved diagnostic sensitivity and specificity of objective, bronchial 
provocation tests of airway function as part of the TUE process. 
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Of the four β2-agonists (salbutamol, terbutaline, formoterol, and salmeterol) allowed, 
salbutamol is most commonly used, and there is growing concern that non-asthmatic athletes 
are using inhaled salbutamol in an attempt to gain a competitive advantage (Pluim et al., 
2011). The main action of inhaled salbutamol is to act as a bronchodilator to reverse the 
bronchoconstriction of airway smooth muscle. These results in the asthmatic airway 
becoming dilated leading to a reduced airway resistance and improvements in VE, increased 
oxygen uptake and exercise performance in asthmatics (Haverkamp et al., 2007). 
Accordingly, a number of studies have examined the impact of acute and chronic inhalation 
of short-acting β2-agonists on exercise performance. The vast majority of these studies have 
focussed on endurance performance (Pluim et al., 2011). 
 
Furthermore, previous studies that have focused on inhaled salbutamol have generally 
focused on non-specific performance trials such as running time to exhaustion or 
physiological markers of performance (Kindermann et al., 2007). These previous studies 
have demonstrated no improvement following acute inhalation of up to 800 µg of salbutamol 
on running time to exhaustion, VO2max, peak power and total work during a 30s Wingate test 
(Pluim et al., 2011). In supportting of these findings and agreement with the findings in study 
1 and 2, a number of previous studies have reported no ergogenic effect of acute inhalation of 
short-acting β2-agonists on overall performance i.e. 20 km cycling performance and running 
to exhaustion (Pluim et al., 2011).  
 
Study 1 and 2 of this thesis are one of the first to examine the impact of inhaled salbutamol 
up to the World Anti-Doping Authority (WADA) recommended upper limit dose in a 24 hour 
period of 1600 µg versus 800 µg and placebo on time-trial endurance running performance 
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and simulated association football performance in male and female athletes. Furthermore, 
these studies are the first to examine the pharmacokinetics of inhaled salbutamol at a dose of 
1600 µg and 800 µg following endurance and simulated association football performance in 
male and female athletes in temperate (18ºC; 40% RH) and hot (30ºC; 40% RH) 
environments. 
 
The FIFA (Fédération Internationale de Football Association) has stated that the fundamental 
aims of doping controls and anti-doping policies to prevent any doping behavious, the 
policies are (FIFA Anti-Doping Regulations, 2016): 
- to uphold and preserve the ethics of sport; 
- to safeguard the physical health and mental integrity of the player; 
- to ensure that all competitors have an equal chance. 
 
There are many individual cases and programs were suspended by UEFA (The European 
football union) or FIFA after testing positive in doping test accoss 9 different countries in 
Europe (including Albania, Argentina, Australia, East Germany, England, France, Italy and 
Spain) in the recent decades (UEFA, 2007; BBC News, 2000; A-League, 2008; Focus 
Online, 1994; Hamburger Abendblatt, 2007; BBC Sport, 2003; The Daily Telegraph, 2008; 
ABC Sport, 2006). FIFA applies the minimum two-year ban for first-time offenders, 
however, there are exceptions. When a player accused of doping can prove the substance was 
not intended to enhance performance (i.e. inhalation of salbutamol for asthma or EIB), FIFA 
can reduce the sanction to a warning in a first offense, a two-year ban for a second offense 
and lifetime ban in case of repetition (The Associated Press, 2006). Therefore, in order to 
 168 
avoid misjudgement, it is important for footballers to understand the maximum dosage of 
salbutomal to inhale at each time/day when it is used for necessary treatment. 
 
To date, there are no published studies examining the impact of inhaled short acting β2-
agonists on team game performance. Given the global importance of team games such as 
football (soccer) it is imperative that the performance impact of inhaled short acting β2-
agonists be examined to support their inclusion in the WADA prohibited substance list. 
Accordingly, Study 2 investigated the ergogenic impact of salbutamol up to the WADA 
upper limit in associated football (soccer).  
 
The results from Study 2 add to the current body of knowledge by focusing on an intermittent 
team sport, association football (soccer). No significant improvement in performance 
following the inhalation of up to 1600 µg of salbutamol was found in study 1, which suggests 
that the current WADA list of banned substances, which allows athletes to inhale up to 1600 
µg in a 24 hour period is sufficient given the findings from this and previous studies. It is 
clear that salbutamol in a single bolus up to the WADA permitted daily limit of 1600 µg has 
no ergogenic effect on endurance performance. Further to our data, a recent study by (Elers et 
al., 2012) reported that inhaling an acute dose of up to 4000 µg of salbutamol resulted in no 
improvement in cycling time to exhaustion or oxygen uptake kinetics. According to Study 2 
however, there is a possible improvement in performance following the inlalation of up to 
1600 µg of salbutamol in non-asthmatic male and female association football (soccer) plers, 
it shows ergogenic effect on sprint, repeated sprint performance. Further studies with larger 
amount of participants are required, to corroborate whether inhalation of up to 1600 µg is 
sufficient to avoid pharmaceutical induced team performance enhancement according to 
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current WADA guidelines. Accordingly, from a performance perspective the current WADA 
upper limit of 1600 µg per day appears appropriate for endurance and team (multi-sprint) 
events given the absence of improvement in performance in non-asthmatic athletes. 
 
There exists some ambiguity in terms of the therapeutic use of inhaled salbutamol. Whilst the 
recommended salbutamol maximal dosing regimen is 100 to 400 µg up to four times daily, it 
is typically prescribed pro re nata (PRN; when required) which may lead to confusion. 
Individuals encouraged to administer salbutamol PRN may dose up to the upper daily limit 
acutely (1600 µg) or over and above the maximal recommended daily dose either 
intentionally or inadvertently, however, in both instances individuals intent to dope for 
performance enhancement purposes may be nil. Such circumstances may lead to the current 
urinary threshold being unintentionally breached and thus bring about an adverse analytical 
finding (AAF). Clearly individuals administering inhaled salbutamol up to, and above the 
1600 µg dose indicates uncontrolled asthma. Desensitisation or tolerances are experienced by 
those regularly administering inhaled salbutamol, which not only increases the risk of 
unsuccessful treatment in an emergency but also increases the likelihood of further 
overdosing in an attempt to control EIB.  
 
The current urinary threshold imposed by WADA is intended to enable differentiation 
between the use of oral and inhaled salbutamol and also approved therapeutic use and misuse. 
Oral use has been linked with performance enhancement since it typically represents doses in 
the region of 10 times that of inhaled use, which is absorbed directly into the systemic 
circulation. Care is warranted in the continued promulgation of this assumed hypothesis as 
there has been limited research to examine this association. A small number of animal studies 
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have reported increased protein synthesis and muscle hypertrophy following the 
administration of oral β2-agonists, particularly long acting β2-agonists such as Clenbuterol 
(Beermann, 2002). From an endurance performance perspective in humans, only Collomp et 
al. (2000) have demonstrated enhanced performance whereby short-term oral administration 
of salbutamol (12 mg·day-1 for 3 weeks) improved time to exhaustion during sub-maximal 
cycling exercise.  (Caruso et al., 1995) and (Martineau et al., 1992) have demonstrated an 
increase in muscle strength following prolonged oral administration of salbutamol (16 
mg/day) The paucity of research examining the impact of oral salbutamol indicates the need 
for future research to examine further the claim that oral administration has a positive impact 
on sports performance.   
 
The maximal recommended dosing regimen for salbutamol acts as an upper limit for those 
requiring immediate relief of asthma symptoms. Whilst there is no ergogenic impact on 
acute, single bolus inhalation of this upper limit, individuals who regularly use high doses of 
salbutamol or exceed these recommendations clearly demonstrate poor management of their 
condition. There lies the problem from an anti-doping regulatory perspective when the 
evidence to support any ergogenic properties is not present and the likelihood of poor control 
of asthma and EIB are high leading to a potential anti-doping violation in the absence of 
performance enhancement. From a sports medicine perspective improved care may constitute 
better diagnosis, management and education amongst athletes. 
 
In addition to the absence of published data examining team games the factors effecting the 
presentation of a doping violation following the administration of therapeutic doses of short 
acting β2-agonists remains unclear. The impact of prior exercise (competition), sporting 
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discipline (body composition), gender and race on the pharmacokinetics of short acting β2-
agonists has received little attention. The impact of environmental factors, in particular those 
environments leading to perturbations in hydration status, have been previously cited by 
athletes as a defence of a positive doping test. Exercise-induced sweat loss concentrates the 
urine, thus leading to a higher urine concentration of β2-agonists (Lipworth, 1996; Dickinson 
et al., 2014; Hostrup et al., 2014). Sporer et al. (2008) observed that the urine concentrations 
of salbutamol were close to exceeding the urinary threshold in exercising subjects after 
inhalation of 800 µg. It is likely that the urinary threshold and decision limit for salbutamol 
would have been exceeded in that study, if subjects had inhaled the maximal allowed dose of 
1600 µg salbutamol. Real-life doping control is mostly conducted immediately after a 
competitive event or a training session. Athletes using β2-agonists, usually inhale them a 
prophylaxis prior to competition or training (McKenzie & Fitch, 2011; Price et al., 2014). 
While athletes typically inhale repetitive doses of salbutamol below the current therapeutic 
threshold of 1600 µg, the 2015 WADA anti-doping regulations for salbutamol allow 
inhalation of 1600 µg as a single dose. Therefore, pharmacokinetic data of the maximal 
allowed dose of 1600 µg salbutamol conducted during exercise in hydrated and dehydrated 
state in controlled settings are important to evaluate the WADA urinary threshold and 
decision limit for salbutamol on the list of prohibited substances. To date, not much data is 
available examining the impact of hydration status on the pharmacokinetics of inhaled short 
acting β2-agonists and the resultant effect on urine concentration. Studies in this area will 
better define the upper normal limit following therapeutic administration of inhaled short 
acting β2-agonist across different populations of athletes together with the impact of 
hydration status on urine concentrations. 
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There has been some concern expressed recently regarding the potential impact of 
dehydration on the urine concentration of salbutamol with claims that athletes inhaling up to 
the WADA limit may present with an AAF leading to sanctions. Findings from study three of 
this thesis demonstrates that following the inhalation of 1600 µg of salbutamol and in the 
presence of dehydration up to 5% body mass, it is possible to present with a urine salbutamol 
concentration above the current WADA threshold of 1000 ng·mL-1 (WADA, 2012). 
Furthermore, study three also demonstrated that following such a dosing regimen may also 
result in a urine salbutamol concentration in excess of 1200 ng·mL-1. This concentration is 
significant since it represents a level referred to by WADA as the ‘Decision Limit’ above 
which a sample would be classified as an adverse analytical finding (AAF) and warrant 
further investigation (WADA, 2012). Of note, whilst the findings from study 3 do not suggest 
any differences according to gender or ethnic origin, there are large inter-individual 
variations between at the various salbutamol doses and %BM loss. This large inter-subject 
variation confirms the likelihood that individuals inhaling acute, high doses of salbutamol 
and exercising in conditions that may results in body mass loss, may present with an AAF. 
Study three is the first to investigate the impact of up to 1600 µg of inhaled salbutamol 
concomitant to a 2% and 5% body mass (BM) loss through dehydration on urine salbutamol 
concentration in a multi-ethnic population. 
 
Following performance trials and in the absence of forced dehydration, study 3 demonstrated 
the possibility of a urinary salbutamol concentration above the current threshold following 
therapeutic use. However, the findings from study 1 and 2 would not warrant any sample to 
be reported as an AAF. This finding was true for a hot (30ºC, 40% RH) as well as a temperate 
environment (20ºC, 40% RH). Nevertheless, the inter-individual variation was high in both 
temperate and hot environments and combined with the low subject numbers caution is 
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advised and future studies should aim to examine the impact of high dose Salbutamol (1600 
µg) administration on urine concentration following endurance and team game performance 
to establish the likelihood of the Decision Limit being breached.  
 
Caffeine, taken prior to exercise, has been shown to be an effective prophylaxis for EIB 
(Inman, 1996), and has been examined by many previous studies. Vanhaitsma (2010) 
comparative study on effects of Caffeine and β2-agonists for asthmatic athletes, showed that 
in athletes with asthma and EIB, moderate (6 mL/kg body mass) to high doses (9 mL/kg body 
mass) of caffeine provide a significant protective effect against EIB, and that a high dose of 
caffeine is equally as effective as salbutamol in attenuating the bronchoconstrictor response 
to exercise. Whilst the action of theobromine on the central nervous system (CNS) is 
generally considered weak or non-existent, a small number of studies have reported that 
theobromine primarily acts a diuretic and a bronchial smooth muscle relaxant, and it as 
another methylxanthine with potential bronchodilator properties, has been under researched. 
Theobromine is an active ingredient of bronchodilator drugs that are used in the treatment of 
acute and chronic asthma, and persistent cough (Irwin, 1997). The IOC does not consider 
theobromine an illicit substance in humans, though their administration to racing animals is 
prohibited. A large evidence base exists for the performance enhancing effects from caffeine. 
In contrast, little is known of the ergogenic effect of theobromine. 
 
Caffeine has been shown to enhance several different modes of exercise performance 
including endurance (Graham & Spriet, 1995; Ivy et al., 1979; Hogervorst et al., 2008; 
Graham et al., 1998; McLellan & Bell, 2004; Pasman et al., 1995), high-intensity team sport 
activity (Collomp et al., 1992; Woolf et al., 2008; Glaister et al., 2008; Bruce et al., 2000; 
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Stuart et al., 2005; Schneiker et al., 2006), and strength-power performance (Woolf et al., 
2008; Beck et al., 2006). A study conducted by Lieberman et al. (2002) showed the fact that 
caffeine continued to enhance performance in terms of repeated acquisition (assessment of 
motor learning and short-term memory) and Profile of Mood states fatigue eight hours 
following consumption. These results are in agreement with Bell & McLellan (2002), where 
aerobic capacity was assessed 1, 3, and 6 hours following caffeine consumption (6 mg/kg). 
Caffeine had a positive effect on performance for participants classified as users (≥ 300 
mg/d) and nonusers (≤ 50 mg/d); however, nonusers had a treatment effect at 6 hours post-
consumption, which was not the case for users – this group only had a significant increase in 
performance at 1 and 3 hours post-consumption. Taken together, results of these studies 
(Lieberman et al., 2002; Bell & McLellan, 2002) provide some indication, as well as 
application for the general consumer and athlete. Specifically, while caffeine is said to have a 
half-life of 2.5-10 hour (Magkos & Kavouras, 2005), it is possible performance-enhancing 
effects may extend beyond that time point as individual response and habituation among 
consumers varies greatly. Recently, it was also suggested that caffeine can positively affect 
both cognitive and endurance performance (Hogervorst et al., 2008). Overall, the previous 
studies examining the effects of caffeine on anaerobic exercise is equivocal, with some 
studies reporting a benefit (Collomp et al., 1992; Woolf et al., 2008; Glaister et al., 2008; 
Bruce et al., 2000; Doherty et al., 2004; Wiles et al., 2006) and others suggesting that 
caffeine provides no significant advantage (Greer et al., 1998; Collomp et al., 1991). As with 
all sports nutrition research, results can vary depending on the protocol used, and in 
particular, the training status of the athlete as well as intensity and duration of exercise. 
According to the previous studies (Crowe et al, 2006; Hulston and Jeukendrup, 2008; 
Jackman et al., 1996; Kovacs et al., 1998; Graham et al., 2000), that a low dose of caffeine (3 
mg/kg) was adequate for enhancing performance, but did not lead to increased levels of 
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epinephrine or subsequent effect of free fatty acid mobilization; whereas a high dose of 
caffeine (6 mg/kg) had no significant effect on increasing plasma FFA levels or glycerol 
concentrations, nor did it substantially enhance rates of whole-body fat oxidation during 
endurance exercise even though performance was significantly improved with the caffeine + 
glucose solution. 
 
Theobromine is useful in asthma and in other respiratory tract problems such as cough for 
which no definitive drug has been developed, and it is commonly used by athletes during 
sports; it is a caffeine derivative and metabolite found primarily in chocolate, caffeine and 
theobromine are closely related alkaloid; and both of them are existing broadly in energy 
drinks and food stuffs, therefore, this study investigated whether they have ergogenic effect 
on athletes endurance performance in order to assit WADA with more accurate information 
on their prohibited list. Theobromine has often been described as a stimulant, with one-fifth 
the potency of caffeine on adenosine receptors (Svenningsson et al., 1993). However, 
theobromine had no effect on alertness at any time, although it did decrease blood pressure. 
Thus it is possible that theobromine affects peripheral physiology, but lacks the strong CNS-
activating properties of caffeine. Furthermore, there were no interactions of caffeine and 
theobromine on mood or blood pressure. Theobromine has been used as a bronchodilator in 
combination with caffeine; however, there is no objective information in the literature 
regarding the relative bronchodilator effects of the two drugs in vivo.  
 
Study four explored the impact of a methylxanthine proposed as a bronchodilator, 
theobromine, compared with caffeine, a methylxanthine with known bronchodilator efficacy, 
and placebo on 3 km time-trial running performance in non-asthmatic recreational athletes. 
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The findings of this study suggest that caffeine and theobromine at high dose of 6 mg/kg did 
not result in an improved 3 km time-trial performance, which is similar to the most of the 
findings from previous studies. It has been shown that caffeine supplementation at a low dose 
of 3 mg/kg can significatnly enhance both endurance and high-intensity performance in 
trained athletes. Consequently, the International Olympic Committee mandates an allowable 
limit of 12 µg of caffeine per mL of urine (Graham, 1983; Spriet, 1995). A caffeine dose in 
the range of 9 to 13 mg/kg approximately one hour prior to performance will reach the 
maximum allowable urinary concentration for competition (Graham, 2001). Caffeine 
consumption and urinary concentration is dependent on factors such as gender and body 
weight (Ellender & Linder, 2005). Therefore, consuming 6-8 cups of brewed coffee that 
contain approximately 100 mg per cup would result in the maximum allowable urinary 
concentration (Spriet, 1995; Ellender & Linder, 2005). According to The National Collegiate 
Athletic Association, urinary concentrations after competition that exceed 15 µg/mL are 
considered to be illegal (The National Collegiate Athletic Association, 2009). In addition, the 
World Anti-Doping Agency does not deem caffeine to be a banned substance (World Anti-
Doping Agency, 2009), but has instead included it as part of the monitoring program (World 
Anti-Doping Agency, 2009), which serves to establish patterns of misuse in athletic 
competition.  
 
Although there is no improvement on endurance performance with consumption of caffeine 
or theobromine according to this study, theobromine appeared to enhance performance 
during the later stages of the time-trial to a similar magnitude as caffeine (6 mg/kg BM), with 
the ingestion of caffeine resulting in a more rapid enhancement of running performance than 
theobromine. The present study suggests theobromine abuse may provide an ergogenic effect, 
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which propses a field of future research to examine whether an upper limit of use for 
theobromine should be proposed on WADA list.  
 
7.2 Conclusions 
Prevention and management of exercise-induced bronchoconstriction (EIB) is a key issue in 
athletes. Inhaled corticosteroids are the most effective drug for long-term control of asthma 
and EIB (Carlsen et al., 2008), whereas inhald β2-agonists taken before exercise provide 
immediate protection only (Carlsen et al., 2008). There are numerous negative findings in 
respect to severity, control, ad recovery from EIB when β2-agonists are used daily. Recovery 
from EIB after a standard dose of β2-agonists might, in some cases, be slower and need 
additional therapy when having EIB (Anderson, 1998). The present thesis has demonstrated 
that there is no improvement in endurance performance following the inhalation of up to 
1600 µg of salbutamol in non-asthmatic athletes in temperate or hot environments. 
Furthermore, there is no improvement in association football (soccer) performance following 
the inhalation of up to 1600 µg of salbutamol in non-asthmatic male and female players. This 
would suggest that the current WADA guidelines, which allows athletes to inhale up to 1600 
µg in a 24-hour period is sufficient to avoid pharmaceutical induced performance 
enhancement. However, such high doses not only suggest poor management of asthma they 
also mean that an athlete may be at risk of contravening the WADA current urinary 
threshold. If urine concentration of salbutamol exceeds 1000 ng·mL-1 in a doping test it is 
considered an adverse analytical finding, i.e. doping, unless the athlete proves through a 
controlled pharmacokinetic study performed in a WADA accredited laboratory, that the 
abnormal result was a consequence of use of therapeutic doses, i.e., maximum 1600 µg over 
24 hours, of inhaled salbutamol. 
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Furthermore, 2% body mass loss and greater concomitant with acute inhalation of 1600 µg of 
salbutamol in a single dose may result in a urine concentration above the current WADA 
upper limit and decision limit leading to a positive test finding. Hydration status per se is a 
critical factor relation to doping control. The results of this study suggest that WADA 
consider the role of normalizing drug concentrations to urine specific gravity in an attempt to 
negate the impact of hydration status on doping control tests. The present finding relate to 
urine concentration was independent of gender or ethnic origin. Data from this thesis will 
assist WADA in the implementation of regulations on the use of inhaled short acting β2-
agonist and assist in the resolution of contested doping violations.  
 
The results of this thesis suggested that the consumption of theobromine (6 mg/kg) enhances 
the performance of 3 km time-trial at later stages to a similar magnitude as caffeine (6 
mg/kg), even though the ingestion of caffeine resulting in a more rapid enhancement of 
running performance than theobromine. This indicates that abuse of theobromine may 
provide enhancement of athletic performance, which proposes a field of future research to 
examine whether theobromine should be considered part of the WADA prohibited list.  
 
7.3 Limitations 
One of the limitations to this thesis is the variability in actual dose inhaled. Whilst the use of 
a chamber was aimed to reduce this limitation in study 1, it remains possible that some 
participants with low urine concentration inhaled lower doses of salbutamol. This could have 
an impact on examining the relationship between urine concentration and inhaled salbutamol. 
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In addition, future work should investigate whether there is a relationship between body 
weight and the urinary concentration of salbutamol. A lighter athlete may be at a greater risk 
of breaching the threshold when administering high doses compared to a heavier athlete. 
Such findings would have implications to the care athletes receive in the future. 
 
Funding issues resulted in relatively small participant numbers in the present thesis. Whilst 
participant numbers are commensurate with the majority of previous studies, small numbers 
means the extrapolation of results to the wider athletic population should be viewed with 
caution. An increase in the number of participants may provide more robust findings. Both 
female and male participants were examined in study 2 of this thesis and whilst no significant 
gender differences were observed there may have been value in including gender 
comparisons in all studies.  
 
The same situation is related to the issue of ethnicity in the present thesis, which may also 
have an impact on the findings. Limitations to recruitment location and region issues 
resulting in small pools of potential participants. Whilst the results from the present thesis 
suggest an absence of an inter-race difference care is warranted in extrapolating from the 
small participant numbers in the wider community. Furthermore, this thesis only examined 
Afro-Caribbean Blacks, South East Asians and European Caucasians in study 3. Future 
studies should examine a broader cross-section of race to ensure an accurate understanding of 
the impact of race on pharmacokinetics. Further study is required in a larger number of 
participants including a range of gender and ethnicity to ensure an avoidance of Type II error. 
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Furthermore, the participants were not elite endurance athletes. Elite athletes could not be 
included in this study as they would have been at risk of a doping violation. Therefore we 
cannot claim our results directly represent the effects of inhaled salbutamol or the 
consumption of caffeine/theobromine in elite endurance athletes. 
 
7.4 Future directions 
Future studies should aim to examine higher dosages of salbutamol to discover if a lowest 
influential dose exists, as well as repetitive inhalation of salbutamol with interval for the 
maximal dosage within a day to find out the influence on urine concentration. Furthermore, a 
larger number of the participants including a range of gender and ethnicity would improve 
our understanding of the role of salbutamol on endurance and team game performance. 
Furthermore, the impact of acute short-acting β2 -agonist administration on strength 
performance and cognitive function remains an area for further investigation.  
 
Future work should investigate whether there is a relationship between body weight and the 
urinary concentration of salbutamol. A lighter athlete may be at a greater risk of breaching 
the threshold when administering high doses compared to a heavier athlete. Such findings 
would have implications for the care of athletes and anti-doping. Furthermore, few studies 
have examined the impact of long-term use of short-acting β2- agonists on performance and 
anti-doping.  
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Future research should expand on the findings of study 4 in a larger number of participants 
and establish whether a limit on theobromine use and upper urinary threshold should be 
proposed on WADA prohibition list, it also needs to focus on the effect of combination of 
caffeine and theobeomine on endurance performance, to find out the inter-relations between 
caffeine and theobromine. 
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